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Pyrroline-5-carboxylate reductases (EC 1.5.1.2) are important 
housekeeping enzymes of L-proline biosynthesis, which generate L-proline and 
influence redox cycling of NAD(P)H/NAD(P)+ to support cellular growth in all 
domains of life. Structural evidence from X-ray crystal structures of HsPYCR1 
(PDB codes 5UAT, 5UAU, and 5UAV) shows both NADPH bound in the N-
terminal Rao-Rossmann fold motif and an important hydrogen bond or proton 
donor role for Thr238 with L-P5C. A Thr238Ala mutation results in a 10-fold loss 
in catalytic efficiency with varied L-P5C relative to the wild-type enzyme, thus 
indicating an important role for Thr238 during catalysis. For HsPYCR2, Henri-
Michaelis-Menten kinetic analysis reveals a 164-fold loss in catalytic efficiency for 
the Arg119Cys mutant, with varied L-P5C and fixed NADH, relative to wild-type 
HsPYCR2. Profound effects on thermostability and secondary structure 
characteristics of the Arg251Cys mutant were determined by thermal shift assays 
and circular dichroism spectroscopy, respectively. Product(s) inhibition kinetics 
collectively indicate NADP+ and NAD+ are mixed noncompetitive inhibitors 
against NADPH and NADH, respectively, whereas L-proline is a competitive 
inhibitor against L-P5C. Taken together, these findings support a sequential-
ordered binding enzyme mechanism of L-P5C binding first followed by NAD(P)H-
binding.  
The ability of HsPYCR1 and 2 for reverse enzyme activity was observed 
with L-T4C as the reducing substrate. Structural evidence of a HsPYCR1─L-T4C 
binary complex, reverse direction saturation kinetics for both isozymes, and 
inhibition kinetics showing L-proline as a competitive inhibitor versus L-T4C, all 
indicate L-T4C shares the same active site as L-proline. Upon further evaluation 
of reverse direction reactions, we discovered association reactions between 
tris(alkyl)phosphine compounds and NAD+. Stopped-flow absorbance kinetics 
demonstrated rapid and reversible NAD+─tris(alkyl)phosphine nonenzymatic 
reactions with optimal absorbance at 334 nm for the reaction product. NMR 
spectroscopy identified a covalent adduct between the phosphorus of tris(2-
carboxyethyl)phosphine or tris(3-hydroxypropyl)phosphine interacting at the C4 
of the dihydronicotinamide ring of NAD+. Ultimately, this thesis dissertation 
provides strong structural and kinetic insights into human pyrroline-5-carboxylate 
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Introduction to L-proline biosynthesis in humans 
INTRODUCTION 
 Biochemical and bioenergetic aspects of cellular metabolism rely upon the 
presence and function of proteins, which are assembled based on the cellular 
supply of amino acids. Among the 20 common amino acids in humans, L-proline 
is distinguished as being the only proteinogenic imino acid due to both its amine 
nitrogen and its side chain covalently linked to the alpha carbon as a five-
membered pyrrolidine ring. L-proline is a nonessential amino acid in humans with 
L-glutamate and L-arginine serving as the primary sources for de novo 
biosynthesis of L-proline as shown in Fig. 1.1. 
 In the 1960s, L-Δ1-pyrroline-5-carboxylate reductase (PYCR) activity was 
characterized from animal sources such as rat and bovine tissues.1 The reaction 
of PYCR was observed strongly favoring the direction of L-proline formation with 
little appreciable reversible activity.1 It was then proposed that in mammals the 
reduction of L-glutamate to L-proline proceeds through a reaction pathway that is 
distinct from that of the oxidation of L-proline to L-glutamate (Fig. 1.1).1 Over the 
years, structural and biochemical studies have confirmed that in human 
mitochondria, L-glutamate initially is reduced to L-glutamic-γ-semialdehyde (L-
GSAL) by the bifunctional enzyme ALDH18A1 (synonymous with L-Δ1-pyrroline-
5-carboxylate synthetase (P5CS)), which possesses an ATP-dependent 
glutamate-5-kinase domain and a NAD(P)H-dependent L-glutamyl-γ-5-phosphate 
reductase domain (Fig. 1.1).2 Upon nonenzymatic dehydration, the open-chain L-
GSAL molecule undergoes ring closure to form L- Δ1-pyrroline-5-carboxylate (L-
2 
P5C). Next, the NAD(P)H-dependent PYCR enzyme functions to reduce L-P5C 













































































































































































































































 A distinct pathway exists for the conversion of L-proline back to L-glutamate. 
The first step of L-proline oxidation into L-P5C is catalyzed by the FAD-
dependent enzyme L-proline dehydrogenase (PRODH).4 L-P5C is then 
dehydrated nonenzymatically into L-GSAL, which is subsequently oxidized by the 
NAD+-dependent enzyme ALDH4A1 (synonymous with  L-GSAL dehydrogenase 
(GSALDH)) to yield L-glutamate.4 L-glutamate itself has several fates, some of 
which include enzymatic conversion into L-glutamine, entry into the citric acid 
cycle as L-α-ketoglutarate, or directly functioning as an excitatory amino acid 
neurotransmitter in the central nervous system. All of these potential fates for L-
glutamate explain how L-proline metabolism is linked to overarching processes of 
central metabolism such as bioenergetics, anaplerotic reactions replenishing 
citric acid cycle intermediates, and cell signaling.5 
 The coupling of L-proline metabolism to regulatory networks suggests a 
versatility beyond that of the L-proline requirement for protein synthesis. For 
instance, Hancock et al. (2016) utilized a PRODH-expressing DLD colorectal 
cancer cell model and mouse mitochondria to demonstrate that PRODH 
mediates the transfer of electrons from L-proline directly to coenzyme Q1 
(CoQ1).6 The subsequent electron transfer from CoQ1 to the electron-transport 
chain (ETC) Complexes III and IV occurs during acute nutrient deprivation.6 
Elevated PRODH expression can eventually lead to downregulation of ETC 
component proteins through production of reactive oxygen species (ROS).6 
These findings corroborate earlier observations that the initial catabolism of L-
proline by PRODH modulates cellular bioenergetics and ATP generation in vivo. 
In a study by Liu et al. (2015) using a P493 human B lymphoma cancer cell line, 
4 
genetic knockdown of P5CS and all three PYCRs hindered the oxidative arm of 
the pentose phosphate pathway as evidenced by a marked decrease in both 
NAD+ and NADP+ levels that were not rescued by exogenous treatment with L-
proline or L-P5C.7 Thus, it seems that an important function of L-proline 
biosynthetic enzymes is to drive cellular bioenergetics through the pentose 
phosphate pathway via shuttling of NAD(P)+, not necessarily for ATP generation 
but to help provide the cell with ribose-5-phosphate for the synthesis of pyridine 
nucleotides. In the context of cell signaling, D’Aniello et al. (2015) provide the first 
evidence that mouse embryonic stem cell (ESC) identity depends on the 
autoregulatory loop between L-Pro biosynthetic enzymes (P5CS and PYCR1) 
and the Gcn2-Eif2α-Atf4 amino acid starvation response pathway.8 Herein, the 
authors concluded that L-Pro starvation, either intrinsic or pharmacological 
inhibition of prolyl-tRNA synthetase by halofuginone, activates autophagy and 
signals massive apoptosis.8 Hence, L-Pro is a multifaceted imino acid that 
influences aspects of cellular bioenergetics and cell signaling with the aid of its L-
proline metabolic machinery. 
 The other primary source for L-proline biosynthesis is L-arginine (Fig. 1.1). 
Both groups Mepham et al. (1966) and Yip et al. (1972) confirmed in rats and 
goats that the enzymatic composition of the lactating mammary gland is poised 
for the metabolic conversion of L-arginine into L-proline.9,10 Building upon those 
findings, structural and biochemical studies have established that in human 
mitochondria, L-arginine initially undergoes catalytic hydrolysis by Mn2+-
dependent arginase to yield urea and L-ornithine.11 Next, two half-transamination 
reactions catalyzed by pyridoxal-5-phosphate-dependent enzyme L-ornithine 
5 
aminotransferase (OAT) converts L-ornithine and L-α-ketoglutarate substrates 
into L-GSAL and L-glutamate products, respectively.12 This intersection at L-
GSAL reveals how L-arginine metabolism contributes to L-proline synthesis. 
Within the mammalian system, glucocorticoid hormones, such as cortisol and 
corticosterone, differentially regulate intestinal L-proline and L-ornithine 
production from L-glutamine and L-arginine sources to provide substrates for the 
synthesis of extracellular matrix proteins, i.e. collagen, and of polyamines.13     
CLINICAL CORRELATIONS WITH ALTERED PYCR EXPRESSION AND 
FUNCTION  
 In humans, altered PYCR expression and function has been associated with 
several cancers and tumor growths, neurodegenerative diseases, and cutaneous 
and connective tissue diseases. Humans have three genes encoding isozymes 
PYCR1, PYCR2, and PYCRL (a.k.a. PYCR3).14 Isozymes PYCR1 and PYCR2 
are mitochondrial whereas PYCRL is cytosolic, and they have varied sensitivities 
to product inhibition, which contributes to their specialized function in proline 
metabolism.14 The functional consequences of depleting PYCR1, PYCR2, and 
PYCRL have implicated proline metabolism in various pathologies, including 
cancers like melanoma, breast cancer, prostate cancer, esophageal tumors, lung 
metastasis, and Kaposi’s sarcoma-associated herpesvirus (KSHV) – mediated 
tumorigenesis, along with cases of acute pancreatitis, hyperprolinemia, 
schizophrenia, hypomyelinating leukodystrophy type 10 with microcephaly, and 
cutis laxa.5,15,16 Human PYCR1 and 2 (HsPYCR1 and 2) have been separately 
implicated in specific cancers:  non-small cell lung cancer, viral-related 
hepatocellular carcinoma, papillary renal cell carcinoma, melanoma, breast and 
6 
prostate cancers, esophageal squamous cell carcinoma, KSHV – mediated 
tumorigenesis, lung adenocarcinoma, and colorectal  
cancer.15,17,18,19,20,7,21,22,23,24,25 Also, studies have shown all three human PYCR 
isozymes are transcriptionally up-regulated by the c-MYC oncogene in many 
types of cancers.5,15,7 A study by Olivares et al. (2017) found that the collagen in 
the extracellular matrix of the tumor microenvironment of pancreatic ductal 
adenocarcinoma cells serves as a critical nutrient reserve of L-proline that fuels 
the citric acid cycle and prolongs tumor cell survival under restrictive nutrient 
conditions.26 Thus, L-proline biosynthesis promotes tumorigenesis particularly 
through the activity of HsPYCR1 and 2. 
 Another set of pathologies linked to L-proline biosynthesis concerns 
neurodegenerative and psychiatric diseases. For instance, animal-based studies 
have revealed that alterations in the reactions of L-arginine and L-proline 
metabolism that are involved in neurotransmission have been identified as strong 
contributors to the progression of schizophrenia.27 In Zaki et al.’s (2016) study on 
PYCRs in lethal microcephaly and failure to thrive pathologies, HsPYCR2 was 
proposed to promote redox cycling of NAD(P)H/NAD(P)+ to support cellular 
growth and  neuronal development.28 In a landmark study, Nakayama et al. 
(2015) found that in human patients affected with specific neurological 
phenotypes of hypomyelination and microcephaly, there was a strong genetic 
linkage with individual HsPYCR2 missense mutations R119C and R251C.29 
Despite the phenotypic overlap between autosomal recessive disorders of 
HsPYCR1 and 2 mutations in terms of microcephaly, global developmental delay, 
and joint hyperlaxity, mutations in HsPYCR1 uniquely lead to cutis laxa type IIB 
7 
(OMIM # 612940)30,31 whereas mutations in HsPYCR2 uniquely lead to genetic 
hypomyelinating leukodystrophy type 10 with microcephaly (OMIM # 
616420).28,29,32 Therefore, dysfunctions in HsPYCR2 are more strongly 
associated with neurodegenerative diseases than dysfunctions in HsPYCR1. 
 Cutaneous and connective tissue diseases have been associated with 
HsPYCR1 dysfunctions. Collagen is a structural scaffold protein found in all 
connective tissue, bone, and the extracellular matrix of the human body. The 
most abundant amino acid in collagen is L-proline, thus collagen is often 
considered as a L-proline reservoir. Studies on the role of collagen in fibrotic 
diseases and tumorigenesis are therefore often linked to L-proline metabolism.33 
In a study by Reversade et al. (2009), cultured skin fibroblasts were examined 
from individuals with mutations in HsPYCR1 and afflicted with autosomal 
recessive cutis laxa.31 The mutations in HsPYCR1 were shown to cause aberrant 
mitochondrial morphology and dysfunction.31 These observations provided new 
insights into how HsPYCR1 deficiency could contribute to progeroid changes in 
connective tissues besides disrupting L-proline biosynthesis.31 In addition to L-
proline biosynthesis, important research has focused on understanding post-
translational modifications of L-proline in collagen. Prolyl-4-hydroxylase and 
prolyl-3-hydroxylase have a non-heme iron center that catalyzes the addition of 
an oxygen atom at the C4 and C3 positions of the pyrrolidine ring of peptidyl L-
proline, respectively, using L-α-ketoglutarate and O2. Early work by Englard et al. 
(1986), involved in vivo studies supporting a mechanism proposed by Hanauske-
Abel et al. (1982) in which L-ascorbate from the endoplasmic reticulum lumen 
acts as an effective reductant of the iron center to replenish the ferrous form after  
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each catalytic cycle of the prolyl hydroxylase enzymes.34  
SUMMARY  
 Although L-proline is a nonessential amino acid in humans, its importance 
spans the realms of protein synthesis, bioenergetics, structural scaffolding in the 
extracellular environment, and cell signaling.5 De novo biosynthesis of L-proline 
stems from two major sources:  L-glutamate and L-arginine. Dysfunctional 
expression or activity of HsPYCR1 and 2 have been linked to human pathological 
conditions including various cancers and tumors, neurodegenerative and 
psychiatric disorders, and cutaneous and connective tissue diseases. Taken 
together, this dissertation aims to provide a clear understanding of the molecular 
mechanisms of L-proline biosynthesis with structural and functional in vitro 
characterization of human PYCR1 and PYCR2. 
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ABSTRACT  
 Pyrroline-5-carboxylate reductase (PYCR) is the final enzyme in L-proline 
biosynthesis, catalyzing the NAD(P)H-dependent reduction of L-pyrroline-5-
carboxylate (L-P5C) into L-proline (L-Pro). Mutations in the PYCR1 gene alter 
mitochondrial function and cause the connective tissue disorder cutis laxa. 
HsPYCR1 is overexpressed in multiple cancers, and the HsPYCR1 knock-out 
suppresses tumorigenic growth, suggesting that HsPYCR1 is a potential cancer 
target. However, inhibitor development has been stymied by limited mechanistic 
details for the enzyme, particularly in light of a previous crystallographic study 
that placed the cofactor-binding site in the C-terminal domain rather than the 
anticipated Rao-Rossmann fold of the N-terminal domain. To fill this gap, we 
report X-ray crystallographic, sedimentation-velocity, and kinetics data for human 
PYCR1. Structures of the binary complexes of HsPYCR1 with NADPH or L-
proline determined at 1.9 Å resolution provide insight into cofactor and substrate 
recognition. We see NADPH bound to the Rao-Rossmann fold, over 25 Å from 
the previously proposed C-terminal site. The 1.85 Å resolution structure of a 
ternary complex containing NADPH and an L-P5C/L-Pro analog, namely L-
tetrahydro-2-furoic acid (L-THFA), provides a model of the Michaelis complex 
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formed during hydride transfer. Sedimentation velocity shows that PYCR1 forms 
a concentration-dependent decamer in solution, consistent with the pentamer-of-
dimers assembly seen crystallographically. Steady-state kinetic and mutational 
analysis along with product inhibition kinetic analyses confirmed several features 
seen in the crystal structure, including the importance of a hydrogen bond 
between Thr238 and the substrate as well as limited cofactor discrimination 
between NADPH and NADH.  
INTRODUCTION 
 L-proline, a unique imino acid that lacks a primary amino group, is a key 
building block of proteins and plays an important role in stress protection and 
redox balance of cells across multiple kingdoms of life.1,2,3 From a biosynthetic 
standpoint, the two biological sources of L-glutamate and L-arginine converge on 
enzyme L-pyrroline-5-carboxylate (L-P5C) reductase (P5CR, EC 1.5.1.2), which 
catalyzes the final reduction of L-P5C into L-proline (L-Pro) using NAD(P)H. In 
humans, P5CR is known as PYCR. The human genome contains three 
homologous PYCR genes, PYCR1, PYCR2, and PYCRL (also known as 
PYCR3). The various human PYCR (HsPYCR) isoforms have specialized roles in 
L-Pro biosynthesis and different subcellular localizations. A study of PYCRs in 
melanoma cells showed that both HsPYCR1 and 2 function primarily in the L-
glutamate-to-L-proline pathway, whereas HsPYCRL functions mainly in the L-
arginine-to-L-proline pathway.4 HsPYCR1 and 2 localize to mitochondria, 
whereas HsPYCRL is cytosolic.4,5 Other studies have shown that HsPYCR1 and 
2 are recoverable from the cytosol, suggesting the possibility that the enzymes 
associate with the outer mitochondrial membrane.6 
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 HsPYCR has been implicated in various cancers and has emerged as a 
potential therapeutic target. A study of mRNA profiles from 1,981 tumors 
identified PYCR1 as one of the most consistently overexpressed metabolic genes 
across 19 different cancer types.7 Additional studies highlight an abundance of 
HsPYCR1 in melanoma cells as compared with healthy melanocytes, indicating 
this enzyme as a potential therapeutic target in skin cancer treatment.4,8 Similarly, 
depletion of PYCR1 in different types of cancers, such as breast, prostate, and 
renal cell carcinoma, is associated with diminished cell proliferation and 
tumorigenic growth.4,9,10,11 
 Deficiencies in PYCR are also linked to inherited metabolic disorders. Certain 
mutations in the PYCR1 gene cause the autosomal recessive connective tissue 
disorder cutis laxa.5 The decrease in HsPYCR1 activity is thought to impair 
mitochondrial function, leading to developmental defects through increased 
apoptosis.5 Mutations in the PYCR2 gene cause a developmental disorder of the 
brain characterized by microcephaly, hypomyelination, and reduced white 
matter.12 As with cutis laxa, the pathogenicity of the disorder involves 
mitochondria-induced apoptosis in the central nervous system.12 
 Although X-ray crystal structures of P5CRs from microorganisms and a plant 
species have been characterized13,14,15, before this work, only one X-ray 
structural study has been characterized and discussed previously on human 
P5CR. Fourteen years ago, Meng et al. (2006) reported 3.1 Å crystal structures of 
HsPYCR1 complexed with NADPH and NADH.16 A major conclusion of that study 
was that the NAD(P)H cofactor binds to the C-terminal domain rather than in the 
canonical site within the N-terminal Rao-Rossmann fold domain.16 This result is 
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notable because it contradicts other P5CR structures and departs from the 
accepted structure-function paradigm of Rao-Rossmann fold enzymes, which 
asserts that the cofactor binds to the N-termini of the strands of the Rao-
Rossmann dinucleotide-binding fold.17,18 
 Herein we reexamine the structure of HsPYCR1 at high resolution to better 
establish the location of the active site and to elucidate the interactions 
responsible for cofactor and substrate recognition. X-ray crystal structures of 
binary complexes of HsPYCR1 with NADPH and L-Pro have been determined at 
1.9 Å resolution. The structure of a ternary complex with NADPH and the 
L-P5C/L-Pro analog L-tetrahydro-2-furoic acid (L-THFA) has been obtained at 
1.85 Å resolution. Furthermore, we present Furthermore, we present analytical 
ultracentrifugation analysis of PYCR1 in solution and steady-state kinetic data of 
the wild-type and active-site mutant enzymes for the forward reaction of L-P5C 
reduction into L-Pro, along with product inhibition kinetic analyses. In contrast to 
Meng et al.’s (2006) study, our electron density maps unequivocally identify the 
location of the cofactor-binding site and show that HsPYCR1 follows the 
canonical structure-function paradigm of Rao-Rossmann fold enzymes.   
MATERIALS AND METHODS 
Expression and purification of HsPYCR1 
 DNA encoding human mitochondrial PYCR1 transcript variant 1 (NCBI 
RefSeq number NP_001269209.1) in pET-24b(+) with codons optimized for 
expression in Escherichia coli was synthesized by GenScript Biotech Corp. The 
construct encodes residues 1–300 of the full-length 319-residue protein plus an 
N-terminal hexahistidine tag and tobacco etch virus protease cleavage site. This  
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construct was designed for enhanced crystallization based on unpublished PDB 
entry 2IZZ. 
 The HsPYCR1 construct was transformed into BL21(DE3)-competent E. coli 
cells and plated onto LB agar containing 50 µg/ml kanamycin. A starter culture of 
Luria broth medium, shaken overnight at 37 °C and 250 rpm, was used to 
inoculate two 1 L cultures. After 2 h of shaking at 37 °C and 250 rpm, the larger 
cultures were induced with 0.5 mM isopropyl thiogalactopyranoside and grown 
with continued shaking at 18 °C overnight. Centrifugation at 3,000 x g for 20 min 
at 4 °C was used to collect the cells, which were then resuspended in 50 mM 
HEPES, pH 7.8, 300 mM NaCl, 10 mM imidazole, and 5% (w/v) glycerol (buffer 
A). The resuspended pellet was stored at 80 °C until ready for purification. 
 A mixture of DNase I, lysozyme, and GoldBio ProBlock protease inhibitor 
mixture was added to thawed cells and stirred at 4 °C for 20 min. After lysing cells 
via sonication, cell debris was removed by centrifugation at 16,000 rpm for 1 h at 
4 °C. The resulting supernatant was passed through a 0.45 µm Millex-HV syringe 
filter and loaded onto a 5 ml HisTrap Ni2+-nitrilotriacetic acid column (GE 
Healthcare) pre-equilibrated in buffer A using an AKTA Pure chromatography 
instrument. The column was washed with buffer A supplemented with 30 mM 
imidazole and eluted with 300 mM imidazole. The fractions containing PYCR1 as 
determined by SDS-PAGE were collected and dialyzed at 4 °C overnight into 
dialysis buffer containing 300 mM NaCl, 2% (w/v) glycerol, 50 mM HEPES, pH 
7.5. Following dialysis, the protein was concentrated to 5 ml using a centrifugal 
concentrator (Amicon Ultra-15) and then further purified on a HiLoad 16/600 
Superdex 200 size-exclusion column (GE Healthcare) using a column buffer with  
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the same composition as the dialysis buffer. The His-tag was not removed. 
Crystallization of HsPYCR1, crystal soaking, and X-ray diffraction data collection 
 Experimental conditions for growing crystals of HsPYCR1, soaking them with 
ligands, and X-ray diffraction of crystals with tabulated values of diffraction data 
collection and refinement statistics are fully explained in Christensen et al. 
(2017).19 In brief, the sitting drop vapor diffusion technique was used for the 
crystallization of HsPYCR1, and then diffraction-quality crystals in the space 
groups P21212 and C2 were grown.19 Ligand-free P21212 protein crystals were 
more amenable for ligand soaking to prepare binary complexes of HsPYCR1 with 
NADPH bound, HsPYCR1 with L-proline bound, and ternary complex of 
HsPYCR1 with NADPH and the L-P5C/L-proline analog of L-THFA bound, 
whereas the C2 protein crystal form was examined as the ligand-free enzyme.19 
X-ray diffraction data were collected on Advanced Light Source beamline 4.2.2 at 
Lawrence Berkeley National Laboratory using a Taurus-1 detector in shutterless 
mode, and the initial phases of crystal diffractions were calculated with molecular 
replacement using PHASER.19,20 
Analytical ultracentrifugation 
 Sedimentation-velocity experiments were conducted with a Beckman XL-I 
analytical ultracentrifuge using an An50Ti rotor and a two-sector cell. Sample 
sedimentation was continuously monitored at 20 °C using Rayleigh interference 
optics at 35,000 rpm for a total of 300 scans spaced at 2-min intervals. To 
observe the concentration dependence of oligomerization, sedimentation-velocity 
experiments were performed at two different protein concentrations (0.8 and 6.0  
mg/ml) as determined by the Pierce BCA protein assay. 
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 Sedimentation-velocity data were processed using Sedfit,21 assuming a partial 
specific volume of 0.73 ml/g. Analysis of the data in Sedfit allowed for the 
determination of apparent sedimentation coefficient (c(S)) and molecular mass 
(c(M)) distributions. The approximate frictional ratio for decameric HsPYCR1 was 
determined by allowing the value to vary in the c(S) calculation of the 6.0 mg/ml 
protein sample. The frictional ratio was refined to a value of 1.94. This value was 
applied to the analysis of the 0.8 mg/ml protein sample for consistency in 
decamer peak identification. Analyzed data were normalized and plotted using 
Origin 2016. 
Kinetic measurements 
 All HsPYCR1 kinetic data were collected in triplicate using a Varian Cary BIO 
50 UV-visible spectrophotometer (Agilent Technologies) following procedures 
adapted from previous studies.4,14,22,13,23 PYCR enzyme activity assays were 
performed by measuring the L-P5C-dependent oxidation of NADPH (Sigma-
Aldrich) or of NADH (Sigma-Aldrich) at 340 nm and at 380 nm, using millimolar 
extinction coefficients 6.22 mM-1 cm-1 and 1.314 mM-1 cm-1, respectively.4,24 DL-
P5C was synthesized according to the protocol by Williams and Frank,25 which 
involved the metaperiodation of DL-5-hydroxylysine hydrochloride at 4 °C with 
the reaction product purified by Dowex 50WX4 cation exchange column 
chromatography using 1 M HCl to elute the fractions of DL-P5C. Additional 
details concerning the synthesis and mass spectrometry characterization of DL-
P5C are provided in Appendix Chapter 1. DL-P5C was neutralized to pH 7.5 with 
1 M Tris-HCl (pH 9.0) buffer immediately before assays. NADH and NADPH 
stock concentrations were spectrophotometrically determined at 340 nm. Assays 
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(600-µl total volume) were performed in 1.5 mL rectangular polystyrene cuvettes 
(1 cm pathlength) (USA Scientific) at 37 °C in 0.1 M Tris-HCl (pH 7.5) reaction 
buffer, 0.01% Brij-35 detergent (Santa Cruz Biotechnology), 1 mM EDTA 
disodium salt (Fisher), using 0.006 and 0.06 µM HsPYCR1 wild-type and mutant 
T238A enzymes. For assays in which DL-P5C was varied, the ionic strength was 
maintained at approximately 450-480 mM Tris+Cl- at each DL-P5C concentration 
by adding a balance of 1 M Tris-HCl (pH 7.5) buffer.26  
Enzyme activity was calculated from the linear portion of the initial 
absorbance decrease using the Beer-Lambert-Bouguer law.27,28,29 Assays were 
performed in triplicate and data were expressed as mean ± standard deviation. 
Data were fit by nonlinear regression to the Henri-Michaelis-Menten equation 
using SigmaPlot 12.0 (version 12.0.0.182, Systat Software) to estimate the 
maximal reaction velocity limit (Vlim) and the apparent Michaelis-Menten constant 
(KM app) values (value ± standard error). The KM app for L-P5C was assumed to be 
half the KM app value for the racemic DL-P5C mixture. The apparent catalytic 
turnover rate (kcat app) and substrate specificity constant or catalytic efficiency 
values (kcat app/KM app) were calculated from Vlim and KM app. Product(s) inhibition 
kinetics were analyzed by global fitting of the data to different inhibition models 
using the Enzyme Kinetics Wizard Module in SigmaPlot 12.0 and by Hanes-
Woolf plot analysis. For NAD+ product inhibition, the data fit best to a mixed 
inhibition (Full) model with enzyme-inhibition constants KIC app and KIU app = α(KIC 
app) (α = 0.4728). The mixed inhibition model had the highest squared correlation 
coefficient (R2)-ranking among eight tested inhibition models. For L-Pro product  
inhibition, the highest R2-ranking model was competitive inhibition (Full) (KIC app). 
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RESULTS  
Tertiary and quaternary structure of HsPYCR1 
 High-resolution crystal structures of HsPYCR1 revealed that the protomer 
consists of an N-terminal α/β domain and a C-terminal α domain (Fig. 2.1A).  
 
Figure 2.1. Structures of the PYCR1 protomer and dimer. A, structure of the 
protomer of the ternary complex with NADPH and with the L-proline/L-P5C 
analog of L-THFA. The N-terminal NAD(P)H-binding domain is colored according 
to secondary structure, with β-strands in pink and α-helices in blue. The C-
terminal oligomerization domain is colored gray. NADPH appears in gold sticks. 
L-THFA is shown as cyan sticks. β-strands are labeled 1–8; α-helices are labeled 
A–M. Helix-disrupting Pro-178 is shown. B, structure of the dimer. The α-helices 
of the C-terminal domain are labeled H–M for the gray protomer and H’–M’ for the 
purple protomer. NADPH and L-THFA are colored gold and cyan, respectively. 
The arrow represents the 2-fold axis of the dimer. 
 
The N-terminal domain features the classic Rao-Rossmann dinucleotide-binding 
fold, which consists of a pair of βαβαβ motifs that interact across a pseudo-2-fold 
axis to form a six-stranded parallel β-sheet with strand order 321456.30,31 An 
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additional βαβ substructure follows strand 6 such that the full β-sheet of the N-
terminal domain has eight β-strands, with the last two β-strands antiparallel to the 
Rao-Rossmann β-strands. β-strand 8 of the N-terminal domain connects to the C-
terminal domain, which consists of a bundle of six α-helices. The C-terminal 
domain plays a major role in oligomerization. For example, the C-terminal domain 
mediates dimerization (Fig. 2.1B). In the dimer, the C-terminal domains of two 
protomers form an interlocking bundle of α-helices. Overall, the domain 
architecture of HsPYCR1 is typical for P5CRs.13 
 The oligomeric state of HsPYCR1 in solution was determined with analytical 
ultracentrifugation using sedimentation-velocity. Initial studies performed at 0.8 
mg/ml (24 µM) revealed a distribution of apparent sedimentation coefficient that 
exhibits a series of peaks in the range 1–7.5 S (Fig. 2.2A).  
  
 
Figure 2.2. Oligomerization of PYCR1 in solution. A, apparent sedimentation 
coefficient distribution determined at 6.0 mg/ml (solid line) and 0.8 mg/ml (dashed 
line). B, molecular mass distribution determined at 6.0 mg/ml (solid line) and 0.8 
mg/ml (dashed line). 
 
The corresponding distribution of molecular masses reveals multiple species in 
solution spanning from ~30 to 350 kDa (Fig. 2.2B). Because the theoretical   
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molecular mass of a monomer is 34 kDa, the c(M) distribution is consistent with 
the presence of multiple oligomeric states ranging from monomer to decamer. To 
further investigate the possibility that decamer formation is concentration-
dependent, sedimentation velocity was also performed at the higher 
concentration of 6.0 mg/ml (180 µM). This experiment yielded a sedimentation 
coefficient distribution with a single peak at 7.47 S (Fig. 2.2A), corresponding to a 
molecular mass of 350 kDa (Fig. 2.2B). Thus, at a concentration of 180 µM, 
HsPYCR1 is almost entirely decameric. These results are consistent with P5CR 
forming a self-association equilibrium in solution. 
 Analysis of crystal packing with PDBePISA32 reveals a pentamer-of-dimers 
assembly in both crystal forms (Fig. 2.3), consistent with the decamer observed 
in sedimentation-velocity experiments.  
 
Figure 2.3. The PYCR1 pentamer-of-dimers decamer. A, two orthogonal views of 
the decamer, with each chain differently colored. B, two orthogonal views of the 
decamer, with the N-terminal domains colored blue and the C-terminal domains 
colored gray. Note that the C-terminal domains mediate all protein-protein 
interactions in the decamer. 
 
This assembly is also present in other P5CR crystal structures from a variety of  
organisms.13,14,15 The consistency of this assembly across space groups and  
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kingdoms suggests the decamer is a fundamental structural property of P5CRs. 
 The decamer is a pentamer-of-dimers assembly that resembles an 
“hourglass-shaped barrel”13 when viewed perpendicular to the 5-fold axis (Fig. 
2.3). The dimers are arranged such that the N-terminal domains form pentameric 
rings at the top and bottom of the barrel, and the C-terminal domains form a 
cylinder that connects the two rings. A notable feature of the decamer is that most 
of the interfacial surface area results from the interaction between C-terminal 
domains, whereas the N-terminal domains are relatively isolated from other 
protomers (Fig. 2.3B). 
Identification of the NAD(P)H-binding site 
 Electron density maps revealed the location and conformation of NADPH 
bound to HsPYCR1 (Fig. 2.4).  
 
Figure 2.4. Electron density and interactions for NADPH bound to PYCR1. 
The cage represents a simulated annealing (Fo - Fc) map contoured at 3σ. 
Selected α-helices and β-strands are labeled in accordance with Fig. 2.1. α-helix 
K (purple) is from the opposite protomer of the dimer. The conserved water 
molecule of the Rao-Rossmann dinucleotide-binding fold is colored green.33 
 
In the enzyme─NADPH binary complex structure, the density is very strong in 
two of the five chains in the asymmetric unit, allowing modeling of the complete  
N230 
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cofactor with occupancy of 1.0 (chains C and E). We note that high occupancy of 
NADPH appears to be correlated with the stabilization of residues 34–40, which 
form a loop that interacts with the adenosine portion of NADPH. Density for this 
loop is very strong in chains C and E but much weaker in chains A, B, and D. The 
loop was omitted in chain A. 
 NADPH binds at the C-termini of the strands of the Rao-Rossmann 
dinucleotide-binding fold (Fig. 2.4). The cofactor adopts an extended 
conformation with the pyrophosphate poised above the N-terminus of the first α-
helix of the Rao-Rossmann fold (αA). The adenosine group interacts with the first 
 βαβαβ motif, whereas the nicotinamide riboside contacts the second βαβαβ 
motif. In summary, NADPH adopts the canonical pose expected for nicotinamide 
adenine dinucleotides bound to Rao-Rossmann fold domains.33 
 NADPH forms several noncovalent interactions with the enzyme (Fig. 2.4). 
The ribose hydroxyls and pyrophosphate hydrogen bond exclusively with protein 
backbone atoms. Only two side chains participate in hydrogen bonding with 
NADPH. Asn56 hydrogen bonds with the adenine ring, whereas Ser34 interacts 
with the 2’-phosphoryl group. Nonpolar side chains help position the bases of 
NADPH, with Pro35, Val70, and Ile78 contacting the adenine and Leu11 packing 
against the nicotinamide.  
 The carboxamide of NADPH has a 2-fold rotational degeneracy at the 
resolution of our structures; however, hydrogen bonding can be used to deduce 
the correct orientation of this group. The carboxamide amino group has been 
modeled so it forms an intramolecular hydrogen bond with the pyrophosphate 
and another hydrogen bond with the backbone carbonyl of Asn230 (Fig. 2.4). In 
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contrast, rotation by 180° places the carboxamide carbonyl next to obligate 
hydrogen bond acceptors, resulting in no hydrogen bonds. 
The L-proline-binding site 
 The structure of HsPYCR1 complexed with the product L-proline was 
determined at 1.90 Å resolution from a crystal that had been soaked in 1.8 M L-
proline (Fig. 2.5). The electron density allowed modeling of L-proline in the active 
site of all five chains with occupancy of 1.0.  
  
 
Figure 2.5. The L-proline-binding site. A, electron density and interactions for L-
proline (cyan) bound to PYCR1. The cage represents a simulated annealing (Fo - 
Fc) map contoured at 3σ. The two protomers of the dimer are colored purple and 
gray. Note that L-proline binds in the dimer interface, and a hydrogen bonding 
water molecule in the vicinity of the carboxylate of L-proline and Ser233 is 
colored red. Selected α-helices are labeled in accordance with Fig. 2.1. B, space-
filling representation of the L-proline-binding site highlighting nonpolar residues 
that contact the methylene groups of L-proline. 
 
L-proline was also modeled into an election density feature on the surface of the 
protein near Thr137. The adventitious binding of L-proline to the protein surface 
is common when used in high concentration as a cryoprotectant, as is the case 
here.34 
 L-proline binds in a section of the dimer interface where the αK-αL loop of one  
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protomer meets α-helices H, I, and M of the other protomer (Figs. 2.1B and 2.5A). 
The carboxylate and imino groups of L-proline are anchored to the αK-αL loop via 
several hydrogen bonds, some of which are mediated by a water molecule (Fig. 
2.5A). Of note is the hydrogen bond between Thr238 and the imine nitrogen of L-
proline. It has been proposed that this conserved Thr residue functions in 
catalysis by donating a proton to the imine nitrogen atom of L-P5C.13 
 The roof of the binding site provides nonpolar contacts for the methylene 
groups of L-proline. These contacts include Ala97 of the Rao-Rossmann fold and 
the kink between α-helices H and I (Fig. 6B). The kink is caused by the presence 
of conserved Pro178 and appears to be a common feature of P5CRs because it 
is also present in structures of P5CR from microorganisms.14 Within the kink, the 
carbonyls of residues 174 and 175 splay outward to avoid a steric clash with the 
Cδ of Pro178, and as a result, these groups do not form (i to i + 4) hydrogen 
bonds, and the helical structure is disrupted. Thr171 and Gly175 of the kink 
region provide nonpolar contacts with the methylene groups of L-proline. These 
interactions bury the carboxylate face of L-proline, leaving the other face solvent-
exposed and available for catalysis (Fig. 2.5B). 
The ternary complex with NADPH and L-THFA 
 The structure of HsPYCR1 complexed with NADPH and L-THFA was 
determined at 1.85 Å resolution (Fig. 2.6). The electron density is very strong for 
both ligands in all five chains, allowing the inclusion of the ligands in the model at 
an occupancy of 1.0. This is the first structure of any P5CR that mimics the 
enzyme─NADPH─L-P5C Michaelis complex. 
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Figure 2.6. Structure of the ternary complex of PYCR1 with NADPH and L-THFA. 
The cage represents a simulated annealing (Fo - Fc) map contoured at 3σ. 
NADPH and L-THFA are colored gold and cyan, respectively. Water molecules 
are colored red. The two protomers of the dimer are colored purple and gray. Two 
orthogonal views are shown. Selected α-helices are labeled in accordance with 
Fig. 2.1A. 
 
 The structure shows that dimerization is essential for catalytic activity. 
NADPH interacts with the Rao-Rossmann fold of one protomer, and L-THFA 
binds in the αK-αL loop of the opposite protomer of the dimer (Fig. 2.1B). NADPH 
adopts the same conformation as in the binary enzyme-NADPH complex, 
whereas L-THFA occupies the aforementioned L-proline site. Water-mediated 
hydrogen bonding appears to play a role in stabilizing the ternary complex, 
because five water molecules with strong electron density connect L-THFA, 
NADPH, and the protein (Fig. 2.6). The ring of L-THFA stacks in parallel with the 
nicotinamide ring such that C5 of L-THFA, which represents the hydride acceptor 
atom of L-P5C, is 3.7 Å from C4 of the nicotinamide ring. The structure is 
consistent with a direct hydride-transfer mechanism. 
Henri-Michaelis-Menten kinetics and product(s) inhibition Hanes-Woolf kinetics  
 Steady-state kinetics assays showed that HsPYCR1 utilizes both NADH and 
NADPH cofactors (Fig. 2.7, A-C). When keeping L-P5C fixed (3.5 mM) while  
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Figure 2.7. Initial velocity data for PYCR1 wild-type and T238A mutant. (A) varied 
NADH (0-660 µM) and fixed DL-P5C (3.5 mM) with 0.006 µM HsPYCR1. (B) 
varied NADPH (0-2000 µM) and fixed DL-P5C (3.5 mM) with 0.06 µM HsPYCR1. 
(C) varied DL-P5C (0-3.5 mM) and fixed NADPH (500 µM) with 0.06 µM 
HsPYCR1. (D) HsPYCR1 T238A mutant (0.06 µM) with varied NADPH (0-1200 
µM) and fixed DL-P5C (3.5 mM). (E) HsPYCR1 T238A mutant (0.06 µM) with 
varied DL-P5C (0-3.5 mM) and fixed NADPH (500 µM). Assays were performed 
at 37 °C in 0.1 M Tris-HCl (pH 7.5) reaction buffer. Data (mean ± standard 
deviation) are plotted as variable substrate concentration (µM) versus initial 
reaction velocity of NAD(P)+ product formation (µM s-1) with non-linear least-
squares fits to the Henri-Michaelis-Menten equation from which the kinetic 
parameters reported in Table 2.1 were derived. Apparent substrate inhibition is 
observed with wild-type HsPYCR1 and varied NADPH (panel B) but the data 
could not be fit satisfactorily to an equation for general substrate inhibition. 
 
varying the dinucleotide concentration, KM app values of 70 and 283 µM for NADH 
and NADPH were obtained (Table 2.1). The kcat app value was nearly 3-fold higher   
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aValue ± std error are the apparent best-fit parameters from non-linear least-
squares fit of the data to the Henri-Michaelis-Menten equation using SigmaPlot 
12.0 (version 12.0.0.182, Systat Software). Data plotted as the (mean ± SD) of 
n=3 technical replicates. 
bFinal enzyme concentration of 0.006 µM (for varied NADH with fixed DL-P5C) 
and 0.06 µM in remaining assays. 
cFinal enzyme concentration of 0.06 µM in the assay. 
dDL-P5C concentration fixed at 3500 µM. 
eNAD(P)H concentration fixed at 500 µM. 
fReported value is the concentration of L-P5C, which is assumed to be half the 
concentration of the DL-P5C racemic mixture. 
 
higher with NADH, resulting in a 12-fold greater catalytic efficiency (kcat app/KM app) 
relative to NADPH (Table 2.1). A previous study reported a 6.5-fold higher 
catalytic efficiency of HsPYCR1 with NADH over NADPH.4 Kinetic values of kcat 
app as 31 s-1 and KM app as 667 µM L-P5C were determined for wild-type 
HsPYCR1 from assays varying L-P5C while keeping NADPH fixed (Table 2.1, 
Fig. 2.7C). 
 The importance of Thr238 was tested with the site-directed mutation T238A. It 
has been proposed that this universally conserved residue functions in catalysis 
by donating a proton to the imine nitrogen of L-P5C.13 This proposition was based 
on the observation of a hydrogen bond between the hydroxyl group of the 
conserved Thr and the imine nitrogen of the product L-proline in P5CR structures 
Table 2.1. Steady-state kinetic parameters for PYCR1a 






(kcat app/KM app )        
 (M-1 s-1) 
Wild-typeb 
NADH DL-P5Cd 70 ± 11 218 ± 8 (31 ± 5.) x 105 
NADPH DL-P5Cd 283 ± 119 74 ± 8 (2.6 ± 1.1) x 105 
DL-P5C NADPHe 667 ± 88f 31 ± 2 (0.47 ± 0.07) x 105 
T238Ac NADPH DL-P5C
d 159 ± 47 23 ± 2  (1.4 ± 0.4) x 105 
DL-P5C NADPHe 2887 ± 774f 14 ± 3 (0.05 ± 0.02) x 105 
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from microorganisms14, an interaction that is also seen in HsPYCR1 (Fig. 2.5A). 
The analogous hydrogen bond to L-THFA is also present in the ternary complex 
(Fig. 2.6). 
 Kinetic parameters for the T238A mutant enzyme were determined by varying 
NADPH and L-P5C (Fig. 2.7, D and E). Values of kcat app as 23 s-1 and 14 s-1 with 
KM app as 159 µM and 2887 µM for NADPH and L-P5C, respectively, were 
determined (Table 2.1). Because the KM app is near the upper concentration of L-
P5C available, a kcat app/KM app value of 16,700 M-1 s-1 was also estimated from the 
slope of the linear region ([S] << KM app) of the Henri-Michaelis-Menten plot. The 
nearly 10-fold lower kcat app/KM app value of the T238A mutant relative to wild-type 
HsPYCR1 with L-P5C is consistent with the proposed role of Thr238 hydrogen 
bonding to the substrate. 
 The binding order of L-P5C and NADPH to HsPYCR1 was evaluated by 
product(s) inhibition studies.35 The inhibition of HsPYCR1 by NADP+ was first 
examined by varying NADPH and holding DL-P5C constant. Table 2.2 shows that 
increases in NADP+ concentration (0-15 mM) results in a decreasing trend in 
kcatapp and a slightly lower apparent KM. With increasing NADP+ concentration, 
trends of both increasing values of (1/KMapp) and (1/Vlim) support the model of 
mixed inhibition by NADP+ (Table 2.2 and Figure 2.8, A and B).35 Global fitting of 
the data to a mixed inhibition model provided estimates of apparent competitive 
(KIC) and uncompetitive (KIU) inhibition constants for NADP+ (Table 2.2). L-proline 
inhibition of HsPYCR1 was evaluated by varying DL-P5C (0-5500 µM) and 







Figure 2.8. Product(s) inhibition kinetics of wild-type HsPYCR1. Henri-Michaelis-
Menten plots of assays performed at (A) different NADP+ concentrations (0-15 
mM) while varying NADPH and holding DL-P5C constant (5000 µM) and (C) at 
different L-proline concentrations (0-5 mM) while varying DL-P5C and holding 
NADPH constant (500 µM). Hanes-Woolf plots of the data in panels B and D for 
inhibition of HsPYCR1 by (A) NADP+ and (C) L-proline, respectively.  Data 
plotted as (mean ± SD) of n=3 technical replicates with non-linear least-squares 
fits to the Henri-Michaelis-Menten equation and linear regression fits to the 
Hanes-Woolf equation using SigmaPlot 12.0. 
 








(kcat app/KM app ) 
(M-1 s-1) KIC 
app (mM) KIU app (mM) 
0 587 ± 92 22.7 ± 0.2 (38.7 ± 6.1) x 103 
8.28 ± 1.36d 3.92 ± 0.64d 5 426 ± 91  9.7 ± 1.1 (22.7 ± 5.5) x 10
3 
10 501 ± 98  7.1 ± 0.8 (14.1 ± 3.2) x 103 
15 284 ± 30  4.6 ± 0.2 (16.1 ± 1.9) x 103 
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aValue ± Std error are reported for the apparent best-fit parameters of non-linear least-
squares fit to the Henri-Michaelis-Menten equation using SigmaPlot 12.0 (version 
12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=3 technical 
replicates.  
bFinal enzyme concentration of 0.06 µM was used for the assays.  
cDL-P5C concentration was fixed at 5000 µM while NADPH concentration was varied 0-
580 µM. 
dApparent inhibition constants, KICapp (competitive inhibition) and KIUapp (=α(KICapp)) 
(uncompetitive inhibition) were estimated by fitting data (25-580 µM NADPH) to the 
Mixed Inhibition (full) model with α=0.4728 using the Enzyme Kinetics Wizard Add-In on 
SigmaPlot 12.0 (version 12.0.0.182, Systat Software). 
 
 
aValue ± Std error are reported for the apparent best-fit parameters of non-linear least-
squares fit to the Henri-Michaelis-Menten equation using SigmaPlot 12.0 (version 
12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=3 technical 
replicates.  
bFinal enzyme concentration of 0.06 µM was used for the assays.  
cNADPH concentration was fixed at 500 µM while DL-P5C concentration was varied 0-
5500 µM. 
dReported value is the concentration of L-P5C, which is assumed to be half the 
concentration of the DL-P5C racemic mixture. 
eApparent competitive inhibition constant, KICapp, was estimated by fitting data (250-5500 
µM DL-P5C) to a competitive inhibition (full) model using the Enzyme Kinetics Wizard 
Add-In on SigmaPlot 12.0 (version 12.0.0.182, Systat Software). 
 
(0-5 mM), the value of KMapp increased whereas Vlim remained fairly unchanged 
consistent with competitive inhibition by L-proline.35 Best fits of the data to a 
competitive inhibition model yielded an apparent KIC value of 145 µM L-proline 
(Table 2.3). Hanes-Woolf plots of the NADP+ and L-proline inhibition data also 




app (µM)d kcat app (s-1) (kcat 
app/KM app ) 
(M-1 s-1) KIC 
app (mM) 
0 1463 ± 176 17.4 ± 1.0 (11.9 ± 1.6) x 103 
2.61 ± 0.25e 
1 1664 ± 219 17.0 ± 1.1 (10.2 ± 1.5) x 103 
2.5 1725 ± 210 15.7 ± 0.9   (9.1 ± 1.2) x 103 
5 2898 ± 396 12.6 ± 1.0   (4.3 ± 0.7) x 103 
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show linear regressions consistent with mixed and competitive inhibition, 
respectively (Figure 2.8, B and D). In these plots, linear trends converging at a 
common negative horizontal axis intercept with an increasing slope (1/Vlim) effect 
(Figure 2.8B) indicates NADP+ is a mixed noncompetitive inhibitor35 of HsPYCR1 
with respect to NADPH. Parallel linear trends with an increasing vertical axis 
intercept (KMapp/Vlim) effect (Figure 2.8D) indicate L-proline is a competitive 
inhibitor35 with respect to L-P5C. Taken together, these modes of inhibition by 
each product ligand support a sequential-ordered binding mechanism of L-P5C 
binding first to the enzyme followed by NADPH. 
DISCUSSION 
 In this work, we describe the first high-resolution structures of a human PYCR 
isozyme. Notably, the complex of HsPYCR1 with NADPH and the L-P5C/L-Pro 
analog of L-THFA is the first structure of a relevant ternary complex for any 
P5CR. This structure provides new information about the mechanism of the 
enzyme. Considering it to represent the E─NADPH─L-P5C Michaelis complex, 
the structure implies that L-P5C binds with its ring approximately parallel to the 
nicotinamide ring with C2 of L-P5C close to C4 of NADPH, as expected for a 
hydride-transfer mechanism. The donor-acceptor distance inferred from the 
structure is 3.7 Å, whereas the expected distance in the transition state for 
hydride-transfer reactions is ~2.7 Å.36 It is possible that fluctuations of the 
enzyme are needed to achieve the transition state from the configuration 
represented in the crystal structure. Alternatively, our structure represents the 
product complex (E─NADP+─L-Pro) rather than the substrate complex. 
 The structure also immediately suggests the stereochemistry of hydride  
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transfer. Because the B-side of the nicotinamide of NADPH contacts the implied 
substrate, HsPYCR1 is predicted to catalyze the transfer of the pro-4S hydrogen 
to L-P5C. This assignment agrees with a previous prediction based on 
superimposing separate structures of P5CR─NADP+ and P5CR─L-Pro 
complexes.13 To date, we are not aware of any reports of the determination of the 
stereochemistry of P5CR by kinetic isotope effect measurements. 
 It has been suggested that a conserved Thr or Ser in the active site functions 
as a general acid that donates a proton to the imine nitrogen of L-P5C.13 Ser and 
Thr are not usually considered to be general acid/base catalysts due to their high 
pKa values. It is possible for the protein micro-environment to lower the pKa of an 
active site residue so it can function as a general acid, as occurs for Lys199 of 
the NAD-malic enzyme37 and Arg69 of Sin resolvase.38 However, the active site 
of HsPYCR1 does not have a preponderance of positively charged residues that 
could depress the pKa of the proposed Thr residue. We mutated Thr238, which 
forms a hydrogen bond to the imine nitrogen of L-proline in our structure (Fig. 
2.5A). The mutation to Ala did not substantially diminish the kcat app, suggesting 
that Thr238 is not essential for catalysis, whereas the kcat app/KM app of T238A 
mutant enzyme with varied L-P5C was 10-fold lower relative to wild type, 
indicating that the loss of Thr238 impacts L-P5C binding. The observed  T238A 
mutant’s kcat app as 14 s-1 may be due to a small acid or proton donor such as a 
water molecule that could enter and occupy the space devoid of steric bulk from 
the side chain of Thr at residue 238, thus allowing a proton abstraction by the 
imine nitrogen of L-P5C that affords some catalytic activity to occur. To rule out 
this possibility and to determine if the polarity present in the side chain hydroxyl 
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group of Thr is critical for catalytic activity, a prudent course of action would be an 
isosteric mutation that removes the polar side chain group as in a Thr238Val 
mutation. For reference, we note that mutation of Lys199 to Ala in the NAD-malic 
enzyme decreases Vlim by 105-fold magnitude.37 Thus, it is concluded that Thr238 
does not function as the general acid in HsPYCR1 but appears to have important 
interactions with the imine nitrogen of L-P5C, as corroborated by the structural 
and kinetic data. 
 Product(s) inhibition kinetics studies revealed L-Pro behaving as a 
competitive inhibitor and NADP+ behaving as a mixed inhibitor against wild-type 
HsPYCR1 enzyme, which is diagnostic of a sequential binding order with L-P5C 
binding first to the enzyme followed by NADPH. This binding order is atypical of 
the general family of dehydrogenase enzymes, i.e. lactate dehydrogenase, which 
first binds NAD+/NADH before the second substrate.39 The proposed binding 
order is supported by the X-ray crystal structure of HsPYCR1 in complex with L-
THFA and NADPH (Fig. 2.6), which shows that L-THFA, an analog of both L-
proline and L-P5C, is buried within the active site. The binding site for L-THFA 
would be obstructed if NADPH were to bind first, thus supporting the sequential 
binding order of the smaller L-P5C molecule followed by binding of the larger 
NAD(P)H molecule. These findings are consistent with previous studies in which 
bacterial (S. pyogenes) and plant (A. thaliana) P5CRs were also proposed to 
follow a sequential-ordered binding mechanism with L-P5C binding prior to 
NAD(P)H.13,40 Having the sequential-ordered binding mechanism of HsPYCR1 
established will help guide development of new inhibitors and/or substrate 
analogs as molecular probes for modulating HsPYCR1 activity. 
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 The noncanonical dinucleotide-binding site of HsPYCR1 proposed by Meng et 
al. (2006)16 is not supported by the experimental data. The original NAD(P)H 
cofactor ligand density was poor, the difference density was uniformly and 
strongly negative, and the PDB_REDO pipeline essentially removed the 
contribution of the cofactor and Glu ligands by elevating their temperature factors 
to non-physical values. The NAD(P)H cofactor also had poor geometry and 
formed several bad contacts, all of which are inconsistent with a well-defined 
ligand-binding site. 
 This is in sharp contrast to the highly conserved nature of dinucleotide-binding 
sites in other Rao-Rossmann fold proteins. First reported in the 1970s, the Rao-
Rossmann fold consists of repeated βα motifs and comprises six (typically) 
parallel β-strands with α-helices packed on either side of the β-sheet.30,41,42 The 
dinucleotide binds with an extended conformation in the cleft found at the C-
termini of the strands, with the pyrophosphate interacting with the N-terminus of 
αA and the Gly-rich β1-αA loop. Each base interacts with the opposing faces of 
the β-sheet, forming a network of polar and non-polar interactions. A previous 
analysis of 102 Rao-Rossmann fold protein structures representing 43 enzymes 
and 40 species demonstrated a remarkably high consistency of the binding site 
structure and cofactor conformation.33 In fact, the binding site is so consistent that 
a conserved water molecule bridging the Gly-rich β1-αA loop and the 
pyrophosphate could effectively be considered part of the dinucleotide-binding 
motif.33 Indeed, this water molecule is present in our structures (Fig. 2.4). In this 
context, it is surprising that a completely novel dinucleotide-binding mode for 
HsPYCR1 was proposed with almost no discussion of the important way in which  
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the site deviated from conventional wisdom. 
 Strong evidence from other structural studies also points to the mistaken 
nature of the unconventional binding site16 of Meng et al. (2006). The core 
structural elements of HsPYCR1 are superimposable with those of available 
bacterial P5CR structures, and the dinucleotide ligands in the bacterial enzyme 
structures conform to the classic paradigm for Rao-Rossmann fold proteins.13 
Furthermore, the PDB contains an unpublished human PYCR1 structure (PDB 
code 2IZZ) that contains NAD+ bound in the same location as our structure and 
bacterial P5CR structures. All of the above structural work also supports the 
conclusion that the binding site described by Meng et al. (2006)16 is incorrect. 
 Incorrect ligand-binding site notwithstanding, there are positive aspects to the 
work of Meng et al. (2006). They were the first to establish that the fold of 
HsPYCR1 is consistent with homologous enzymes. Also, they documented the 
oligomeric state as a pentamer of intertwined dimers. These contributions to the 
literature remain valid. Nevertheless, the record must be corrected regarding the 
erroneous NAD(P)H-binding-site, and we recommend that correction take place. 
We also recommend that the recent in silico analysis of cutis laxa HsPYCR1 
mutants, which is based on the incorrect active site, be reevaluated with the 
correct HsPYCR1 structure.43 
 Our results might explain why the canonical dinucleotide-binding site was 
unoccupied in the Meng et al. (2006) structures. To obtain complexes, Meng et 
al. (2006) soaked crystals in 0.3 mM NADH or NADPH.16 Our measurements with 
HsPYCR1 indicate a KM app of 0.07 mM for NADH and 0.3 mM for NADPH (Table 
2.1). Thus, the dinucleotide concentrations used by Meng et al. (2006)16 may not  
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have been high enough for saturation. 
 Many examples of incorrectly built structures or misplaced ligands have 
appeared in the crystallographic literature over the past few years.44,45,46,47 Some 
have arisen from updates in genomic databases that revealed older structures 
solved with incorrect sequences.44,48,49 Others are due to the very large number 
of new structures appearing each year coupled with the fact that many of them 
come from laboratories with little crystallographic experience.50 Further, there is 
pressure now to produce faster, more numerous, and more novel results in 
science,51 and ligand-binding density would be an important source of novelty. 
Finally, reviewers are often judging structures without access to coordinate files 
and electron density maps, making detailed verification of ligands difficult. Taken 
together, this leads to a risk of inappropriate ligand placement. 
 It has been suggested that the risk of errors in ligand placement could be 
mitigated by utilizing currently available structural tools.52,53 These tools 
emphasize the inspection of electron density, stereochemistry, and ligand 
environment.45,52 We suggest that the historical context of the ligand site also be 
considered. In the case of a family like Rao-Rossmann dinucleotide-binding 
proteins, which contain a highly conserved fold, strong proof should be required 
of the authors before proposing a completely new binding site. 
REFERENCES 
[1] Phang, J. M. (1985) The regulatory functions of proline and pyrroline-5-
carboxylic acid, Curr Top Cell Regul 25, 91-132. 
[2] Adams, E., and Frank, L. (1980) Metabolism of proline and the 
hydroxyprolines, Annu Rev Biochem 49, 1005-1061. 
39 
[3] Tanner, J. J. (2008) Structural biology of proline catabolism, Amino Acids 35, 
719-730. 
[4] De Ingeniis, J., Ratnikov, B., Richardson, A. D., Scott, D. A., Aza-Blanc, P., 
De, S. K., Kazanov, M., Pellecchia, M., Ronai, Z. e., Osterman, A. L., and 
Smith, J. W. (2012) Functional Specialization in Proline Biosynthesis of 
Melanoma, PLoS ONE 7, e45190 EP -. 
[5] Reversade, B., Escande-Beillard, N., Dimopoulou, A., Fischer, B., Chng, S. 
C., Li, Y., Shboul, M., Tham, P. Y., Kayserili, H., Al-Gazali, L., Shahwan, 
M., Brancati, F., Lee, H., O'Connor, B. D., Schmidt-von Kegler, M., 
Merriman, B., Nelson, S. F., Masri, A., Alkazaleh, F., Guerra, D., Ferrari, 
P., Nanda, A., Rajab, A., Markie, D., Gray, M., Nelson, J., Grix, A., 
Sommer, A., Savarirayan, R., Janecke, A. R., Steichen, E., Sillence, D., 
Hausser, I., Budde, B., Nürnberg, G., Nürnberg, P., Seemann, P., Kunkel, 
D., Zambruno, G., Dallapiccola, B., Schuelke, M., Robertson, S., Hamamy, 
H., Wollnik, B., Van Maldergem, L., Mundlos, S., and Kornak, U. (2009) 
Mutations in PYCR1 cause cutis laxa with progeroid features, Nat Genet 
41, 1016-1021. 
[6] Phang, J. M., Liu, W., and Zabirnyk, O. (2010) Proline metabolism and 
microenvironmental stress, Annu Rev Nutr 30, 441-463. 
[7] Nilsson, R., Jain, M., Madhusudhan, N., Sheppard, N. G., Strittmatter, L., 
Kampf, C., Huang, J., Asplund, A., and Mootha, V. K. (2014) Metabolic 
enzyme expression highlights a key role for MTHFD2 and the 
mitochondrial folate pathway in cancer, Nat Commun 5, 3128. 
[8] Ou, R., Zhang, X., Cai, J., Shao, X., Lv, M., Qiu, W., Xuan, X., Liu, J., Li, Z., 
and Xu, Y. (2016) Downregulation of pyrroline-5-carboxylate reductase-2 
induces the autophagy of melanoma cells via AMPK/mTOR pathway, 
Tumour Biol 37, 6485-6491. 
[9] Loayza-Puch, F., Rooijers, K., Buil, L. C., Zijlstra, J., Oude Vrielink, J. F., 
Lopes, R., Ugalde, A. P., van Breugel, P., Hofland, I., Wesseling, J., van 
Tellingen, O., Bex, A., and Agami, R. (2016) Tumour-specific proline 
vulnerability uncovered by differential ribosome codon reading, Nature 
530, 490-494. 
[10] Phang, J. M., Liu, W., Hancock, C., and Christian, K. J. (2012) The proline 
regulatory axis and cancer, Front Oncol 2, 60. 
[11] Zeng, T., Zhu, L., Liao, M., Zhuo, W., Yang, S., Wu, W., and Wang, D. (2017) 
Knockdown of PYCR1 inhibits cell proliferation and colony formation via 
cell cycle arrest and apoptosis in prostate cancer, Med Oncol 34, 27. 
[12] Nakayama, T., Al-Maawali, A., El-Quessny, M., Rajab, A., Khalil, S., Stoler, 
Joan M., Tan, W.-H., Nasir, R., Schmitz-Abe, K., Hill, R. S., Partlow, 
40 
Jennifer N., Al-Saffar, M., Servattalab, S., LaCoursiere, Christopher M., 
Tambunan, Dimira E., Coulter, Michael E., Elhosary, Princess C., Gorski, 
G., Barkovich, A. J., Markianos, K., Poduri, A., and Mochida, 
Ganeshwaran H. (2015) Mutations in PYCR2, Encoding Pyrroline-5-
Carboxylate Reductase 2, Cause Microcephaly and Hypomyelination, The 
American Journal of Human Genetics 96, 709-719. 
[13] Nocek, B., Chang, C., Li, H., Lezondra, L., Holzle, D., Collart, F., and 
Joachimiak, A. (2005) Crystal structures of delta1-pyrroline-5-carboxylate 
reductase from human pathogens Neisseria meningitides and 
Streptococcus pyogenes, J Mol Biol 354, 91-106. 
[14] Ruszkowski, M., Nocek, B., Forlani, G., and Dauter, Z. (2015) The structure 
of Medicago truncatula δ(1)-pyrroline-5-carboxylate reductase provides 
new insights into regulation of proline biosynthesis in plants, Front Plant 
Sci 6, 869. 
[15] Franklin, M. C., Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M., Gary, 
E., Hillerich, B., Yao, Z. K., Carlier, P. R., Totrov, M., and Love, J. D. 
(2015) Structural genomics for drug design against the pathogen Coxiella 
burnetii, Proteins 83, 2124-2136. 
[16] Meng, Z., Lou, Z., Liu, Z., Li, M., Zhao, X., Bartlam, M., and Rao, Z. (2006) 
Crystal Structure of Human Pyrroline-5-carboxylate Reductase, Journal of 
Molecular Biology 359, 1364-1377. 
[17] Rao, S. T., and Rossmann, M. G. (1973) Comparison of super-secondary 
structures in proteins, J Mol Biol 76, 241-256. 
[18] Kleiger, G., and Eisenberg, D. (2002) GXXXG and GXXXA motifs stabilize 
FAD and NAD(P)-binding Rossmann folds through C(alpha)-H... O 
hydrogen bonds and van der waals interactions, J Mol Biol 323, 69-76. 
[19] Christensen, E. M., Patel, S. M., Korasick, D. A., Campbell, A. C., Krause, K. 
L., Becker, D. F., and Tanner, J. J. (2017) Resolving the cofactor-binding 
site in the proline biosynthetic enzyme human pyrroline-5-carboxylate 
reductase 1, Journal of Biological Chemistry 292, 7233-7243. 
[20] McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, 
L. C., and Read, R. J. (2007) Phaser crystallographic software, J Appl 
Crystallogr 40, 658-674. 
[21] Schuck, P. (2000) Size-distribution analysis of macromolecules by 
sedimentation velocity ultracentrifugation and lamm equation modeling, 
Biophys J 78, 1606-1619. 
41 
[22] Merrill, M. J., Yeh, G. C., and Phang, J. M. (1989) Purified human erythrocyte 
pyrroline-5-carboxylate reductase. Preferential oxidation of NADPH, 
Journal of Biological Chemistry 264, 9352-9358. 
[23] Szoke, A., Miao, G. H., Hong, Z., and Verma, D. P. (1992) Subcellular 
location of delta-pyrroline-5-carboxylate reductase in root/nodule and leaf 
of soybean, Plant Physiol 99, 1642-1649. 
[24] Deutch, C. E., Klarstrom, J. L., Link, C. L., and Ricciardi, D. L. (2001) 
Oxidation of l-Thiazolidine-4-Carboxylate by Δ1-Pyrroline-5-Carboxylate 
Reductase in Escherichia coli, Current Microbiology 42, 442-446 LA - 
English. 
[25] Williams, I., and Frank, L. (1975) Improved chemical synthesis and 
enzymatic assay of delta-1-pyrroline-5-carboxylic acid, Anal Biochem 64, 
85-97. 
[26] Moxley, M. A., Sanyal, N., Krishnan, N., Tanner, J. J., and Becker, D. F. 
(2014) Evidence for hysteretic substrate channeling in the proline 
dehydrogenase and Δ1-pyrroline-5-carboxylate dehydrogenase coupled 
reaction of proline utilization A (PutA), J Biol Chem 289, 3639-3651. 
[27] Beer. (1852) Bestimmung der Absorption des rothen Lichts in farbigen 
Flüssigkeiten, Annalen der Physik 162, 78-88. 
[28] Lambert, J. H., and Klett, E. (1760) Photometria sive de mensura et gradibus 
luminis, colorum et umbrae, Klett. 
[29] Bouguer, P. (1729) Essai d'optique sur la gradation de la lumière, chez 
Claude Jombert, ruë S. Jacques, au coin de la ruë des Mathurins, à l …. 
[30] Adams, M. J., Ford, G. C., Koekoek, R., Lentz, P. J., McPherson, A., 
Rossmann, M. G., Smiley, I. E., Schevitz, R. W., and Wonacott, A. J. 
(1970) Structure of lactate dehydrogenase at 2-8 A resolution, Nature 227, 
1098-1103. 
[31] Rossmann, M. G., Moras, D., and Olsen, K. W. (1974) Chemical and 
biological evolution of nucleotide-binding protein, Nature 250, 194-199. 
[32] Krissinel, E., and Henrick, K. (2007) Inference of macromolecular assemblies 
from crystalline state, J Mol Biol 372, 774-797. 
[33] Bottoms, C. A., Smith, P. E., and Tanner, J. J. (2002) A structurally 
conserved water molecule in Rossmann dinucleotide-binding domains, 
Protein Sci 11, 2125-2137. 
[34] Pemberton, T. A., Still, B. R., Christensen, E. M., Singh, H., Srivastava, D., 
and Tanner, J. J. (2012) Proline: Mother Nature's cryoprotectant applied to 
protein crystallography, Acta Crystallogr D Biol Crystallogr 68, 1010-1018. 
42 
[35] Cornish-Bowden, A. (2012) Fundamentals of enzyme kinetics, 4th 
completely rev. and greatly enl. ed., Wiley-VCH, Weinheim. 
[36] Hammes-Schiffer, S. (2002) Comparison of hydride, hydrogen atom, and 
proton-coupled electron transfer reactions, Chemphyschem 3, 33-42. 
[37] Liu, D., Karsten, W. E., and Cook, P. F. (2000) Lysine 199 is the general acid 
in the NAD-malic enzyme reaction, Biochemistry 39, 11955-11960. 
[38] Keenholtz, R. A., Mouw, K. W., Boocock, M. R., Li, N. S., Piccirilli, J. A., and 
Rice, P. A. (2013) Arginine as a general acid catalyst in serine 
recombinase-mediated DNA cleavage, J Biol Chem 288, 29206-29214. 
[39] Shoemark, D. K., Cliff, M. J., Sessions, R. B., and Clarke, A. R. (2007) 
Enzymatic properties of the lactate dehydrogenase enzyme from 
Plasmodium falciparum, The FEBS journal 274, 2738-2748. 
[40] Forlani, G., Giberti, S., Berlicki, L., Petrollino, D., and Kafarski, P. (2007) 
Plant P5C reductase as a new target for 
aminomethylenebisphosphonates, J Agric Food Chem 55, 4340-4347. 
[41] Buehner, M., Ford, G. C., Olsen, K. W., Moras, D., and Rossman, M. G. 
(1974) Three-dimensional structure of D-glyceraldehyde-3-phosphate 
dehydrogenase, J Mol Biol 90, 25-49. 
[42] Branden, C. I., and Tooze, J. (1991) Introduction to protein structure, Chapter 
10, Garland Publishing Inc., New York. 
[43] Sang, P., Hu, W., Ye, Y.-J., Li, L.-H., Zhang, C., Xie, Y.-H., and Meng, Z.-H. 
(2017) In silico screening, molecular docking, and molecular dynamics 
studies of SNP-derived human P5CR mutants, Journal of Biomolecular 
Structure and Dynamics 35, 2441-2453. 
[44] Stec, B. (2013) Time passes yet errors remain: comments on the structure of 
N10-formyltetrahydrofolate synthetase, Protein Sci 22, 671-674. 
[45] Weichenberger, C. X., Pozharski, E., and Rupp, B. (2013) Visualizing ligand 
molecules in Twilight electron density, Acta Crystallogr Sect F Struct Biol 
Cryst Commun 69, 195-200. 
[46] Weiss, M. S., Diederichs, K., Read, R. J., Panjikar, S., Van Duyne, G. D., 
Matera, A. G., Fischer, U., and Grimm, C. (2016) A critical examination of 
the recently reported crystal structures of the human SMN protein, Hum 
Mol Genet 25, 4717–4725. 
[47] Muller, Y. A. (2013) Unexpected features in the Protein Data Bank entries 
3qd1 and 4i8e: the structural description of the binding of the serine-rich 
repeat adhesin GspB to host cell carbohydrate receptor is not a solved 
issue, Acta Crystallogr Sect F Struct Biol Cryst Commun 69, 1071-1076. 
43 
[48] Celeste, L., Lovelace, L., and Lebioda, L. (2013) Response to Boguslaw 
Stec's letter to the editor of Protein Science, Protein Sci 22, 675-676. 
[49] Celeste, L. R., Chai, G., Bielak, M., Minor, W., Lovelace, L. L., and Lebioda, 
L. (2012) Mechanism of N10-formyltetrahydrofolate synthetase derived 
from complexes with intermediates and inhibitors, Protein Sci 21, 219-228. 
[50] Wlodawer, A., Minor, W., Dauter, Z., and Jaskolski, M. (2013) Protein 
crystallography for aspiring crystallographers or how to avoid pitfalls and 
traps in macromolecular structure determination, FEBS J 280, 5705-5736. 
[51] Edwards, M. A., and Roy, S. (2017) Academic Research in the 21st Century: 
Maintaining Scientific Integrity in a Climate of Perverse Incentives and 
Hypercompetition, Environ Eng Sci 34, 51-61. 
[52] Deller, M. C., and Rupp, B. (2015) Models of protein-ligand crystal 
structures: trust, but verify, J Comput Aided Mol Des 29, 817-836. 
[53] Pozharski, E., Weichenberger, C. X., and Rupp, B. (2013) Techniques, tools 
and best practices for ligand electron-density analysis and results from 
their application to deposited crystal structures, Acta Crystallogr D Biol 
















Kinetic and Structural Characterization of the Enzyme Mechanism 
of wild-type HsPYCR2 and Disease Variants 
 
ABSTRACT  
Pyrroline-5-carboxylate reductase (PYCR) catalyzes the final step of L-proline 
biosynthesis by reducing L-P5C into L-proline using NAD(P)H as the hydride 
donor (Fig. 3.1). In humans, three isoforms (PYCR1, PYCR2, and PYCRL) are 
known. Human PYCR1 and PYCR2 are localized in the mitochondrion and share 
84% amino acid sequence identity, yet interestingly different disease symptoms 
are found in patients that have mutations in PYCR1 or PYCR2. Recent genome-
wide association and clinical studies have revealed that homozygous mutations 
in human PYCR2 lead to postnatal microcephaly and hypomyelination, including 
hypomyelinating leukodystrophy type 10. To uncover biochemical and structural 
insights into human PYCR2, we characterized the steady-state kinetics of wild-
type enzyme along with two mutant variants, Arg119Cys and Arg251Cys, that 
were previously identified in patients with microcephaly and hypomyelination. 
Here we establish the substrate binding order for the human PYCR2 mechanism 
and report the biochemical penalties of the PYCR2 disease variants. Structural 
insights into human PYCR2 were also inferred by examining the X-ray crystal 
structure of human PYCR1. From this model, Arg119 and Arg251 are predicted 
to be important for the catalytic activity and structural stability of PYCR2, 
respectively, which supports our kinetic assays showing a 164-fold loss in 
catalytic activity for the Arg119Cys mutant relative to wild-type enzyme. The 
Arg251Cys mutation has a profound effect on the thermostability and secondary 
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structure of human PYCR2 as determined by fluorescence-based thermal shift 
assays and circular dichroism, respectively. The PYCR2 disease variants are 
concluded to impair PYCR2 function in patients by significantly lowering catalytic 
activity (Arg119Cys) and stability (Arg251Cys).  
 
Figure 3.1. Enzymatic reactions of L-proline metabolism in the mitochondrion. 
Structural images are PyMol renderings of the following X-ray crystal structures:  
dimeric TtPRODH (PDB code 2EKG), dimeric HsPYCR1 (PDB code 5UAV), 
tetrameric HsALDH4A1 (PDB code 4OE5), and monomer of the L-glutamyl-γ-5-
phosphate reductase domain of HsALDH18A1 (PDB code 2H5G). 
 
INTRODUCTION  
Delta-1-pyrroline-5-carboxylate reductases (PYCRs or P5CRs) have been 
identified as important housekeeping enzymes of L-proline (L-Pro) biosynthesis 
and are broadly distributed across all three domains of life (eukaryota, bacteria, 
and archaea).1 L-proline is synthesized from L-glutamate by the sequential action 
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of L-Δ1-pyrroline-5-carboxylate synthase (a.k.a. aldehyde dehydrogenase 18A1, 
ALDH18A1) and PYCR as shown in Fig. 3.1. L-proline is converted back to L-
glutamate via L-proline dehydrogenase (PRODH) and L-glutamic-γ-
semialdehyde dehydrogenase (GSALDH) (a.k.a. aldehyde dehydrogenase 4A1, 
ALDH4A1) as shown in Fig. 3.1. Both pathways share the intervening L-pyrroline-
5-carboxylate (L-P5C)/L-glutamic semialdehyde (L-GSAL) equilibrium step.  
In terms of the current state of knowledge for human PYCR (HsPYCR, EC 
1.5.1.2), a 2012 study on L-proline biosynthesis from melanoma tissue extracts 
characterized three separate human genes encoding isozymes PYCR1, PYCR2, 
and PYCRL (a.k.a. PYCR3).2 Subcellular localization studies identified HsPYCRL 
as a cytosolic enzyme whereas HsPYCR1 and HsPYCR2 were identified as 
mitochondrial enzymes.2 Pairwise global sequence alignment3 of HsPYCR1 
(NCBI ref seq NP_008838.2, UniProtKB P32322) and HsPYCR2 (NCBI ref seq 
NP_037460.2, UniProtKB Q96C36) indicates 84.4% amino acid sequence 
identity between the two proteins. To date, structural knowledge of PYCR 
consists of 20 total X-ray crystal structures from seven organisms (Homo 
sapiens, Bacillus cereus, Coxiella burnetii, Streptococcus pyogenes, Neisseria 
meningitides, Plasmodium falciparum, and Medicago truncatula) deposited in the 
Research Collaboratory for Structural Bioinformatics-Protein Data Bank.4 Thus 
far, two sets of X-ray crystal structures of human PYCR have been reported in 
the literature.5, 6 The most recent is a 1.85 Å X-ray crystal structure determined by 
Christensen et al. (2017) of the ternary complex of HsPYCR1 + NADPH + L-
proline analog, L-tetrahydro-2-furoic acid (L-THFA) (PDB code 5UAV).6 The 
structure by Christensen et al. resolved the location of the enzyme active site with 
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NADPH binding in the canonical Rao-Rossmann motif GXGXXA/G7 at the N-
terminus, which is consistent with known X-ray crystal structures of PYCR from 
plants and bacteria.8 Although progress has been made on the structural and 
functional characterization of HsPYCR1, considerably less is known about 
HsPYCR2, which is the focus of this work. 
L-proline biosynthesis has been implicated in different types of cancers. 
Besides supporting protein synthesis, L-proline biosynthesis has been shown to 
promote tumorigenesis by providing NAD(P)+ redox equivalents to support 
aerobic glycolysis and the oxidative branch of the pentose phosphate pathway.9 
Upregulation of HsPYCR2 has been found in different cancers such as 
melanoma, breast, prostate, esophageal tumors, lung metastasis, Kaposi’s 
sarcoma and primary effusion lymphoma, and cervical cancer.2,10,11,12,13 In a 
mass spectrometry-based screening of metabolites in tissue sections from 256 
esophageal squamous cell carcinoma (ESCC) patients, Sun et al. (2019) found a 
significant upregulation of L-Pro metabolism in the cancer region compared to the 
normal epithelium and muscle regions.11 Immunohistochemistry staining of the 
ESCC tissue sections identified HsPYCR2 as the most enriched metabolic 
enzyme in the cancer region, consistent with increased L-proline found in the 
same tissue region.11 In two separate human melanoma cell lines, tumor cell 
death was induced by silencing HsPYCR2 expression, indicating a critical role for 
HsPYCR2 in cancer cells.14   
More recently, Choi et al. (2020) verified a role for HsPYCR2 in Kaposi’s 
sarcoma cells. With GST-tag pull down assays and mass spectrometry analysis, 
the authors showed that Kaposi’s sarcoma-associated herpesvirus K1 
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oncoprotein binds endogenous human PYCR2 to commandeer L-proline 
biosynthesis for increased intracellular L-Pro concentration that promotes in vitro 
3D spheroid culture and in vivo tumorigenesis.12 From a kinetic standpoint, the 
authors also demonstrated that the presence of viral K1 protein not only activated 
and enhanced PYCR2 enzymatic affinity with L-P5C substrate with a 4-fold 
decrease in the KM value, but also the viral K1 protein curtailed L-Pro product- or 
ATP-mediated competitive inhibition of PYCR2.12 In the clinical setting of one 
hospital in Bangkok, Thailand, Keeratichamroen et al. (2020) recently conducted 
a pilot study examining changes in disease-relevant proteins in 31 patients with 
human papilloma virus (HPV)-associated cervical cancer compared with 16 
healthy control patients using immunoaffinity-depleted serum processing of blood 
samples followed by liquid chromatography mass spectrometry analysis.13 
Through the use of capillary electrophoresis-based western blot analysis and 
receiver operating characteristic curves data analysis to quantify serum levels of 
the candidate protein biomarkers for the detection of HPV-associated cervical 
cancer, the authors identified high expression levels of PYCR2 in patients with 
advanced-stage III-IV cervical cancer compared to either patients with early-
stage I-II cervical cancer or with HPV positive normal controls, in a statistically 
significant manner.13 In lieu of the current standard of practice for cervical cancer 
screening tests including the Papanicolaou smear, visual inspection with acetic 
acid, HPV DNA testing, and liquid-based cytology, the authors conjecture that 
this unprecedented association between PYCR2 expression levels and cervical 
cancer in tandem with the quantification of five other serum protein biomarkers 
(A1AT, TTR, ApoA-I, VDBP, and MMRN1) can serve as a minimally invasive yet 
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highly sensitive and specific screen for the detection of HPV-associated cervical 
cancer.13 
Autosomal recessive disorders of HsPYCR1 and HsPYCR2 have been 
specifically linked to hypoprolinemia, cutis laxa and progeroid syndrome, 
microcephaly, and neurological disorders. More specifically, mutations in 
HsPYCR1 generally lead to cutis laxa type IIB (OMIM # 612940)15 whereas 
mutations in HsPYCR2 are uniquely linked to genetic hypomyelinating 
leukodystrophy type 10 with microcephaly (OMIM # 616420).16,17,18 Thus, it has 
been suggested that PYCR1 mutations are most strongly associated with skin 
disorders while PYCR2 mutations appear more prominent in neurological 
disorders.18 In a study by Zaki et al. (2016) of HsPYCR2 mutations in patients 
with lethal microcephaly, loss of HsPYCR2 was proposed to impair mitochondria 
function and disrupt oxidative balance, namely NAD(P)+ levels.18 Thus it appears 
HsPYCR2 not only helps drive the cellular supply of L-proline, but it also performs 
redox cycling of NAD(P)H/NAD(P)+ to support cellular growth, which can have 
profound effects in different disease contexts such as in cancers with upregulated 
HsPYCR2 or neurological disorders associated with HsPYRC2 variants. 
The need to investigate HsPYCR2 and disease variants stems in part from a 
study by Nakayama et al. (2015) which showed that two families of human 
patients were affected by the same allelic autosomal-recessive condition in the 
PYCR2 gene.17 Two HsPYCR2 variants, R119C and R251C, were each identified 
by a genome-wide association study to have a statistically significant linkage to 
the observed neurological traits of hypomyelination and microcephaly in the 
patients. These findings, along with the growing recognition of HsPYCR2 being 
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implicated in different cancers (non-small cell lung cancer, viral-related 
hepatocellular carcinoma, papillary renal cell carcinoma, melanoma, breast and 
prostate cancers, and esophageal squamous cell carcinoma, Kaposi’s sarcoma, 
and cervical cancer)19,20,21,14,9,11,12,13 motivated our investigation of the kinetic 
mechanism of wild-type HsPYCR2 and the biochemical penalties of the clinically 
relevant R251C and R119C mutations on HsPYCR2 function. Here we report the 
steady-state kinetic parameters of HsPYCR2 wild-type and mutants R251C and 
R119C along with thermostability and secondary structure analysis. Product(s) 
inhibition studies of wild-type HsPYCR2 indicate a sequential-order binding 
mechanism with L-P5C binding first. 
MATERIALS AND METHODS.  
Materials and Reagents  
 Milli-Q Ultrapure water was used for all experiments. The following reagents 
were purchased from Millipore-Sigma:  DL-5-hydroxylysine hydrochloride, sodium 
metaperiodate, Dowex 50WX4 hydrogen form (200-400 mesh) cation exchange 
resin, NaH2PO4, ε-amino-N-caproic acid, N-tosyl-L-phenylalanine chloromethyl 
ketone, bovine serum albumin, nicotinamide adenine dinucleotide phosphate 
reduced form (NADPH), nicotinamide adenine dinucleotide reduced form 
(NADH), and ammonium fluoride (NH4F). The following reagents were from 
Fisher Scientific:  LB Agar Miller, ampicillin, yeast extract, NaOH, NaCl, 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), and ethylenediamine 
tetraacetic acid (EDTA) disodium salt. Glycerol and tryptone were purchased 
from Research Products International. Reagents β-octyl-D-glucopyranoside (β-
OG) and L-proline were from Combi-Blocks. Ethanol (190- or 200-proof) was 
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from Decon Labs. Tris(hydroxymethyl)aminomethane (Tris), glycine, isopropyl β-
D-thiogalactopyranoside (IPTG), phenylmethylsulfonyl fluoride (PMSF), leupeptin 
hemisulfate, and NAD+ were purchased from Gold Biotechnology. Imidazole and 
(O)2-aminobenzaldehyde (o-AB) were purchased from Acros Organics, and 
hydrochloric acid (HCl) 34-37% OmniTrace  was purchased from EMD-Millipore.  
DL-P5C synthesis  
DL-P5C was synthesized according to the protocol by Williams and Frank,22 
which involved the metaperiodation of DL-5-hydroxylysine hydrochloride at 4 °C 
with the reaction product purified by Dowex 50WX4 cation exchange column 
chromatography using 1 M HCl to elute the fractions of DL-P5C. Synthesized DL-
P5C was quantified using the o-AB assay in which DL-P5C and o-AB react to 
form a yellow conjugate that is measured at 443 nm (ε443 = 2590 M-1 cm-1).23 DL-
P5C stock solutions were stored in 1 M HCl at 4 °C. DL-P5C as the main reaction 
product was confirmed by liquid chromatography-electrospray ionization-multiple 
reaction monitoring (LC-ESI-MRM) mass spectrometry. Additional details 
concerning the synthesis and mass spectrometry characterization of DL-P5C are 
provided in Appendix A. 
Site-Directed Mutagenesis of HsPYCR2  
The DNA sequence encoding human (Homo sapiens) PYCR2 transcript 
variant 1 (NCBI RefSeq NM_013328.3) was subcloned into the pKA8H vector at 
the BamHI and NdeI sites with a N-terminal 8x-Histidine tag (pKA8H/HsPYCR2). 
The pKA8H/HsPYCR2 construct includes an ampicillin resistance marker gene 
and was used as a template for generating mutants R119C and R251C. We used 
a modified protocol from the GeneTailor Site-Directed Mutagenesis System 
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(Invitrogen, Life Technologies) to introduce mutations via overlapping mutagenic 
and non-mutagenic sequence PCR-based reactions.  Primers were generated 
using New England BioLabs NEBaseChanger online tool and Eurofins Genomics 
oligonucleotide primer synthesis services. Forward mutagenic primers consisted 
of an overlapping region, the mutation site, and an extended region, whereas the 
reverse non-mutagenic primers consisted of a complementary overlapping region 
and an extended region. The 21-bp forward 5ʼ-TGGGGGCTTCTGCTCTCTGCT-
3ʼ and reverse 5ʼ-CTCTCTAGAAAGTGCAGGGCG-3ʼ primers were used for 
generating the R251C mutant, and the 29-bp forward 5ʼ-
CAAAGTGATTTGCTGCATGACCAACACAC-3ʼ and 18-bp reverse 5ʼ-
GGGGCTGGCTGGAATGCC-3ʼ primers were used for generating the R119C 
mutant. The triplet codon of the mutation site is underlined in bold for each 
forward primer. The wild-type and mutant constructs were confirmed by DNA 
sequencing of the entire PYCR2 gene insert. 
Expression and purification of HsPYCR2 wild-type and mutants  
The pKA8H/HsPYCR2 constructs for wild-type and the R251C and R119C 
mutant proteins were transformed into E. coli BL21 (DE3) pLysS competent cells 
(Novagen-EMD Millipore Sigma) for recombinant protein expression. Cells were 
grown on LB Agar Miller plates containing 50 μg/ml ampicillin and 34 μg/ml 
chloramphenicol (Chem-Impex International). Starter cultures from the growth 
plates were then made in LB broth, grown overnight and used to inoculate six 1 
L-cultures of Terrific Broth (TB) media (prepared from recipe in Sambrook et al. 
(1989) consisting of tryptone, yeast extract, glycerol, and water)24, which also 
contained 50 μg/ml ampicillin and 34 μg/ml chloramphenicol. The 1-L cultures 
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were grown at 37 °C (180 rpm) until reaching an optical density at 600 nm 
(OD600) ≈ 0.8-1.0. The temperature was then lowered to 18 °C and IPTG (0.4 mM 
final concentration) was added to the cultures to induce recombinant protein 
expression. After induction with IPTG for 10 h (18 °C, 180 rpm), cultures were 
then treated with 100 μg/ml chloramphenicol with continued shaking at 180 rpm 
at 18 °C for an additional 2 h. The chloramphenicol treatment was found to 
improve the solubility of the HsPYCR2 proteins, as chloramphenicol was 
previously reported to enhance chaperone-assisted folding of target proteins.25 
Cells were then harvested by centrifugation (5400 x g) (Avanti J-E High-Speed 
Centrifuge, Beckman Coulter) for 20 min at 4 °C. Cell pellets were stored at -80 
°C. Upon thawing, the cell pellets were resuspended in NPI-5 cell lysis buffer (5 
mM imidazole, 500 mM NaCl, 50 mM NaH2PO4, pH 7.5) containing 500 μM 
Tris(3-hydroxypropyl)phosphine (THPP) reducing agent (Strem Chemicals), 
0.01% TritonX-100 detergent (Amresco), 0.01% Brij-35 polyoxyethylene 
detergent (Santa-Cruz Biotechnology), 10 mM β-OG, and five protease inhibitors 
(ε-amino-N-caproic acid, phenylmethylsulfonyl fluoride, leupeptin hemisulfate, N-
tosyl-L-phenylalanine chloromethyl ketone and N-α-p-tosyl-L-lysine chloromethyl 
ketone). The cell suspension was then sonicated for 5 min with 5 sec on and 15 
sec off pulse settings using a Sonic Dismembrator (Model F 550, Fisher 
Scientific). The resulting cell lysates were centrifuged (30960 x g) for 1.5 h at 4 
°C to obtain the supernatant with the HsPYCR2 protein.  
HsPYCR2 proteins were purified at 4 °C by immobilized metal affinity column 
chromatography using a Ni2+-NTA Superflow resin (Qiagen). A stepwise gradient 
of 5 mM, 60 mM, and 500 mM imidazole in 50 mM NaH2PO4-based column 
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buffers was used to elute the HsPYCR2. Eluted fractions were analyzed by 
sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-PAGE) using 
(β)2-mercaptoethanol (Acros Organics) as a reducing agent. Fractions containing 
HsPYCR2 were pooled and dialyzed (10 kDa molecular weight cutoff (MWCO) 
Dialysis Snakeskin Tubing, ThermoFisher Scientific-Pierce Biotech) into 50 mM 
HEPES (pH 7.5) buffer containing 250 mM NaCl, 0.5 mM EDTA, 500 μM 
THPP, and 10 % (v/v) glycerol. HsPYCR2 proteins were concentrated using an 
ultrafiltration stirrer cell (Model 8050, Amicon, EMD Millipore-Sigma) and a 5 kDa 
PLCC low bind 44.5 mm diameter ultrafiltration disc (EMD Millipore-Sigma) at 4 
°C until the protein solution volume was reduced to approximately 5 ml. Aliquots 
of 1 ml were then placed into 2 ml microtubes and flash-frozen in liquid nitrogen. 
The tube lids were subsequently pierced with fine needle and the frozen samples 
were then further concentrated by freeze-dry vacuum lyophilization (FreeZone 
Bulk Tray Dryer, Labconco) for 3-5 h until the volume was reduced to 250 μl. The 
resulting concentrated protein was next exchanged into fresh 50 mM HEPES (pH 
7.5) buffer as described above by microdialysis using inverted 15kDa MWCO 
Tube-O-Dialyzer tubes (G Biosciences-Geno Technology). Protein concentration 
was quantified by the 660 nm Pierce Protein Dye Assay (ThermoFisher Scientific-
Pierce Biotech) as per manufacturer’s instructions. Finally, all protein samples 
were  flash-frozen in liquid nitrogen in 500 μl aliquots and stored at -80 °C. 
Proteins were analyzed by SDS-PAGE under reducing conditions on a 4-20 % 
gradient gel and visualized using Bio-Safe Coomassie Blue G250 stain (Fig. 3.2). 
The N-terminal 8x-His tag was retained in all the purified HsPYCR2 proteins. A 
more thorough description of methods and procedures used for HsPYCR2 
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protein purification can be found in Appendix B.  
 
Figure 3.2. SDS-PAGE of HsPYCR2 enzymes. HsPYCR2 wild-type (2 µg), and 
R251C (10 µg) and R119C mutant (2 µg) enzymes (each in 50 mM HEPES (pH 
7.5) buffer containing 250 mM NaCl, 0.5 mM EDTA, 10% (v/v) Glycerol, 500 µM 
THPP reducing agent) were mixed with denaturing loading dye buffer (50 mM 
Tris-HCl pH 6.8, 2% SDS, 10% Glycerol, 0.02% Bromophenol Blue, and 10% 
β(2)-Mercaptoethanol). Samples were thermally denatured at 100 oC and then 
loaded onto a 4-20% gradient precast polyacrylamide-Tris-Gly HCl, 10-well MP 
TGX gel (Bio-Rad). After the electrophoresis of the gel, it was stained with Bio-
Safe Coomassie Blue G250 (Bio-Rad). The PageRuler Prestained Protein 
Ladder (ThermoFisher Scientific) was used as reference to estimate the 
molecular weight of the HsPYCR2 wild-type and mutant enzymes (each 
containing an N-terminal (8x)His-tag). The predicted molecular weight of the 
HsPYCR2 polypeptides is 36.1 kDa, which is consistent with the observed band 
(black arrow) immediately above the 35 kDa marker.   
 
Kinetic characterization of HsPYCR2 enzymes  
 Kinetics assays of HsPYCR2 were performed at 37 °C in 0.1 M Tris-HCl (pH  
7.5) reaction buffer containing 0.01% Brij-35 detergent and 1 mM EDTA using a  
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protocol modified from previous studies.26,8,27,28 The catalytic activity of HsPYCR2 
wild-type and mutants R251C and R119C were monitored by measuring the L-
P5C-dependent oxidation of NAD(P)H at 340 nm and at 380 nm, using millimolar 
extinction coefficients 6.22 mM-1 cm-1 and 1.314 mM-1cm-1, respectively.29,2  The 
concentrations of NADPH and NADH along with NADP+ (VWR International) and 
NAD+ in 10 mM Tris-HCl pH 8 buffer, were spectrophotometrically determined 
and stored at -80 °C. DL-P5C substrate solution stored at 4 °C in 1 M HCl, was 
neutralized to pH 7.5 just prior to enzyme assays by adding 1 M Tris-HCl (pH 9.0) 
buffer. NAD(P)H  was varied (0-580 μM) while holding DL-P5C fixed at 5000 μM 
and, DL-P5C was varied (0-5500 μM) while holding NAD(P)H fixed at 500 μM. 
NAD+ product inhibition assays were performed by holding DL-P5C constant 
(5000 μM) while varying NADH (0-580 µM) at different NAD+ concentrations (0-
500 µM). L-Pro inhibition assays were conducted by holding NADH constant (500 
µM) and varying DL-P5C (0-5500 µM) at different L-Pro concentrations (0-500 
µM). For assays in which DL-P5C was varied, the ionic strength was maintained 
at approximately 450-480 mM Tris+Cl- at each DL-P5C concentration by adding a 
balance of 1 M Tris-HCl (pH 7.5). The final assay volume was 600 μl in 1.5 ml 
rectangular polystyrene cuvettes (1 cm pathlength) (USA Scientific). Reactions 
were prewarmed at 37 °C and initiated by adding the enzyme last. The 
absorbance decrease due to oxidation of NAD(P)H was monitored at 340 and 
380 nm in a Varian Cary Bio 50 UV-Vis Spectrophotometer (Agilent 
Technologies) against blanks from which the varied substrate had been omitted. 
Final concentrations of enzyme used in the assays were 0.06 µM wild-type, 0.6 
µM R251C mutant, and 3 µM R119C mutant.  
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Enzyme activity was calculated from the linear portion of the initial 
absorbance decrease using the Beer-Lambert-Bouguer law.30,31,32  Assays were 
performed in triplicate and data were expressed as mean ± standard deviation. 
Data were fit by nonlinear regression to the Henri-Michaelis-Menten equation 
using SigmaPlot 12.0 (version 12.0.0.182, Systat Software) to estimate the 
theoretical maximal velocity limit (Vlim) and the apparent Michaelis-Menten 
constant (KM app) values (value ± standard error). The KM app for L-P5C was 
assumed to be half the KM app value for the racemic DL-P5C mixture. The 
apparent catalytic turnover rate (kcat app) and substrate specificity constant or 
catalytic efficiency values (kcat app/KM app) were calculated from Vlim and KM app. 
Product(s) inhibition kinetics were analyzed by global fitting of the data to 
different inhibition models using Enzyme Kinetics Wizard Module in SigmaPlot 
12.0 and by Hanes-Woolf plot analysis. For NAD+ product inhibition, the data fit 
best to a mixed inhibition (Full) model with enzyme-inhibition constants KIC app and 
KIU app = α(KIC app) (α = 0.4112). The mixed inhibition model had the highest 
squared correlation coefficient (R2)-ranking among eight tested inhibition models. 
For L-Pro product inhibition, the highest R2-ranking model was competitive 
inhibition (Full). 
Thermal Stability Assays 
Thermofluor assays were used to determine the thermal stabilities of wild-type 
HsPYCR2 and the mutants. Thermal stabilities of wild-type, R251C, and R119C 
were measured in 50 mM HEPES (pH 8.0) buffer containing 150 mM NaCl, 0.5 
mM EDTA, 500 µM THPP reducing agent, and 10 % (v/v) glycerol. Assays were 
performed in a 50 μl reaction volume using white 8-strip 0.2 ml PCR tubes with 
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individual flat optically clear caps (Phenix Research Products). The reaction 
mixtures included 6.4 µM of HsPYCR2 wild-type and mutant enzymes, various 
single additions and combinations of 1 mM NADH, 1 mM DL-P5C (pH 7.5), 1 mM 
NAD+, and 1 mM L-Pro (pH 8.0), and the reaction volume balanced with 100 mM 
potassium phosphate (pH 7.0) buffer. Sypro Orange fluorescent dye (λex = 470 
nm, λem = 570 nm, Molecular Probes) was added last at (25X) final concentration 
strength, and then the PCR tubes were covered with aluminum foil to protect from 
light during mild agitation using a rocking shaker for 4 h at 4 °C.  
Next, a mini plate spinner (Model MPS C1000, LabNet) was used for 60 sec 
at 2500 rpm to force liquid contents towards the bottom of the tubes. Sample 
tubes were then loaded into an iCycler chassis (Bio-Rad) to initiate data 
collection using the MyiQ Single-Color Real-Time PCR Detection System with 
optics module (CCD camera bandpass optical Filter 2 position at (λex = 485 ± 20 
nm, λem = 530 ± 30 nm)) using iQ5 Optical System software (Bio-Rad, version 
2.1). Thermal denaturation curves were recorded using a 10 min thermal 
equilibration period at 20 °C followed by increasing temperature increments at 
0.2 °C per 15 sec from 20-90 °C. The instrument’s software provided overlay 
plots of relative fluorescence units (RFU) vs. temperature (T) and of (–d(RFU)/dT) 
vs. T. From the raw numerical data, mean values of triplicate control blank curves 
without the enzyme were subtracted from corresponding mean values of 
quadruplicate curves with the enzyme for data analysis using Microsoft Excel 
2017 and SigmaPlot 12.0.  
The data was fit to a non-linear Boltzmann model:  
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𝑓𝑓 =
𝑦𝑦0 +  (𝑎𝑎 − 𝑦𝑦0)




where f  is the fluorescence intensity at temperature x, y0 and a are 
pretransitional and posttransitional fluorescence intensities, respectively, and b is 
a slope factor. Analysis of the Boltzmann model fit curve facilitated determination 
of x0 as the melting point temperature (Tm) that occurs at the midpoint of inflection 
in the unfolding transition of (RFU vs. T) plots. Statistical comparisons between 
paired groups of data were performed using Student’s t-test calculations in 
Microsoft Excel 2017 with p < 0.05 and at 95% confidence level considered 
statistically and significantly different. 
Circular Dichroism (CD) Spectroscopy 
 Wild-type HsPYCR2 and mutants R251C and R119C were microdialyzed into 
10 mM NaH2PO4 (pH 8.0) containing 250 mM NH4F buffer for 16 h at 4 °C. Then, 
1200 µl of each protein sample (final concentration 4 µM) was loaded into an 
individual 0.01 cm-optical length micro-cylindrical Suprasil cell (Starna Cells) and 
spectra in the far UV wavelength range of 180-260 nm were collected at 22 °C 
using a CD spectrophotometer (Jasco, Model J-815) with Spectra Manager 
software (Jasco, version 2.10.01). Averaged baseline scans of buffer alone were 
measured before averaged sample scans of each protein sample. Instrument 
scanning parameters were 0.5 nm data pitch interval, standard sensitivity, 4-sec 
data integration averaging time, bandwidth = 1.00, continuous scan mode with 
scanning speed of 100 nm/min, baseline correction = baseline measured, and 
accumulation scans = 16. The raw data was converted into Mean Residue  
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Ellipticity (θ, in units deg cm2 dmol-1) using the following equation: 




(CD Jasco value in units mdeg) × � 1 deg
103 mdeg
�
(0.01 cm pathlength) × (4 µM) × � 1 µmol 1 µM ∙ 1 L�  ×  �
1 mol
106 µmol�  ×  �
10 dmol
1 mol �  × �
1 L
10−3m3�  ×  �
1m3





 Secondary structure elements (8 individual components) for each protein 
were determined from a mathematical fit to the experimental CD spectra (190-
250nm) using the online BeStSel algorithm.33 The CD spectra (plotted as Mean 
Residue Ellipticity (θ) in units deg cm2 dmol-1 vs. Wavelength (λ) in units nm) and 
corresponding high tension (HT) voltage spectra of HsPYCR2 wild-type and 
mutants R119C and R251C  (codes CD0006228000, CD0006229000, and 
CD0006230000, respectively) have been deposited in the publicly accessible 
Protein Circular Dichroism Data Bank (http://pcddb.cryst.bbk.ac.uk).  
RESULTS  
Steady-state Kinetic Parameters of HsPYCR2 Wild-type and Mutants 
 In previous studies, the enzymatic activity of the inherited HsPYCR2 mutants 
leading to microcephaly and hypomyelination in human patients was not 
reported.  Proline levels in patients were found to be normal by plasma amino 
acid analysis, suggesting proline depletion was not a biochemical factor in the 
pathophysiology.17,18,34 However, cells harboring the HsPYCR2 mutants exhibited 
higher apoptosis rates under oxidative stress and were characterized by a lower 
mitochondrial membrane potential.17 To provide further insight into the 
biochemical penalties of the R119C and R251C mutations, we determined the 
steady-state kinetic parameters of HsPYCR2 wild-type and mutants with respect 
to L-P5C and NAD(P)H substrates.  
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Table 3.1 provides the kinetic parameters for HsPYCR2 wild-type and 
mutants R251C and R119C.  
aValue ± std error are the apparent best-fit parameters from non-linear least-squares fit 
of the data to the Henri-Michaelis-Menten equation using SigmaPlot 12.0 (version 
12.0.0.182, Systat Software). Data plotted as the (mean ± SD) of n=3 technical 
replicates. 
bFinal enzyme concentration of 0.06 µM  in the assay. 
cFinal enzyme concentration of 0.6 µM  in the assay. 
dFinal enzyme concentration of 3 µM in the assay. 
eNAD(P)H concentration fixed at 500 µM. 
fDL-P5C concentration fixed at 5000 µM. 
gReported value is the concentration of L-P5C, which is assumed to be half the 
concentration of the DL-P5C racemic mixture. 
h(Values) are the apparent best-fit parameters from non-linear least-squares fit of the 
data (single replicate, n=1) to the Henri-Michaelis-Menten equation using SigmaPlot 
12.0. 
 
Wild-type HsPYCR2 did not show a strong preference for NADH or NADPH when 
keeping L-P5C fixed as indicated by similar apparent kcat/KM values of (160 ± 44) 
x 103 M-1 s-1 and (111 ± 9) x 103 M-1 s-1, respectively. Accordingly, wild-type 
Table 3.1. Steady-state kinetic parameters for HsPYCR2a 
Enzyme Varied Substrate 
Fixed 
Substrate KM 
app (µM) kcat app (s-1) 
(kcat app/KM app ) 
(M-1 s-1) 
Wild-typeb DL-P5C NADH
e 1509 ± 69g 61.3 ± 1.4 (41 ± 2) x 103 
DL-P5C NADPHe 994 ± 134g 26.0 ± 1.5 (26 ± 4) x 103 
R251Cc DL-P5C NADH
e 1315 ± 291g 3.2 ± 0.3  (2.4 ± 0.6) x 103 
DL-P5C NADPHe 1499 ± 152g 3.1 ± 0.1 (2.1 ± 0.2) x 103 
R119Cd DL-P5C NADH
e 317 ± 90g 0.08 ± 0.01   (0.25 ± 0.08) x 103 
DL-P5C NADPHe 334g,h 0.13h  0.4h  x 103 
Wild-typeb NADH DL-P5C
f 298 ± 73 47.9 ± 5.3 (161 ± 44) x 103 
NADPH DL-P5Cf 216 ± 17 24.0 ± 0.7 (111 ± 9) x 103 
R251Cc NADH DL-P5C
f 953 ± 321  5.9 ± 1.4 (6.2 ± 2.5) x 103 
NADPH DL-P5Cf 119 ± 10 1.8 ± 0.1  (15 ± 1) x 103 
R119Cd NADH DL-P5C
f 34 ± 5  0.015 ± 0.001  (0.44 ± 0.07) x 103 
NADPH DL-P5Cf 537h  1.5h  2.8h  x 103 
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HsPYCR2 displayed similar kcat/KM values when varying L-P5C and keeping 
NADH or NADPH constant. These findings contrast with a previous study by De 
Ingeniis et al. in which HsPYCR2 was reported to have 2.5-fold higher activity 
with NADH relative to NADPH.2 Both HsPYCR2 mutants R251C and R119C 
exhibit substantially lower activity relative to the wild-type enzyme. Figure 3.3 
shows Henri-Michaelis-Menten plots of the kinetic data in which L-P5C is varied 
and NADH is held constant.  
 
Figure 3.3. Steady-state kinetics of HsPYCR2. Overlay of Henri-Michaelis-
Menten kinetics traces of 0.06 µM wild-type HsPYCR2 (dark blue), 0.6 µM R251C 
mutant (dark gray), and 3 µM R119C mutant (dark orange) enzymes. Assays 
were performed in 0.1 M Tris-HCl (pH 7.5) reaction buffer at 37 °C with varying 
DL-P5C (0-5500 µM) concentration and holding NADH fixed at 500 µM. Each 
data trace is plotted as (mean ± SD) of three technical replicates with non-linear 
least-squares fit to the Henri-Michaelis-Menten equation using SigmaPlot 12.0. 
 
The kcat app values with L-P5C as the varying substrate were 19-fold and 766-fold  
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lower for R251C and R119C mutants, respectively, than wild-type HsPYCR2.  
Similarly, significant lower activities were observed with the mutants when 
NADPH was held fixed. The resulting kcat app/KM app values for R251C and R119C 
were estimated to be 12-fold and 104-fold lower, respectively, than the wild-type 
enzyme. The apparent kcat/KM values when varying NADH and holding L-P5C 
fixed were 26-fold and 366-fold lower than wild-type HsPYCR2 for R251C and 
R119C mutants, respectively. Thus, the R119C mutation clearly has the most 
significant impact on HsPYCR2 activity. 
This loss of catalytic activity may be explained by inference from the 
homologous structure of the ternary complex HsPYCR1 + NADPH + L-THFA 
(PDB code 5UAV),6 in which the Arg119 site occurs near the posterior wall of the 
enzyme’s active site (Fig. 3.4). Mutation at sites Arg119 or Arg251 may have 
disrupted the conformation flexibility of the HsPYCR2 structure, perhaps in 
vicinity of the cofactor substrate binding site, thus leading to decreased kinetics of 
cofactor substrate entrance and egress.36 When performing the R119C mutant 
enzyme activity assays with DL-P5C and NADPH substrates, we encountered an 
obstacle of limited amounts of R119C mutant enzyme to carry out more technical 
replicates, yet we still suspect that the drastic loss of catalytic activity is due to 
this mutation in proximity to the enzyme’s active site. 
Product(s) Inhibition and Substrate Binding Order 
 The binding order of L-P5C and NADH to HsPYCR2 was evaluated by 
product(s) inhibition studies.37 The inhibition of HsPYCR2 by NAD+ was first  
examined by varying NADH and holding DL-P5C constant. Table 3.2 shows that 
increases in NAD+ concentration (0-500 µM) results in a decreasing trend in  
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Figure 3.4. Illustration of Arg119 and Arg251 impacting α-helices H and I in 
PYCR. Diagram was prepared with PyMOL35, showing a surface rendering with 
transparency and clipped away perspectives of the dimeric view (light pink and 
deep blue surfaces are partner monomers) of the experimental X-ray crystal 
structure of HsPYCR1 + NADPH + L-THFA (PDB code 5UAV).6 Mutations at 
conserved sites R119 and R251 (shown as green and light gray stick figures, 
respectively) in HsPYCR2 enzyme perhaps locally destabilize α-helices H and I 
(residues Glu164 - Lys194). In reference to the Arg119 site on the posterior wall 
of the active site containing NADPH and L-THFA (shown as orange and yellow 
stick figures, respectively, the latter of which is in proximity (2.6 Å) to the deep 
blue monomer’s side chain hydroxyl group of Thr238 active site residue) within 
the same (light pink) protein monomer, a side-chain guanidinium nitrogen of 
Arg119 may be hydrogen-bonded within close proximity (2.9 Å) to the side chain 
carboxyl oxygen of Glu164 (shown as magenta stick figure), which projects from 
the α-helix H backbone. In reference to the other (deep blue) protein monomer’s 
Arg251 site, its side chain guanidinium nitrogen may be hydrogen-bonded within 
close proximity (2.8 Å) to the side chain carboxyl oxygen of the same (light pink) 
protein monomer’s Asp186 (shown as magenta stick figure), which projects off of 
the α-helix I backbone and may be affecting the α-helical H and I kink region’s 
Pro178 site (shown as deep teal stick figure). 
 
kcat app and a slightly lower apparent KM. With increasing NAD+ concentration, 
trends of both increasing values of (1/KM app) and (1/Vlim) support the model of 
mixed inhibition by NAD+ (Table 3.2 and Figure 3.5, A).38 Global fitting of the data 
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aValue ± std error are reported for the apparent best-fit parameters of non-linear least-
squares fit to the Henri-Michaelis-Menten equation using SigmaPlot 12.0 (version 
12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=3 technical 
replicates. 
bFinal enzyme concentration of 0.06 µM in the assays. 
cDL-P5C concentration was held constant at 5000 µM and NADH concentration was 
varied from 0-580 µM. 
dApparent inhibition constants, KIC app (competitive inhibition) and KIU app (= α (KIC app)) 
(uncompetitive inhibition) were estimated by fitting the data to the Mixed Inhibition (full) 
model with α = 0.4112 using the Enzyme Kinetics Wizard Add-In on SigmaPlot 12.0 
(version 12.0.0.182, Systat Software).  
 
to a mixed inhibition model provided estimates of apparent competitive (KIC) and 
uncompetitive (KIU) inhibition constants for NAD+ (Figure 3.5, A). L-proline 
inhibition of HsPYCR2 wild-type was evaluated by varying DL-P5C (0-5500 µM) 
and holding NADH fixed. Table 3.3 shows that with increasing the L-proline (0-
500 µM) the value of KM app increased whereas Vlim remained fairly unchanged 
consistent with competitive inhibition by L-proline (Table 3.3 and Figure 3.5, C).38 




app (µM) kcat app (s-1) 
(kcat app/KM app) 
(M-1 s-1) KIC 
app (µM) KIU app (µM) 
0 298 ± 73 47.9 ± 5.3 (161 ± 44) x 103 
792 ± 248d 326 ± 102d 100 259 ± 53 37.3 ± 3.2 (144 ± 32) x 10
3 
250 209 ± 31 26.5 ± 1.5 (127 ± 20) x 103 
500 211 ± 15 19.1 ± 0.5 (90.5 ± 7.0) x 103 




app (µM)d kcat app (s-1) 
(kcat app/KM app ) 
(M-1 s-1) KIC 
app (µM) 
0 1509 ± 69 61.3 ± 1.4 (40.6 ± 2.1) x 103 
145 ± 8e 100 2126 ± 147 52.6 ± 2.0 (24.7 ± 1.9) x 10
3 
250 1627 ± 272 34.5 ± 2.8 (21.2 ± 4.0) x 103 
500 3149 ± 590 42.3 ± 4.9 (13.4 ± 3.0) x 103 
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aValue ± std error are reported for the apparent best-fit parameters of non-linear least-
squares fit to the Henri-Michaelis-Menten equation using SigmaPlot 12.0 (version 
12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=3 technical 
replicates.  
bFinal enzyme concentration of 0.06 µM in the assays.  
cNADH concentration was held constant at 500 µM while DL-P5C concentration was 
varied 0-5500 µM. 
dReported value is the concentration of L-P5C, which is assumed to be half the 
concentration of the DL-P5C racemic mixture. 
eApparent competitive inhibition constant, KIC app, was estimated by fitting the data to the 
Competitive Inhibition (full) model using the Enzyme Kinetics Wizard Add-In on 
SigmaPlot 12.0 (version 12.0.0.182, Systat Software). 
 
  A   C 
  
  B   D 
  
Figure 3.5. Product(s) inhibition kinetics of wild-type HsPYCR2. Henri-Michaelis-
Menten plots of assays performed at (A) different NAD+ concentrations (0-500 
µM) while varying NADH and holding DL-P5C constant (5000 µM) and (C) 
different L-proline concentrations (0-500 µM) while varying DL-P5C and holding 
NADH constant (500 µM). Hanes-Woolf plots of the data in panels A and C for 
inhibition of HsPYCR2 by (B) NAD+ and (D) L-proline.  Data are plotted as (mean 
± SD) of three technical replicates with non-linear least-squares fits to the Henri-
Michaelis-Menten equation and linear regression fits to the Hanes-Woolf 
equation using SigmaPlot 12.0. 
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Best fits of the data to a competitive inhibition model yielded an apparent KIC 
value of 145 µM L-proline (Figure 3.5, C). Hanes-Woolf plots of the NAD+ and L-
Pro inhibition data also show linear regressions consistent with mixed and 
competitive inhibition, respectively (Figure 3.5, B and D). In these plots,  linear 
trends converging at a common negative horizontal axis intercept with an 
increasing slope (1/Vlim) effect (Figure 3.5, B) indicates NAD+ is a mixed 
noncompetitive inhibitor39 of HsPYCR2 with respect to NADH. Parallel linear 
trends with an increasing vertical axis intercept (KMapp/Vlim) effect (Figure 3.5, D) 
indicate L-proline is a competitive inhibitor39 with respect to L-P5C. Taken 
together, these modes of inhibition by each product ligand support the proposed 
sequential-ordered binding mechanism shown in Figure 3.6.37 
 
Figure 3.6. Cleland diagram of the proposed sequential-ordered binding 
mechanism of HsPYCR2. First (A) and second (B) substrates bind in order to 
HsPYCR2 and, following the chemical step, the first (P) and second (Q) products 
are released in sequential order. 
 
 Because PYCR has been reported to catalyze the reverse reaction with L-
proline and NAD+,40,41 we thought it would be prudent to test whether HsPYCR2 
exhibits reversible activity which would interfere with the above product inhibition 
assays. No formation of NAD(P)H was observed over 10 min (Fig. 3.7). Thus, 
HsPYCR2 activity is only detected in the forward direction toward L-proline  
E E
NADH
(A) (B) (P) (Q)
L-P5C L-ProNAD+
E• L-P5C E• L-P5C• NADH E• L-Pro• NAD+ E• L-Pro
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production.   
A  B  
  
Figure 3.7. Test for HsPYCR2 reverse activity with L-proline. Absorbance traces 
of HsPYCR2 wild-type enzyme (0.6 µM final concentration) with L-proline (10 
mM) and (A) 1 mM NAD+ or (B) 1 mM NAD(P)+. Assays (600 µL total volume) 
were performed in 0.1 M Tris-HCl (pH 7.5) containing 0.01% Brij-35 detergent, 
and 1 mM EDTA at 37 °C and absorbance at 340 nm was monitored for 10 min.  
 
Thermal Stability of HsPYCR2 Wild-type and Mutants  
The thermal unfolding of HsPYCR2 proteins was measured in the absence 
and presence of all combinations of substrates and products to examine 















Wild-typed R251Cd R119Cd 
None 69.2 ± 0.1† 54.2b 67.6 ± 0.1£ 
NADH 69.0 ± 0.1 54.9b 66.4 ± 0.1 
DL-P5C 69.0 ± 0.1 53.4 ± 0.1 67.2 ± 0.1 
NADH + DL-P5C 53.2 ± 0.1† 55.4b 54.9 ± 0.1£ 
NAD+ 69.6 ± 0.1 53.0 ± 0.2 67.6 ± 0.1 
L-Pro 69.4 ± 0.1§ 52.9 ± 0.1§‡ 67.6 ± 0.1‡ 
NAD+ + L-Pro 69.3 ± 0.1֎ 56.6b 67.4 ± 0.1֎ 
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aMelting point temperatures (Tm) are reported as value ± std error and were determined 
from the apparent best fit estimates of dynamic curve fits to a user-defined sigmoidal, 4 
parameter equation modeled as the Boltzmann equation in SigmaPlot 12.0 (version 
12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=4 technical 
replicates. 
bMelting point temperatures reported as the local minimum value from the plot of (–
d(RFU)/dT vs. T) using SigmaPlot 12.0 (version 12.0.0.182, Systat Software) with data 
plotted as (mean ± SD) of n=4 technical replicates. 
cEach ligand concentration was 1 mM in the assays. 
dEnzyme concentration was 6.4 µM in all the assays. 
†According to Student's t-statistic, wild-type (none) and wild-type (NADH + DL-P5C) Tm 
values are statistically different at 95% confidence level (n=4). 
§According to Student's t-statistic, wild-type (+ L-Pro) and R251C mutant (+ L-Pro) Tm 
values are statistically different at 95% confidence level (n=4). 
‡According to Student's t-statistic, R251C mutant (+ L-Pro) and R119C mutant (+ L-Pro) 
Tm values are statistically different at 95% confidence level (n=4). 
֎According to Student's t-statistic, wild-type (NAD+ + L-Pro) and R119C mutant (NAD+ + 
L-Pro) Tm values are statistically different at 95% confidence level (n=4). 
£According to Student's t-statistic, apo-R119C mutant and R119C mutant (NADH + DL-
P5C) Tm values are statistically different at 95% confidence level (n=4). 
 
mutations. HsPYCR2 unfolding was monitored using the Sypro orange reporter dye 
which increases in fluorescence emission at 610 nm upon binding to surface-exposed 
hydrophobic-patches as the protein unfolds.42 The thermal unfolding traces for 
HsPYCR2 wild-type and mutants are in shown in Figure 3.8 and the 
corresponding melting point temperatures (Tm) are summarized in Table 3.4. 









Figure 3.8. Thermal stability assays of HsPYCR2. Relative fluorescence intensity 
units (RFU)  vs. T (°C) from Thermofluor assays are shown for (A) HsPYCR2 
wild-type, and mutant enzymes (B) R251C and (C) R119C. The legend indicates 
the different combinations of substrate and product ligands (1 mM) each trace. 
(D) A derivative plot of the thermal shift data for HsPYCR2 wild-type (dark blue), 
R251C mutant (dark grey), and the R119C mutant (dark orange) in the presence 
of 1 mM L-proline. The local trough minimum indicates the melting point 
temperature (Tm) for each enzyme.  All Thermofluor assays were performed with 
6.4 µM enzyme. 
 
the R251C mutant displayed a Tm value (54.2 °C) that was nearly 15 °C lower 
than the wild-type enzyme (69.2 °C). Unfortunately, some of the unfolding 
transitions could not be fit to the Boltzmann Equation model used for Tm 
determinations, particularly for several R251C mutant curves (Fig. 3.8, B).  
To verify the lower melting point temperatures of R251C, the data was also 
visualized as -d(RFU)/dT vs. T plots (Fig. 3.9). Figure 3.8, panel D shows a plot 
of wild-type HsPCYR2, R251C, and R119C in the presence of L-proline which 
clearly shows local minimum values of the troughs confirming significantly left-
shifted Tm values for the R251C mutant (ranging 53-56 °C) indicating lower 
thermostability relative to HsPYCR2 wild-type (Tm ≈ 69 °C) and the R119C  
mutant (Tm ≈ 67 °C).  
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Figure 3.9. Fluorescence-based protein thermal shift profiles of R251C mutant 
enzyme with no ligand or combinations of substrate ligands or product ligands. 
Thermofluor assay traces of (-d(RFU)/dT) vs. T (°C) for 6.4 µM R251C mutant 
enzyme with (A) no ligand, (B) 1 mM NADH, (C) 1 mM DL-P5C, (D) 1 mM NADH 
+ 1 mM DL-P5C, (E) 1 mM NAD+, (F) 1 mM L-Pro, and (G) 1 mM NAD+ + 1 mM 
L-Pro. Local minima of the troughs in the plots represent melting point (Tm) 
determinations. The trough minima of the traces are annotated. 
 
Adding substrates individually had no effect on the thermal stability of the 
HsPYCR2 enzymes, however, the combination of NADH and DL-P5C induced 
significantly lower (95% confidence level, n=4) Tm values for the wild-type 
enzyme (53.2 °C) and the R119C mutant (54.9 °C). Incubation of the HsPYCR2 
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enzymes with products had no effect on the observed Tm values. Because the 
observed effect on Tm is only observed when both substrates (NADH + DL-P5C) 
are present, the ternary complex of HsPYCR2-P5C-NADH may induce a 
conformational change during catalytic turnover that is less stable than the 
enzyme alone.  
Secondary Structure of HsPYCR2 Wild-type and Mutants  
The CD spectra of HsPYCR2 wild-type and mutants are shown in Figure 3.10. 
The CD spectrum of the R119C mutant was typical of a protein with strong α-
helical character whereas the spectrum of wild-type HsPYCR indicates less α-
helical character. Most notably, the R251C mutant displays the lowest amount of 
α-helical character of the HsPYCR2 proteins. 
To provide more insight into the observed differences in the CD spectra, 
secondary structure analysis was performed using the β-structure selection 
(BeStSel) method that takes into account the twist of β-structures.33 BeStSel 
accommodates for the spectral diversity of β-structures which is sometimes a 
drawback of CD spectroscopy, and was recently shown to outperform 11 other 
secondary structure estimation algorithms.33 Figure 3.10, panels B-D show 
secondary structural analysis of HsPYCR2 wild-type, and the mutants R251C  
                                     A 
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Figure 3.10. Secondary structure analysis of HsPYCR2 wild-type and mutant 
enzymes. (A) CD spectra of HsPYCR2 wild-type (dark blue), and the mutants 
R251C (dark grey) and R119C (dark orange) (4 µM each). Secondary structure 
analysis of (B) HsPYCR2 wild-type, and the mutants (C) R251C and (D) R119C. 
The experimental CD spectrum of each protein was fit with the BeStSel 
algorithm33 and analyzed for eight secondary structure components:  α-helix, 
regular; α-helix, distorted; left-hand twisted antiparallel β-strand or sheet; relaxed 
antiparallel β-strand or sheet; right-hand twisted antiparallel β-strand or sheet; 
parallel β-strand or sheet; turns; and other (310-helix, π-helix, β-bridge, bend, 
loop/irregular, and other invisible regions). The different secondary structure 
component contributions to the CD spectrum of each protein are expressed as a 
normalized percent.  
 
and R119C, respectively. The overlay traces of the BeStSel algorithm fits to the 
experimental CD spectra (190-250 nm) of HsPYCR2 wild-type, R251C, and 
R119C shown in Fig. 3.11 exhibited high calculated values of Pearson correlation 
coefficients43 of 0.9928, 0.9975, and 0.9790, respectively, suggesting a strong 
reliability of the secondary structure estimations for each protein (Table 3.5). 
A B C 
   
Figure 3.11. BeStSel algorithm fits to experimental CD spectra of HsPYRC2 
proteins. Shown is the overlay of the experimental CD spectra (solid line) and the 
best-fit CD spectra (dotted line) generated by the BeStSel algorithm.33 Data are 
plotted as Molar Circular Dichroism (Δε) in units M-1 cm-1 versus wavelength for 
(A) HsPYCR2 wild-type, (B) R251C mutant, and (C) R119C mutant enzymes.  
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The BeStSel structural explanations for the observed CD spectra indicate that 
the R119C mutant has an overall α-helical character (fαR + fαD) that is over 2-fold 
(14.9 %) higher than HsPYCR2 wild-type (6.3 %) (Figure 3.10, B and D and 
Table 3.5). The R251C mutant is estimated to have substantially lower α-helical 
character than HsPYCR2 wild-type but has 2-fold (44.9%) higher antiparallel β-
strand character (fβAnti1 + fβAnti2 + fβAnti3) than the wild-type enzyme (20.6 %) 
(Figure 3.10, B and C and Table 3.5) .  
DISCUSSION 
In this work, functional and structural characterization of HsPYCR2 mutants 
R119C and R251C was provided to gain insight into how these mutations may 
contribute to hypomyelinating leukodystrophy type 10, an autosomal recessive 
neurological disorder. Different clinical studies have found that patients with 
inborn genetic errors in the PYCR2 gene initially possess normal growth 
parameters and brain anatomy at birth, but then progressively develop 
microcephaly, hypomyelination, and failure to thrive complications that lead to 
cognitive and motor deficits that eventually terminate their lives in childhood.34,44 
Zaki et al.’s (2016) study of 14 affected individuals ascertained that the patients 
harbored either a stop codon mutation that results in depletion of PYCR2 or one 
of five missense mutations in the dimerization domain, such as Arg199Trp and 
Cys232Gly.18 Expression levels of missense PYCR2 mutants were not found to 
be significantly decreased relative to wild-type PYCR2, however, based on 
coimmunoprecipitation experiments of PYCR2 in 293T cells, the authors reported 
on impaired protein multimerization of the patient protein variants,18 indicating the 





PYCR1 is a pentamer-of-dimers.6  
More recently, Escande-Beillard et al. (2020) developed a Pycr2-/- mouse 
model, in which both PYCR2 and incidentally PYCR1 protein expression was 
limited, indicating that the loss of PYCR2 was not compensated by the 
engagement of PYCR1 activity to counteract the pathogenesis of recessive 
hypomyelinating leukodystrophy type 10.44 Upon performing liquid 
chromatography-tandem mass spectrometry of Pycr2-/- mouse brain tissue 
samples, analysis of several amino acids that behave as neurotransmitters was 
unremarkable except for substantially and significantly high levels of glycine, an 
excitatory neurotransmitter, in all tested brain regions. Based on marked neuronal 
and oligodendroglial morphological changes indicative of axonopathy, 
hypomyelination, and premature apoptosis found in both brain MRI scans of 
HLD10 patients and immunofluorescence analysis of Pycr2-/- mouse brain 
tissues, the authors remarked that PYCR2 deficient patients and mice showed 
signs of cerebral hyperglycinemia with encephalopathy.44 Using proximity-based 
BirA-protein label proteomics on primary human cell lines, serine 
hydroxymethyltransferase (SHMT2), the rate-limiting mitochondrial enzyme 
responsible for glycine synthesis, was not only found among the top five PYCR 
protein-protein interaction candidates, but endogenous protein expression (as 
well as mRNA levels in mice) of SHMT2 were significantly upregulated in the 
absence of PYCR2.44 Further immunofluorescence staining and quantitative 
analyses demonstrated that knockdown of SHMT2 could rescue both axonal 
beading and reduced neurite length (phenotypes of axonal injury) of cultured 
Pycr2-/- mouse neurons.44 
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Here we show two missense mutations (R251C and R119C) in the PYCR2 
gene that are linked to HLD10 marked by axonal injury and microcephaly, impair 
HsPYCR2 catalytic activity. The observed loss in activity results from different 
underlying causes in the two mutants. Currently X-ray crystal structures of 
HsPYCR2 are not available. However, Arg119 and Arg251 are conserved in 
HsPYCR1, thus allowing their structural contributions to be examined. The 
structure of HsPYCR1 in complex with NADPH and L-THFA (PDB code 5UAV) is 
shown in Figure 3.4.6 Arg119 (green sticks) and Arg251 (light gray sticks) are 
from different protomers but interact with Glu and Asp residues of one protomer 
on α-helices H and I, which are split by a kink formed by Pro178. The active site 
is formed at the dimer interface with Thr238 of one protomer (see chapter two, 
Fig. 2.6) forming a key hydrogen bonding interaction with the ring oxygen of L-
THFA, which is synonymous with the imine nitrogen of L-P5C or L-Pro. Arg119 
resides on a β-strand of the Rao-Rossmann fold with its side chain guanidinium 
group within 2.9 Å to the side chain carboxylate groups of Glu164 of α-helix H of 
the same protomer. Thereby, Arg119 likely helps stabilize α-helix H which has a 
critical role in shaping the active site.6  The loss of enzyme activity in the R119C 
mutant of HsPYCR2 is likely related to disrupting the active site environment. 
Why the R119C would exhibit enhanced α-helical character as observed by CD 
spectroscopy is not clear from the structure of HsPYCR1.  
As shown in Figure 3.4, the partner protomer’s (deep blue) Arg251 site has its 
side chain guanidinium nitrogen within close proximity (2.8 Å) for a hydrogen 
bond with the side chain carboxyl oxygen of the other protomer’s (light pink) 
Asp186 of α-helix I. Thus, Arg251 contributes to interactions at the dimerization 
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interface between the two protomers. The dramatic decrease in thermal stability 
and α-helical content of the R251C mutant relative to wild-type HsPYCR2 
indicates that Arg251 has an important structural role. The loss of the Arg251-
Asp186 interaction in the R251C mutant may destabilize α-helices L and K, 
thereby changing the orientation of Thr238 and negatively impacting the active 
site. Escande-Beillard et al. (2020) rationalized that substitution of residue 
Glu246 into Val with a bulkier side chain most likely results in steric hindrance 
with the partner monomer at the dimer interface of human PYCR2, thus 
disrupting catalytic function as observed with the Glu246Val mutant enzyme.44 
With respect to the Tm values determined here for HsPYCR2, the values are 
higher than typically observed for human proteins. In a survey of 18 human 
proteins within the enzyme classes of sulfotransferases, methyltransferases, and 
isomerases, Vedadi et al. (2006) reported melting point temperatures ranging 
from 34-58 °C using differential scanning fluorimetry.45 The Tm values estimated 
for HsPYCR2 wild-type and R119C mutant are above that conventionally 
expected for human enzymes, however, the observed Tm for HsPYCR2 wild-type 
alone (69 °C) is consistent with a previously reported thermal inactivation of 
HsPYCR1 in which the enzyme activity dropped to 50% within 10 min at 68 °C.5 
Product(s) inhibition kinetics studies revealed L-Pro behaving as a 
competitive inhibitor and NAD+ behaving as a mixed inhibitor against wild-type 
HsPYCR2 enzyme, which is diagnostic of a sequential binding order with L-P5C 
binding first to the enzyme followed by NADH (Fig. 3.6). This binding order is 
atypical of the general family of dehydrogenase enzymes, i.e. lactate 
dehydrogenase, which first binds NAD+/NADH before the second substrate.46     
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Figure 3.12. Single dimer ball-space-filling model views of enzyme-ligand(s) 
complexes. Illustrations were prepared with PyMOL35 as renderings of 
homologous HsPYCR1 experimental X-ray crystal structure that support our 
proposed sequential-binding order mechanism of HsPYCR2. (A and D) 1.92 Å 
structure of HsPYCR1 + L-Pro (PDB code 5UAT)6 as lime green and sea blue 
partner monomers shown with buried L-Pro product ligand (purple sticks and 
dots) in a single active site zoomed in on right panel B, (B and E) 1.90 Å structure 
of HsPYCR1 + NADPH (PDB code 5UAU)6 as black and light blue partner 
monomers shown with bound NADPH substrate ligand (orange sticks and dots) 
in a single active site zoomed in on right panel D, and (C and F) 1.85 Å structure 
of HsPYCR1 + NADPH + L-THFA (PDF code 5UAV)6 as salmon pink and dark 
blue partner monomers shown with buried L-THFA analog ligand (yellow sticks 
and dots) together with bound NADPH substrate ligand (orange sticks and dots) 
in a single active site zoomed in on right panel F.  
 
The proposed binding order is supported by X-ray crystal structures of HsPYCR1 
in complex with THFA and NADPH (Fig. 3.12), which shows that L-THFA, which 
is an analog of both L-proline and L-P5C, is buried within the active site. The 
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binding site for L-THFA would be obstructed if NADPH were to bind first, thus 
supporting the sequential binding order of the smaller L-P5C molecule followed 
by binding of the larger NAD(P)H molecule. Specifically, Figure 3.12, panels C 
and F show that NADPH is more solvent exposed which would facilitate the 
sequential release of NADP+ followed by L-proline. These findings are consistent 
with previous studies in which bacterial (S. pyogenes) and plant (A. thaliana) 
P5CRs were also proposed to follow a sequential-ordered binding mechanism 
with L-P5C binding prior to NAD(P)H.27,47 Having the sequential-ordered binding 
mechanism of HsPYCR2 established will help guide development of new 
inhibitors and/or substrate analogs as molecular probes for modulating HsPYCR2 
activity. 
Interestingly, serum levels of L-proline in healthy adult humans are reported to 
range from 125-633 µM with mean levels around 270 µM.48,49 The competitive 
inhibition constant determined here for L-proline (KIC app= 145 ± 8 µM) as well as 
that previously reported for HsPYCR2 by De Ingeniis et al. (KI = 96 µM)2, is within 
physiological L-proline concentrations suggesting that HsPYCR2 is susceptible to 
product feedback inhibition by L-proline. Because concentrations of normal 
human fasting plasma L-P5C and of L-P5C released into extracellular medium by 
cultured human skin fibroblasts have been observed << 100 µM50,51 and the 
apparent KM determined here for L-P5C is (1509 ± 69 µM), HsPYCR2 is likely 
operating under V/KMapp conditions and thereby sensitive to feedback regulation 
by L-proline.  
On a more clinical note, previous studies which have profiled blood and 
plasma metabolites of HsPYCR2-deficient patients have reported no significant 
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decreases in L-proline .17,18 However, it remains unknown what the 
concentrations of L-proline are in the relevant affected neurological tissue and 
cerebrospinal fluid (CSF) of these patients. In Escande-Beillard et al. (2020)’s 
study, the authors mentioned that no L-proline deficiency in blood or brain tissues 
was found in Pycr2-/- mice.44 Yet, progressive neurological deterioration 
associated with another enzyme (P5CS) deficiency is marked by hypoprolinemia 
and lower urea cycle intermediates (e.g., ornithine, citrulline, arginine) that cannot 
be treated by fortified amino acid supplements.52,53 Unsuccessful 
supplementation therapies may be due to a number of complications such as low 
bioavailability, high clearance rates, different intestinal absorption and plasma 
kinetics between amino acids derived from amino acid supplements and whole 
protein, as well as inadequate delivery to affected tissues.54 Thus, L-proline 
serum levels in HsPYCR2 deficient patients may not be an adequate biochemical 
marker to determine whether HsPYCR2 deficiency causes abnormal L-proline 
bioavailability in patients, especially in the CSF. On a broader scope, Escande-
Beillard et al. (2020) proposed loss of PYCR2 may lead to SHMT2 upregulation 
as the direct cause of cerebral hyperglycinemia in HLD10 patients, which triggers 
excitotoxicity by activation of N-methyl-D-aspartate (NMDA) receptors leading to 
hypomyelination and axonal damage; thus, perhaps therapeutic NMDA receptor 
antagonists or other treatments aimed at lowering cerebral glycine levels might 
be of benefit to PYCR2-deficient patients.44  
In conclusion, we have shown that HsPYCR2 mutants R119C and R251C 
result in impaired enzyme function and structural stability, thus potentially leading 
to disrupted L-proline biosynthesis and metabolic dysfunctions that contribute to  
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hypomyelinating leukodystrophy type 10 with microcephaly.  
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L-thioproline oxidation:  Novel Enzyme Function Discovered for 
human PYCR1 and 2 
 
ABSTRACT 
L-thioproline (L-thiazolidine-4-carboxylate, L-T4C) is a cyclic sulfur imino acid 
analog of L-proline (L-Pro) found in multiple kingdoms of life. The oxidation of L-
T4C leads to L-cysteine (L-Cys) formation in bacteria, plants, mammals, and 
protozoa. The conversion of L-T4C to L-Cys in bacterial cell lysates has been 
attributed to proline dehydrogenase and L-Δ1-pyrroline-5-carboxylate (P5C) 
reductase (PYCR) but detailed kinetic studies have not been conducted. Here, 
we characterize the dehydrogenase activity of human PYCR isozymes 1 and 2 
with L-T4C using NAD(P)+ as the hydride acceptor.  Both PYCRs exhibit 
significant L-T4C dehydrogenase activity, however, PYCR2 displayed nearly 10-
fold higher catalytic efficiency (136 M-1 s-1 versus 13.7 M-1 s-1) than PYCR1. 
Interestingly, no activity was observed with L-Pro and the analog DL-thiazolidine-
2-carboxylate (DL-T2C), indicating that the sulfur at the 4-position is critical for 
PYCRs to utilize L-T4C as a substrate. Structural insights into L-T4C binding 
interactions were gained by solving a 2.30 Å X-ray crystal structure of a (PYCR1 
+L-T4C) complex. L-T4C was found to occupy the same binding site as L-Pro, an 
observation that was corroborated by inhibition kinetics that showed L-Pro is a 
competitive inhibitor of PYCR1 (KIC app = 15.7 mM) with respect to L-T4C. Taken 
together, the evidence assigns a novel enzyme function to human PYCRs, thus 
we propose that PYCR should be classified as a bifunctional enzyme with a new 
name,  L-thiazolidine-4-and-L-pyrroline-5-carboxylate oxidoreductase (TPCOR).  
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INTRODUCTION   
 L-thiazolidine-4-carboxylate (L-T4C) is a metabolite known to occur in various 
organisms throughout nature from protozoa, bacteria, plants, and mammals.1,2,3, 
4,5 L-T4C is an analog of L-Pro (Figure 4.1) thought to derive from L-Cys from the 
mitochondrial reaction of L-Cys and formaldehyde.2 




Figure 4.1. Chemical structures of L-Pro, analogs, and L-Cys. (A) L- Pro, (B) DL-
T2C, (C) L-T4C, and (D) L-Cys.  
 
L-T4C has been reported to have toxic effects in certain organisms when applied 
exogenously such as in bacteria and plants. For instance, the toxic effects of L-
T4C in Escherichia coli are typically attributed to its misincorporation into proteins 
via the bacterial prolyl-tRNA synthetase, which does not discriminate between L-
Pro and L-T4C.6,7 Elthon et al. (1984) presented evidence that L-T4C treatment 
strongly influences the accumulation of L-Pro, an important cellular osmolyte and 
source of energy critical for plant survivability when not in excess, by specific 
inhibition of L-Pro oxidation in mitochondria isolated from etiolated barley 
(Hordeum vulgare) shoots.5 The toxic effects of L-T4C have been exploited in its 
use as an anti-infection agent against various diseases. For instance, Magdaleno 
et al.’s (2009) study analyzed the effects of L-T4C on parasitic cell viability of the 
non-infectious epimastigote forms of Trypanosoma cruzi and on the infection of 
mammalian CHO-K1 cells by T. cruzi, which leads to the pathology of Chaga’s 
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disease in host cells.8 According to their findings, L-T4C significantly reduced 
parasitic cell viability and T. cruzi infection rates in CHO-K1 cells.8 These results 
led to the suggestion that L-T4C may be a viable treatment against Chaga’s 
disease. 
 A mechanism by which cells diminish L-T4C toxicity is to convert it to L-Cys, 
thereby not only removing the L-proline analog but also mobilizing the sulfur into 
a useable form. Utilizing L-T4C as a source of L-Cys has been shown to be 
required for the survival of the protozoan Entamoeba histolytica, which relies on 
L-Cys as the principal low-molecular-weight thiol due to the lack of glutathione.9 
Using stable isotope labeling and mass spectrometry, Jeelani et al. (2014) 
demonstrated that L-T4C was the major source of L-Cys formation in cells, 
thereby promoting trophozoite growth and protecting protozoan cells against 
oxidative stress.9 Consistent with these metabolite findings, lysates of E. 
histolytica were shown to convert L-T4C into L-Cys, however, the enzymes 
responsible for L-T4C oxidase activity were not identified.9  
 The potential of L-T4C (L-thioproline) to serve as a source of L-Cys and to 
trap reactive nitrogen species (RNS) has also been explored in humans for 
various therapeutic applications. The first demonstration of the therapeutic 
potential of L-thioproline can be traced to Mackenzie et al.’s (1957) report on 
finding L-thioproline is about five times more potent than L-cysteine in preventing 
massive pleural effusions and death in thiourea-treated rats.2 From a chemical 
structure standpoint, L-T4C’s sulfur atom is protected in a ring moiety (Fig. 4.1, 
C) that only opens and liberates a sulfhydryl group upon uptake into the liver, 
whereas the sulfur in L-Cys is fully exposed (Fig. 4.1, D) and readily reactive as a 
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nucleophile prior to cellular uptake.2 From several clinical reports in the 1960s-
1980s, oral tablet or intravenous administration of L-thioproline given to patients 
suffering from infectious hepatitis, liver insufficiency, or chronic liver cirrhosis 
demonstrated limited benefits primarily to remedying cell necrosis and correcting 
levels of transaminase and alkaline phosphatase enzyme activities.10 Under the 
moniker of generic Timonacic, L-thioproline (brand names:  Hepalidine, 
Heparegen, etc.) has been used for the treatment of hepatic and biliary diseases, 
particularly in France.10  
 Despite the interest in L-T4C as a therapeutic L-Cys source in humans or an 
oxidative stress protectant in various organisms such as protozoa and plants, 
detailed kinetic studies with L-T4C have yet to be conducted. Two enzymes that 
have been implicated in L-T4C metabolism from numerous studies are L-proline 
dehydrogenase (PRODH) and L-Δ1-pyrroline-5-carboxylate (P5C) reductase 
(PYCR). Genetic knockout studies in E. coli and activity assays with bacterial cell 
lysates suggests PYCR may have a significant role in converting L-T4C into L-
Cys, but the individual contributions of PRODH and PYCR are unclear.11,7  
 Here, we set out to determine the ability of the human PYCR enzymes to 
catalyze the oxidation of L-T4C. The known function of PYCR is to catalyze the 
last step in L-Pro biosynthesis by NAD(P)H-dependent reduction of L-P5C into L-
Pro. In this study, we characterized the ability of PYCR to catalyze the reverse 
reaction of reducing NAD(P)+ with L-Pro and analogs, L-T4C and DL-T2C (Figure 
4.1) at biologically relevant pH 7.5. We report human PYCR1 and 2 do not exhibit 
any enzyme activity with L-Pro or DL-T2C, however, notable activity was 
observed with L-T4C as a substrate.  PYCR2 was found to have an apparent 
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catalytic efficiency with L-T4C of nearly 10-fold higher than PYCR1. A 2.30 Å  
experimental X-ray crystal structure of the binary complex (PYCR1+L-T4C) was 
solved, which implies molecular details for the hydride transfer step from L-T4C 
to NAD(P)+. L-Pro was also shown to be a competitive inhibitor of PYCR1 with 
respect to L-T4C, indicating that L-T4C occupies the L-proline-binding site. In 
summary, the experimental evidence gathered here assigns a novel enzyme 
function to human PYCRs, thus expanding its physiological role.  
MATERIALS AND METHODS   
Materials, Reagents, and Enzymes  
 MilliQ-Ultra purified water was used for the preparation of all buffers and 
chemicals in the experiments. The same reagents mentioned in chapter three 
were accessed and used for these studies, including the purchases of L-
thiazolidine-4-carboxylic acid and DL-thiazolidine-2-carboxylic acid from 
Millipore-Sigma.  Human PYCR1 was graciously provided by Dr. John J. 
Tanner’s group after following an expression and purification procedure as 
described previously in chapter two.12 A detailed description of the expression 
and purification conditions for human PYCR2 is provided in appendix chapter B.  
Kinetic characterization of PYCR reverse activity.  
 The majority of reaction components and reaction conditions from the 
methods described in chapters two and three remain consistent in these studies, 
yet there are some notable exceptions. For instance, stock solutions of L-T4C, 
DL-T2C, and L-Pro were each adjusted to pH 7.5 using 6 M NaOH prior to 
performing the assays. Assays were performed at 37 °C in 0.1 M Tris-HCl (pH 
7.5) reaction buffer containing 0.01% Brij-35 detergent, 1 mM NAD(P)+ (pH 8.0), 1 
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mM EDTA (pH 7.5), and different test substrate compounds of 10 mM L-proline 
(pH 7.5), 10 mM L-T4C (pH 7.5), and 10 mM DL-T2C (pH 7.5). The reaction 
components were pre-warmed for 5 min in a 1.5 mL microtube at 37 °C and then 
transferred to a 1 cm path length polystyrene rectangular cuvette (USA 
Scientific). The assay (600 µl total volume) was initiated by adding PYCR1 or 2 
enzyme (0.6 µM final concentration) and reaction progress was monitored at 340 
nm using a Varian Cary 50-UV/VIS spectrophotometer at room temperature for 
10 min duration.  
 For reverse direction steady-state kinetics, the parameters kcat and KM for L-
T4C were determined by holding NADP+ fixed (1 mM) while varying L-T4C (0-25 
mM). In assays varying L-T4C, 1 M Tris-HCl (pH 7.5) buffer was added to each 
assay to maintain an ionic strength of approximately 450-460 mM Tris+Cl-. L-
proline inhibition studies were performed under the same conditions with 0.6 µM 
PYCR1 enzyme (final concentration) with NADP+ fixed (1 mM) and L-T4C varied 
(0-25 mM) at different concentrations of L-proline (0-20 mM).  
  For both steady-state kinetics and ligand inhibition kinetics, the reaction 
components were all pre-warmed for 5 min, combined in a 1.5 ml microtube, 
positioned in a 37 °C water bath for 5 min, then transferred into a cuvette with the 
addition of enzyme to initiate the reaction. Each cuvette measurement had been 
zeroed against blanks omitting L-T4C, and all assays were performed in triplicate. 
Initial velocities were calculated from the linear increase in absorbance within a 
one minute window in the initial 2.5 min and quantifying NAD(P)H formation (ε340 
= 6.22 mM-1 cm-1)7,13 according to the Beer-Lambert-Bouguer law.14,15,16 Data 
(mean ± standard deviation) are plotted as variable substrate concentration in 
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units mM (horizontal axis) versus initial reaction velocity of NAD(P)H product 
formation in units µM s-1 (vertical axis). The data were fit by nonlinear regression 
analysis to the Henri-Michaelis-Menten equation using SigmaPlot 12.0. Ligand 
inhibition data was analyzed by Henri-Michaelis-Menten and linear Hanes-Woolf 
plots. The apparent enzyme-inhibitor dissociation constant (KIC) was determined 
by a fit of the data to a Competitive Inhibition (Full) Model, which was the highest-
ranked R2 inhibition model of the Enzyme Kinetics Wizard Add-In module in 
SigmaPlot 12.0. 
RESULTS 
 A  C 
  
 B  D 
  
Figure 4.2. PYCR reverse activity with L-Pro and analogs. Final enzyme 
concentration was 0.6 µM for each assay. Progress of the reaction was 
monitored for 10 min by following the absorbance at 340 nm. Time-course 
absorbance profiles of PYCR1 reverse activity with (A) 1 mM NADP+ + 10 mM L-
Pro or with (B) 1 mM NAD+ + 10 mM L-Pro or its analog L-T4C or DL-T2C. Time-
course absorbance profiles of PYCR2 reverse activity with (C) 1 mM NADP+ + 10 
mM L-Pro or with (D) 1 mM NAD+ + 10 mM L-Pro or its analog L-T4C or DL-T2C.   
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PYCR reverse activity with L-Pro, L-T4C, and DL-T2C  
 The ability of PYCR to catalyze the reduction of NAD(P)+ with L-proline, L-
T4C, and DL-T2C was examined at pH 7.5 for 10 min. The results shown in Fig. 
4.2 and Table 4.1 demonstrate that NADPH formation is only observed in PYCR 
reverse activity assays using L-T4C as the substrate. Thus, neither PYCR1 nor 
PYCR2 can catalyze the reverse reaction of L-proline oxidation and NAD(P)+ 
reduction, consistent with the forward reaction toward L-proline biosynthesis 
being strongly favored by PYCRs. 
aEnzyme activity assay involved measurement for the change in absorbance at 
340 nm over 10 min time duration. 
bFinal enzyme concentration of 0.6 µM in assay. 
cFinal concentration of 10 mM for L-Pro, L-T4C, and DL-T2C. 
dFinal NAD(P)H concentration of 1 mM. 
eInitial reaction velocity of NAD(P)H formation calculated with εNAD(P)H at 340 nm = 
6.22 mM−1 cm−1. 
 
In terms of quantitative comparisons of reverse activity, PYCR1 shows nearly 
3.5-fold higher reaction velocity with 10 mM L-T4C in the presence of 1 mM NAD+ 
compared to the corresponding value in the presence of 1 mM NADP+. 
Table 4.1. Human PYCR reverse activity with L-Pro and its analogsa 




L-Pro NADP+ -0.0006 0 
L-Pro NAD+ 0.0059 ~ 0 
L-T4C NAD+ 0.0438 0.1175 
DL-T2C NAD+ 0.0004 ~ 0 
PYCR2 
L-Pro NADP+ -0.0082 0 
L-Pro NAD+ -0.0017 0 
L-T4C NAD+ 0.0374 0.1003 
DL-T2C NAD+ -0.0015 0 
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Conversely, PYCR2 shows nearly 2.5-fold higher reaction velocity with 10 mM L-
T4C in the presence of 1 mM NADP+ compared to the corresponding value in the 
presence of 1 mM NAD+. 
Steady-state kinetics analysis of PYCR reverse activity with L-T4C  
 The apparent steady-state kinetic parameters kcat and KM were then determined 
for L-T4C by keeping NADP+  fixed while varying the L-T4C substrate. Henri-
Michaelis-Menten plots of the data are shown in Fig. 4.2 for PYCR1 and PYCR2.  
A B 
  
Figure 4.3. Steady-state kinetics analysis of PYCR reverse activity with L-T4C. 
Final enzyme concentration of 0.6 µM (A) PYCR1 and (B) PYCR2 were used. 
Data are plotted as (mean ± SD) of three technical replicates and fit to the Henri-
Michaelis-Menten equation by non-linear least-squares regression in SigmaPlot 
12.0. 
 
a(Value ± Std error) are the apparent best-fit parameters from non-linear least-
squares fit of the data to the Henri-Michaelis-Menten equation using SigmaPlot 
12.0 (version 12.0.0.182, Systat Software). Data plotted as the (mean ± SD) of 
n=3 technical replicates. 
bFinal enzyme concentration is 0.6 µM. 
cFinal NADP+ concentration fixed at 1 mM. 
Table 4.2. Steady-state kinetics analysis of PYCR reverse activitya with L-T4C 
Enzymeb Varied Substrate 
Fixed 
Substratec KM 
app (mM) kcat app (s-1) (kcat 
app/KM app ) 
(M-1 s-1) 
PYCR1 L-T4C NADP+ 18.9 ± 2.9 0.26 ± 0.02 13.7 ± 2.3 
PYCR2 L-T4C NADP+   6.8 ± 0.9 0.92 ± 0.04 136 ± 19 
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Both PYCR1 and PYCR2 achieved saturation kinetics with L-T4C substrate for 
nonzero maximal limiting reaction velocities (Vlim) of 0.16 µM s-1 and 0.55 µM s-1, 
respectively. PYCR2 exhibited higher catalytic activity than PYCR1 with kcatapp 
approaching 1 s-1 (Table 4.2). The nearly 4-fold higher kcatapp and 3-fold lower 
Kmapp values for PYCR2 result in a 10-fold higher catalytic efficiency with L-T4C 
relative to PYCR1 (Table 4.2). 
Structural and ligand inhibition kinetics analysis of L-T4C binding in PYCR1 
A B 
  
Figure 4.4. Superimposed X-ray crystal structures of PYCR1─L-T4C and 
PYCR1─L-Pro binary complexes. (A) Ball-space-filling model of dimeric 
superimposed structures of PYCR1─L-T4C (purple blue and wheat partner 
protomers) and PYCR1─L-Pro (lime green and hot pink partner protomers) 
binary complexes. The active site is formed at interface of partner protomers with 
L-T4C (cyan sticks) and L-Pro (gray sticks) present deep in active site. (B) 
Ribbon cartoon model of superimposed structures with zoomed-in view of active 
site showing hydrogen bond interaction (2.7 Å) between side chain hydroxyl 
group of Thr238 and imine nitrogen (blue colored atom) of L-T4C, analogous to 
hydrogen bond interaction (3.4 Å) between side chain hydroxyl group of Thr238 
and imine nitrogen (blue colored atom) of L-Pro. Illustrations of the 2.30 Å X-ray 
crystal structure of the PYCR1─L-T4C complex and of the 1.90 Å X-ray crystal 
structure of PYCR1─L-Pro complex (PDB code 5UAU)12 were made with 
PyMol.17 The X-ray crystal structures of human PYCR1 soaked with 50 mM L-
T4C in the former case and soaked with 1.8 M L-Pro in the latter case, were both 
graciously provided by Dr. John J. Tanner and Dr. Emily Christensen. 
 
 To further characterize L-T4C as a substrate of PYCR, structural and kinetic 
evidence was generated to support that L-T4C binds in the same active site 
region of PYCR1 as L-proline and consequently as the L-P5C substrate. In 
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previous studies (see chapter three) with PYCR1, a 1.90 Å X-ray crystal structure 
of the binary complex of PYCR1+L-Pro was solved (PDB code 5UAU).12 The 
structure, along with evidence from product inhibition kinetics, showed that L-Pro 
and L-P5C occupy the same binding site near NADPH in PYCR1. As shown in 
Fig. 4.4, our collaborators (Dr. Emily Christensen and Dr. John J. Tanner) solved 
a 2.30 Å X-ray crystal structure of L-T4C complexed with PYCR1. The electron 
density of L-T4C is observed in the same active site binding pocket as previously 
shown for L-Pro. Additionally, the highly conserved active site residue Thr238’s 
side chain hydroxyl group forms a 2.7 Å hydrogen bond interaction with the imine 
nitrogen of L-T4C, which is analogous to hydrogen bond interaction (3.4 Å) 
between side chain hydroxyl group of Thr238 and imine nitrogen of L-Pro in the 
superimposed structure of the PYCR1─L-Pro binary complex. Thus, L-T4C 
appears to bind to the PYCR1 active site in a manner similar to L-proline. 
In tow with this structural interpretation, we performed ligand inhibition kinetics 
with L-proline to test whether L-T4C binds to the same site as L-proline in 
PYCR1. Upon holding NADP+ concentration constant at 1 mM and varying L-T4C 
substrate (0-25 mM) at different L-proline concentrations (0-20 mM), the apparent 
KM (KMapp) for L-T4C was observed to trend upward while the apparent kcat 
(kcatapp) stayed relatively constant (Table 4.3 and Fig.4.5). With increasing L-Pro 
concentration, trends of an overwhelming increasing value of the KMapp with a 
fairly unchanging value of the Vmax agree well with the model of competitive 
inhibition with an apparent competitive inhibition constant (KIC app) of 15.7 mM L-
Pro (Fig.4.5, A  and Table 4.3).18 Hanes-Woolf plot analysis of the L-proline 
inhibition data shows a parallel linear pattern that is consistent with competitive 
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inhibition (Figure 4.5, B). In particular, the increasing vertical axis intercept 
(KMapp/Vmax) effect shown in Figure 4.5, panel B indicates L-Pro is a competitive 
inhibitor19 with respect to the L-T4C substrate.  
a(Value ± Std error) are reported for the apparent best-fit parameters of non- 
linear least-squares fit to the Henri-Michaelis-Menten equation using SigmaPlot  
12.0 (version 12.0.0.182, Systat Software) with data plotted as (mean ± SD) of 
n=3 technical replicates.  
bFinal enzyme concentration is 0.6 µM.  
cNADP+ concentration was fixed at 1 mM while L-T4C concentration was varied 
0-25 mM. 
dApparent competitive inhibition constant, KIC app, was estimated by globally fitting 
the data (0.5-25 mM) to a competitive inhibition (full) model using the Enzyme 





Figure 4.5. L-Pro ligand inhibition kinetics of PYCR1 with varied L-T4C substrate. 
(A) Henri-Michaelis-Menten plots of assays performed at different L-proline 
concentrations (0-20 mM) while varying L-T4C (0-25 mM) and holding NADP+ 
concentration constant (1 mM). (B) Hanes-Woolf plot of the (2-25 mM) data in 
Table 4.3. Steady-state kinetic parameters for L-proline ligand inhibition of 
PYCR1 with varied L-T4Ca,b,c 
L-proline  
(mM) KM 
app (mM) kcat app (s-1) (kcat 
app/KM app ) 
(M-1 s-1) KIC 
app (mM) 
0 18.9 ± 2.9 0.26 ± 0.02 13.7 ± 2.3 
15.7 ± 1.1d 5 32.0 ± 6.3 0.27 ± 0.35     8.4 ± 11.1 
10 35.1 ± 6.9 0.26 ± 0.35     7.5 ± 10.1 
20 36.8 ± 7.6 0.23 ± 0.03   6.3 ± 1.6 
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panel A. Final enzyme concentration of 0.6 µM PYCR1 was used. Data are 
plotted as (mean ± SD) of n=3 technical replicates with non-linear least-squares 
fits to the Henri-Michaelis-Menten equation and linear regression fits to the 
Hanes-Woolf equation using SigmaPlot 12.0.  
 
DISCUSSION  
 The kinetic data shown here directs attention to the chemical importance of  
 
Figure 4.6. Proposed catalytic mechanism of L-T4C initial oxidation by PYCR. 
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sulfur in the structure of L-proline analogs. As depicted in Fig. 4.1, the insertion of 
the sulfur atom at the C4 position of the pyrrolidine ring of L-Pro enables 
oxidation of L-T4C whereas sulfur at the C3 position of the pyrrolidine ring of L-
Pro, as in DL-T2C, does not enable oxidation of the L-proline analog. A reaction 
mechanism for the oxidation of L-T4C by PYCR is proposed in Fig. 4.6. The 
mechanism involves a hydride transfer from the C2 position in L-T4C to NADP+ 
followed by nonenzymatic hydrolysis to form products L-cysteine and formate 
(which later becomes formaldehyde). The sulfur being adjacent to the C2 position 
likely lowers the pKa of the hydrogen atoms at C2 and promotes electron 
delocalization between the N1 and C2 atoms. These electronic factors must be 
sufficient enough to enable PYCR to catalyze hydride transfer from the C2 of L-
T4C to NADP+. In DL-T2C, the sulfur is too far removed from the site of hydride 
transfer to have an impact, thus no activity is observed with this L-proline analog.    
 Both PYCR1 and PYCR2 catalyze the oxidation of L-T4C at a significant rate,  
however, PYCR2 exhibits a 10-fold higher catalytic efficiency than PYCR1.  
When comparing the L-T4C oxidative and L-P5C reductive enzyme activities, 
PYCR1 and PYCR2 both exhibit >103-fold higher catalytic efficiency in the 
forward direction reaction with L-P5C (as shown in data from chapter three) 
consistent with the main function of PYCRs in L-proline biosynthesis. 
 L-T4C has long been studied as an anti-aging therapeutic. For example, 
dietary supplementation with L-T4C (2.0 g/kg) in mice was shown to increase 
median and maximal life span by approximately 10–29% in both genders and 
improve neuromuscular coordination and exploratory function.20 The mechanisms 
by which L-T4C enhances lifespan in mice appear to be multifaceted and likely 
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involve the protection of mitochondrial function.  Navarro et al. (2007) found that 
L-T4C-supplemented diets given to mice ad libitum resulted in approximately 51–
74% curtailment of aging-related reductions of brain mitochondrial enzyme 
activities of NADH-dehydrogenase, cytochrome c oxidase, and mitochondrial 
nitric oxide synthase in old and senescent mice.20 
 Other anti-aging effects of T4C include its ability to act as an in vivo protector 
against protein aggregation and as a scavenger of reactive nitrogen and oxygen 
species, and N-nitroso compounds. In a recent mouse study by Lyu et al. (2020), 
L-T4C significantly diminished aggregation of oxidized bovine serum albumin 
(BSA), possibly by directly interacting with BSA via hydrogen bonds and van der 
Waals interactions.21 In the same study, the ability of L-T4C to prevent oxidative 
damage in brain tissue was tested against five other antioxidants. L-T4C showed 
the highest antioxidant effects in oxidized isolates of mouse brain tissue with a 
nearly 1.4-fold drop in malondialdehyde content (readout for membrane lipid 
peroxidative damage) and nearly 1.3-fold increase in superoxide dismutase 
enzyme activity (readout for cellular antioxidant activity).21  
 Over the years, L-T4C’s high capacity for trapping reactive nitrogen species 
and N-nitroso compounds has been exploited on the drug market for protection 
against liver diseases and gastrointestinal disorders. In mammals, many 
carcinogenic N-nitrosamines (e.g., N-nitrosomorpholine) are endogenously 
formed inside the acidic stomach by the reaction between amines and nitrite, 
which originates from nitrate produced by two primary sources: bacterial flora in 
the oral cavity and activated macrophages.22 It has also been established that 
endogenously produced N-nitrosothioproline and N-nitrosoproline comprise the 
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majority of excreted N-nitroso compounds found in urine.22 However, in vitro 
reaction kinetics show that N-nitrosation of L-T4C into N-nitrosothioproline occurs 
103 times faster than that of L-proline into N-nitrosoproline.23 Miwa et al.’s (1989) 
in vitro study reported that the incubation of 5 mM morpholine with activated 
murine macrophages resulted in the formation of 1.06 pM N-nitrosomorpholine, 
which could be strongly curtailed by treatment with 5 mM L-T4C.22 These results 
led Miwa et al. (1989) to propose that L-T4C can trap nitrosating-compounds 
produced by activated macrophages in non-human and human animals.22 In a 
more recent study of pathology with Barrett’s esophagus and development of 
esophageal cancer, Kumagai et al. (2004) evaluated the nitroxide scavenging 
efficacy of L-T4C using a surgically made duodenal reflux model in rats.  
Experimental treatment of 0.5% L-T4C was used to examine whether L-T4C 
could lower reactive nitrogen species (e.g., nitric oxide and peroxynitrite, and N-
nitroso compounds) present in the contents of the gastroduodenal reflux and 
thereby minimize pathology.24 Upon histological examination, the L-T4C treated 
rats had milder forms of mucosal changes with lesser degrees of inflammation 
and zero presence of esophageal adenocarcinoma compared to the control 
group. These exciting results suggest L-T4C inhibits the production of N-nitroso 
compounds in the gastroduodenal reflux contents, a property of potential 
therapeutic benefit in esophageal cancer.24  
 Another important aspect of L-T4C is its impact on biogenic aldehydes. L-T4C 
has been suggested to be a source of formaldehyde, presumably through its 
metabolism by L-proline dehydrogenase and PYCR. Garnier et al. (1980) 
assessed the clinical toxicity of L-T4C in patients and concluded that overdosage 
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of L-T4C overwhelms the metabolic capacity of the liver, thereby leading to L-
T4C distribution throughout the body including the cerebrospinal fluid (CSF). It 
was proposed that metabolic degradation of L-T4C in the intrameningeal tissue 
results in the release of toxic formaldehyde, which causes the acute central 
nervous system (CNS) symptoms of epileptic seizures and convulsions.25 In a 
separate study investigating the therapeutic potential of L-T4C in cancer, 
Newman et al. (1980) showed that the toxicity of L-T4C administered at 400 
mg/kg to mice and rats could be counteracted by barbiturate anesthesia with no 
acute CNS symptoms of epileptic seizures and convulsions.26 Thus, it was 
proposed that the acute toxic effects of L-T4C in animals may not be a direct 
consequence of formaldehyde released from L-T4C, but rather the inactivation of 
important biogenic aldehydes by L-T4C, particularly in the brain.10 From high 
performance liquid chromatography (HPLC) and mass spectrometry experiments, 
Susillo et al. (1989) reported on the involvement of L-cysteine in the brain 
metabolism of biogenic aldehydes, i.e. 5-hydroxyindole-3-acetic acid (5’-HIAAL), 
by forming L-thiazolidine-4-carboxylic acid derivatives, perhaps as a control 
measure to limit labile biogenic aldehydes by the rapid intracellular inactivation of 
the compounds.27 Essentially, the metabolic transformation of indoleamines into 
biologically inactive L-T4C derivatives is catalyzed by two enzymes located in 
separate subcellular compartments of neuronal cells.27 Monoamine oxidase 
located in the outer mitochondrial membrane converts 5-hydroxytryptamine (5-
HT) into biogenic aldehyde (5’-HIAAL) and then carbon-sulfur lyase in the cytosol 
cleaves off the cysteinyl moiety from the spontaneously formed condensation 
product of (L-cysteine + 5’-HIALL), namely (4R)-2-[3’-( 5’-hydroxyindoly1)-
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methyl]-1,3-thiazolidine-4-carboxylic acid (5’-HITCA), to liberate a reactive free 
aldehyde 5’-HIAA product.27  
 In summary, we show here that PYCR1 and PYCR2 exhibit activity with L-
T4C that is likely to be biologically significant and contribute to the physiological 
effects reported thus far with L-T4C. The 2.30 Å X-ray crystal structure of the 
PYCR1+L-T4C complex shows that L-T4C binds in the active site of PYCR1 
which is consistent with the mechanism shown in Fig. 4.6 with hydride transfer 
from L-T4C to NADP+. L-proline ligand inhibition kinetic studies corroborate the 
interpretation of the structural data and indicate that L-T4C and L-proline occupy 
the same binding pocket in PYCR1. Whether L-cysteine and formaldehyde also 
bind to PYCR1 is not known, but would be an important question to pursue in 
future research. A key underlying point of our findings is that human PYCRs 
function as a metabolic lynchpin that links L-Pro biosynthesis with L-Cys 
formation. In conclusion, a new enzyme activity is assigned to human PYCRs. 
We thus propose that PYCR be renamed for its bifunctional activities as L-
thiazolidine-4-and-L-pyrroline-5-carboxylate oxidoreductase (TPCOR).  
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Cautionary tale of using tris(alkyl)phosphine reducing agents with 
NAD+-dependent enzymes 
ABSTRACT  
 Protein purification protocols typically include disulfide bond reducing agents 
to thwart unwanted thiol oxidation and protein aggregation. Various disulfide 
bond reducing agents include dithiothreitol, β-mercaptoethanol, glutathione, and 
phosphine compounds such as tris(2-carboxyethyl)phosphine (TCEP) and tris(3-
hydroxypropyl)phosphine (THPP). Δ1-pyrroline-5-carboxylate (P5C) reductase 
(PYCR) catalyzes the final step of L-proline (L-Pro) biosynthesis by reducing L-
P5C into L-Pro using NAD(P)H as a hydride donor. When probing the ability of 
PYCR to operate in the reverse direction of L-Pro oxidation using NAD+, we 
observed a rapid non-enzymatic reaction between NAD+ and reducing agents 
TCEP and THPP. The product of the reaction with TCEP exhibits a maximum 
absorbance peak at 334 nm and forms with an apparent forward association rate 
constant of 490.5 M-1s-1. The reaction with TCEP is reversible with an apparent 
equilibrium association constant of 20.1 M-1. NMR characterization (1H-, 13C-, and 
31P-NMR) of the reaction product revealed that a covalent adduct is formed with 
the phosphorus of the phosphine compound and the C4 atom of the 
dihydronicotinamide ring of NAD+. The findings here serve to caution researchers 
when using TCEP or THPP in experimental protocols that include NAD(P)+-
dependent enzymes.  
INTRODUCTION 
In all domains of life, L-proline is biosynthesized from L-glutamate via 
three enzymatic steps with the last step catalyzed by L-Δ1-pyrroline-5-carboxylate 
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(L-P5C) reductase (PYCRs or P5CRs). PYCR reduces L-P5C into L-Pro using 
NAD(P)H as the hydride donor. Besides providing L-proline for protein 
biosynthesis, another function of PYCR is to provide NAD(P)+ redox equivalents 
for other pathways such as the oxidative branch of the pentose phosphate 
pathway in plants and animals. 1 PYCR has been found to have important roles in 
plant stress response, bacterial pathogenesis, and in humans, is upregulated in 
different types of cancer.2,3  
 Studies of PYCR or P5CR from various organisms have assayed the reverse 
reduction reaction of NAD(P)+ with L-Pro to characterize the kinetic activity of 
PYCR. In some cases, L-proline analogs such as L-thiazolidine-4-carboxylate (L-
T4C) and 3,4-dehydro-L-proline were used as the substrate.4 Because the L-P5C 
substrate is not commercially available and L-P5C is not amenable for long-term 
storage, PYCR assays in the reverse direction are more easily deployed. In 
particular, PYCR assays in the reverse direction are more readily applied in high-
throughput screening of compound libraries seeking to identify small molecule 
inhibitors of PYCR. We, therefore, sought to test the reverse activity of human 
PYCR, namely of human isoforms 1 (HsPYCR1) and (HsPYCR2).  Under our 
assay conditions, however, we did not detect any reverse activity of PYCR with 
NAD(P)+ and L-Pro, a finding which contrasts with previous reports on PYCRs.5,6  
 Amid these experiments, we unexpectedly discovered a chemical reaction 
between NAD+ and reducing agents tris(3-hydroxypropyl)phosphine (THPP) and 
tris(2-carboxyethyl)phosphine (TCEP). THPP and TCEP are tris(alkyl)phosphine 
compounds commonly used as disulfide reducing agents during protein 
purification and are thought to be more effective than dithiothreitol (DTT) and β-
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mercaptoethanol. In a direct side-by-side comparison of disulfide reducing agents 
at biologically relevant pH 8.0 conditions, THPP demonstrated higher water-
solubility, lower susceptibility to oxidation, and a higher ability to reduce a wide 
range of disulfide substrates into their corresponding thiols than TCEP and DTT.7 
THPP has also found uses in industrial wood pulp applications as an agent for 
bleaching and brightness stabilization in spruce wood pulps.8  
 THPP and TCEP concentrations are commonly maintained at ≤ 1.0 mM 
during protein purification and long-term storage of proteins. In a given enzyme 
assay, the final THPP and TCEP concentrations are typically much lower due to 
dilution effects upon adding the enzyme to the assay. However, THPP and TCEP 
are sometimes added to the assay solution for various reasons resulting in 
millimolar concentrations of the phosphine compound. Examples would include 
enzyme activity assays, biological binding experiments, and protein 
crystallization.  
 Here, we report evidence of a rapid chemical reaction between NAD+ and 
tris(alkyl)phosphine compounds THPP and TCEP under conditions commonly 
used for kinetic and structural studies of enzymes. Stopped-flow kinetics show 
the reaction product with the main UV absorbance peak at 334 nm that is rapidly 
formed upon mixing NAD+ and TCEP. One-dimensional and two-dimensional 
NMR demonstrate that the reaction product is a covalent adduct formed between 
the phosphorus of the phosphine compound and the C4 atom of the 
dihydronicotinamide ring of NAD+. Altogether, our findings here serve as a 
cautionary note when using TCEP and THPP in biological assays and structural 
studies of NAD(P)+-dependent oxidoreductases.  
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MATERIALS AND METHODS.  
Materials and Reagents.  
 MilliQ-Ultra purified water was used for the preparation of all buffers and 
chemicals in the experiments. The following reagents were purchased from 
Millipore-Sigma:  NaH2PO4, ε-amino-N-caproic acid, N-tosyl-L-phenylalanine 
chloromethyl ketone, bovine serum albumin, pyruvate, L-lactate dehydrogenase, 
NADPH, NADH, and NH4F. The following reagents were commercially available 
from Fisher Scientific: NaOH, NaCl, 2-[4(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES), Na2CO3, NaHCO3, and ethylenediamine 
tetraacetic acid (EDTA) disodium salt. Reagents β-octyl-D-glucopyranoside (β-
OG) and L-proline (L-Pro) were commercially available from Combi-Blocks. 
Ethanol (190- or 200-proof) was purchased from Decon Labs. 
Tris(hydroxymethyl)aminomethane (Tris), glycine, isopropyl β-D-
thiogalactopyranoside (IPTG), phenylmethylsulfonyl fluoride (PMSF), leupeptin 
hemisulfate, and NAD+ were purchased from Gold Biotechnology. Imidazole and 
o-aminobenzaldehyde (o-AB) were purchased from Acros Organics. In terms of 
tris(alkyl)phosphine reducing agents used in this study, tris(3-
hydroxypropyl)phosphine (THPP) was purchased from Strem Chemicals, and the 
hydrochloride salt of tris(2-carboxyethyl)phosphine (TCEP-HCl) was purchased 
from ThermoFisher Scientific-Pierce Biotech.  
 Stock solutions of NADH and NAD+ were prepared in 10 mM Tris-HCl (pH 8) 
and stored at -80 °C. NADH and NAD+ concentrations were determined 
spectrophotometrically at wavelengths 340 nm (ε340 = 6.22 x 103 M-1cm-1)9 and 
260 nm (ε260 = 17.37 x 103 M-1cm-1),10 respectively. Each tris(alkyl)phosphine 
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reducing agent, THPP and TCEP, was prepared in 100 mM Tris-HCl (pH 7.5) 
buffer and stored at -80 °C. 
Enzyme expression and PYCR reverse activity assays  
 HsPYCR1 protein was graciously provided by Dr. John J. Tanner’s group after 
following an expression and purification procedure as described previously.11 
Similarly, HsPYCR2 protein was expressed from a pKA8H-PYCR2 construct in E. 
coli BL21 (DE3) pLysS competent cells (Novagen-EMD Millipore Sigma), cultured 
in TB liquid media and induced with 0.4 mM IPTG, followed by centrifugation for 
the harvesting of cell pellets. Next, the cell pellets were resuspended in NPI-5 cell 
lysis buffer (5 mM imidazole, 500 mM NaCl, 50 mM NaH2PO4, pH 7.5) also 
containing 500 µM THPP, 0.01% TritonX-100 detergent (Amresco), 0.01% Brij-35 
polyoxyethylene detergent (Santa-Cruz Biotechnology), 10 mM βOG, and a 
mixture of five protease inhibitors. The cell suspension was then subjected to 
sonication and 4 °C centrifugation, to obtain supernatants of target protein 
solution for further purification by Ni-NTA Superflow (Qiagen) affinity column 
chromatography.  
 Time-course profiles of enzymatic reactions in the direction of NADH 
formation were performed at room temperature with NAD+ substrate to monitor 
gain of absorbance at 340 nm over time under dark lab conditions with overhead 
lights off the entire time, using a modified protocol based on previous 
studies.12,9,4,13 The ability of HsPYCR1 or 2 enzyme to catalyze the reverse 
reaction (L-Pro + NAD+  L-P5C + NADH) was tested in 0.1 M Tris-HCl (pH 7.5) 
buffer containing 0.01% (v/v) Brij-35 detergent, 30 mM MgCl2, 5 mM L-proline 
(pH 7.5), and 0.5 mM NAD+ (pH 8), and with or without tris(alkyl)phosphine 
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compound (1 mM TCEP (pH 7.5) or 1 mM THPP (pH 7.5)). The reaction 
components added into a 1 cm path length rectangular semi-micro, self-masking 
quartz spectrophotometer cuvette (Starna Cells) were cover wrapped in 
aluminum foil to protect from ambient light, placed atop a rocking platform for mild 
agitation at room temperature for 15 min, and then, the reaction was initiated by 
adding PYCR enzyme (0.06 µM final concentration) to achieve final assay 
volume of 600 µl. Followed by immediate parafilm covering the cuvette top, we 
shook it with inversion agitation to mix contents before placing the quartz cuvette 
into the spectrophotometer. Reactions were monitored at 340 nm for 30 min 
using a Varian Cary 50-UV/Vis spectrophotometer (Agilent Technologies) and 
Cary WinUV Kinetics Application software (version 5.0.0.999, Agilent 
Technologies). 
NAD+ reactions with tris(alkyl)phosphine reagents 
 Reactions of NAD+ with THPP and TECP were initially performed at room 
temperature and dark conditions similar to the PYCR enzyme assays above, 
except no enzyme was added. Reaction components (0.5 mM NAD+ and 5 mM L-
proline) were combined with 0.1 M Tris-HCl buffer (pH 7.5, 0.01% (v/v) Brij-35 
detergent, 30 mM MgCl2) in the quartz cuvette for 15 min initial absorbance 
monitoring followed by the addition of THPP and TCEP (1 mM final 
concentration) and immediate parafilm covering the cuvette top for inversion 
agitation to mix contents before placing the quartz cuvette back into the 
spectrophotometer. The absorbance at 340 nm was monitored for 30 min total 
using a Varian Cary 50-UV/Vis spectrophotometer. 
 Stopped-flow absorbance spectrophotometry of the reactions between NAD+  
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and THPP or TCEP were performed in the dark with different 100 mM (pH 7.5) 
reaction buffer compositions:  HEPES, Tris-HCl, Na-Phosphate, and PBS. All 
stopped-flow experiments were conducted on a Hi-Tech KinetAsyst Scientific SF-
61DX2 stopped-flow instrument equipped with a photodiode array detector and 
attached to nitrogen gas pressure, where all instrument settings and data 
collection was controlled and managed by Kinetic Studio software. The 
temperature of the mixing chamber for all experiments was maintained at room 
temperature (23 °C). NAD+ (0.5 mM after mixing) was rapidly mixed with THPP or 
TCEP (25 mM after mixing) and the reaction was monitored in the stopped-flow 
by multiwavelength absorption in the range of 310-702 nm, Run Time = 1 s, 
Number of Scans = 100. In another set of experiments, NAD+ was held fixed at 
0.5 mM (after mixing) while increasing the concentrations of THPP and TCEP (5-
150 mM, after mixing) in 100 mM HEPES (pH 7.5) buffer and monitoring the 
reaction by single-wavelength data collection at 334 nm. The average of three 
collected traces (n=3 technical replicates) was fit by non-linear least-squares 
regression to a single 3 parameter exponential rise equation using SigmaPlot 
12.0 (version 12.0.0.182, Systat Software). The observed rate constant (kobs) 
from the single 3 parameter exponential fitting was then plotted versus THPP and 
TCEP concentrations from which the apparent second-order forward association 
rate constant of the reaction (k+app) was determined as the slope of linear least-
squares fit analysis. The apparent first-order reverse dissociation rate constant of 
the reaction (k−app) was determined by the intercept at the vertical axis. Under the 
pseudo-first-order conditions of the stopped-flow experiments ([THPP or TCEP] 
>> [NAD+]), the following linear relationship holds kobs = (k+app) [THPP or TCEP] + 
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(k−app) and the apparent association equilibrium constant is defined as Kaapp = 
(k+app/k−app).14 
Nuclear Magnetic Resonance (NMR) characterization of the reaction product  
 For NMR measurements, the reaction of NAD+ with THPP and TCEP was 
performed in 100 mM NaHCO3-Na2CO3 (pH 7.5) buffer. Reaction component 
tubes were wrapped in aluminum foil to protect from ambient light. Samples were 
made by reacting NAD+ (30.6 mM) or NADH (25.3 mM) with 400 mM of THPP or 
TCEP and kept on ice before NMR measurements. To assign the chemical 
structure to samples, we examined H2O-D2O (9:1 in volume) deuterated solvent-
based preparations of each reaction component individually as well as in 
approximate (1:1) volume combinations of NAD+ to THPP or TCEP in separate 
NMR glass capillary tubes to gather 1H-, 13C-, and 31P-NMR data, as well as for 
the combination samples 1H-31P-HSQC-TOCSY, 1H-31P-HSQC, 1H-13C HMBC, 
and 1H-13C HSQC data. The NMR spectra were acquired on a Bruker Advance 
600 MHz NMR spectrometer with a 5 mm TXI or 5 mm BBO probe.  All spectra 
were acquired under dark lab conditions with overhead lights off the entire time 
and with the samples at 4 °C. 
RESULTS 
Evidence of (NAD+─tris(alkyl)phosphine) association reaction 
 Evidence for a nonenzymatic reaction between NAD+ and a 
tris(alkyl)phosphine reducing reagent was adduced by several observations. 
Initial assays of HsPYCR1 and 2 with L-Pro and NAD+ generated no increase in 
absorbance at 340 nm over 30 min (Figure 5.1). We then included THPP and 
TCEP in the reaction buffer as was done in the U.S. Patented PYCR1 inhibition  
117 
assay protocol.15 A rapid initial increase was observed with either TCEP or  
A B 
  
Figure 5.1. Test for PYCR activity in the reverse direction. PYCR activity in the 
reverse direction (L-Pro + NAD+  L-P5C + NADH) was assayed using 0.1 M 
Tris-HCl (pH 7.5) buffer with 0.01% (v/v) Brij-35 detergent, 30 mM MgCl2, 5 mM 
L-proline, 0.5 mM NAD+, with or without 1 mM TCEP or 1 mM THPP, and final 
enzyme concentration 0.6 µM (A) HsPYCR1 and (B) HsPYCR2. Progress of the 
reaction was monitored for 30 min by following the absorbance at 340 nm.   
  
THPP, which then leveled off between 10-15 min and sustained absorbance 
intensity up to 30 min (Figure 5.1). Suspecting that we were observing a 
nonenzymatic reaction, we repeated the assay without PYCR and observed a 
sharp increase in absorbance at 340 nm upon adding THPP or TCEP after 15 
min with again a sustained absorbance intensity up to 30 min (Figure 5.2).   
 Because the observed increase in absorbance occurred rapidly upon adding 
TCEP and THPP, we examined the reaction by stopped-flow absorbance 
spectrophotometry. Upon rapidly mixing both TCEP with NAD+ in 100 mM 
HEPES (pH 7.5) reaction buffer, a peak with a maximum absorbance at 334 nm 
appeared within 200 ms (kobs of 35.4 ± 0.4 s-1) (Figure 5.3, A). The reaction was 
repeated using different reaction buffers with each exhibiting a similar kobs value 
(30-35 s-1) for the increase in absorbance, indicating the product formation is 





Figure 5.2. Absorbance changes upon mixing NAD+ with tris(alkyl)phosphine 
compounds. Nonenzymatic reactions with or without NAD+ (0.5 mM) were 
incubated in 0.1 M Tris-HCl (pH 7.5) buffer with 0.01% (v/v) Brij-35 detergent, 30 
mM MgCl2, and 5 mM L-proline. After 15 min, TCEP (A) and THPP (B) were 
added (1 mM final concentration) and the absorbance at 340 nm was recorded 
for an additional 15 min. All data points were normalized to a zero-absorbance 
baseline.   
  
  A   C 
  
  B   D 
  
Figure 5.3. Stopped-flow absorbance spectrophotometry of mixing NAD+ and 
TCEP. NAD+ (0.5 mM after mixing) and TCEP (25 mM after mixing) were rapidly 
mixed and multiwavelength absorbance traces were recorded. Reactions were 
performed in 100 mM (pH 7.5) (A) HEPES, (B) Tris-HCl, (C) Na-Phosphate, and 
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(D) PBS reaction buffer. Plots of the absorbance increase at 334 nm over 0.20 s 
of time were fit to a single 3 parameter exponential equation as shown in the 
inset along with the observed rate constant (kobs).  
 
 Rate constants for the observed increase in absorbance at 334 nm were then 
determined for TCEP and THPP using 100 mM HEPES (pH 7.5) reaction buffer.  
   A    C 
 
 
   B    D 
  
Figure 5.4. Stopped-flow kinetics of the (NAD+─tris(alkyl)phosphine) association 
reaction. NAD+ (0.5 mM) was rapidly mixed with 50 mM (A) THPP and (C) TCEP 
in 100 mM HEPES (pH 7.5) reaction buffer. Plots of the absorbance increase at 
334 nm over 0.30 s of time were fit to a single 3 parameter exponential equation 
are shown in the inset along with the observed rate constant (kobs). The 
dependence of the observed rate constant (kobs) on THPP and TCEP 
concentration was then determined by holding NAD+ concentration fixed (0.5 
mM) and varying THPP and TCEP concentration (5-150 mM). Single wavelength 
data were collected at 334 nm and the corresponding kobs values were 
determined from single 3 parameter exponential fits of the data. The apparent 
forward association (k+ app) and reverse dissociation (k- app) rate constants were 
determined from the plot of kobs versus (B) THPP and (D) TCEP. Data are plotted 
as (mean ± SD) of n=3 technical replicates and fit to a linear equation using 
SigmaPlot 12.0. All concentrations are specified after mixing. 
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Figure 5.4 shows the absorbance changes upon rapidly mixing 50 mM THPP  
(panel A) or 50 mM TCEP (panel B) with NAD+. In another set of experiments, 
NAD+ was then rapidly mixed with increasing concentrations of THPP or TCEP 
(5-150 mM). The observed rate constants (kobs) versus THPP (panel C) and 
TCEP (panel D) concentration were then plotted to determine the apparent 
forward association (k+app) and reverse dissociation (k-app) rate constants. Table 
5.1 summarizes the rate constants and shows that both the apparent forward 
(490.5 M-1 s-1) and reverse (24.4 s-1) rate constants with TCEP are faster than 
with THPP. The apparent equilibrium association constant (Kaapp), however, is 









a(Value ± Std error) is reported for the apparent forward rate constant determined as the 
slope of the plotted data fit to a linear least-squares equation using SigmaPlot 12.0 
(version 12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=3 technical 
replicates. 
b(Value ± Std error) is reported for the apparent reverse rate constant determined as the 
vertical axis intercept of the plotted data. 
cApparent equilibrium association constant determined from the calculation of Kaapp = 
(k+app/k−app). 
 
Characterization of the reaction product 
 L-lactate dehydrogenase and pyruvate were initially added to the reaction 
product to test whether NADH was formed. However, no decrease in absorbance 
(330-340 nm) was observed indicating that the product was not usable by L-
Table 5.1. Pre-steady-state kinetic parameters for the 
reaction of NAD+ and tris(alkyl)phosphine compounds  
Kinetic parameter  THPP TCEP 
k+ app (M-1 s-1)a 230.9 ± 5.7 490.5 ± 24.8 
k- app (s-1)b 6.6 ± 0.4 24.4 ± 1.7 
Ka app (M-1)c 35.1 ± 2.3 20.1 ± 1.7 
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lactate dehydrogenase. We also did not find evidence for NADH by mass 
spectrometry analysis of the reaction product.  
 NMR was then used to characterize and identify the product. Initial NMR 
experiments included one-dimensional (1H and 31P) and two-dimensional (1H-31P 
HSQC, 1H-31P HSQC-TOCSY) analyses. The chemical shift data from these 
experiments indicated the tris(alkyl)phosphine compound’s phosphorus atom was 
interacting with the C4 position of the dihydronicotinamide ring of NAD+.  
Additionally, two-dimensional NMR data as shown in Fig. 5.5 with corresponding 
spectral data provided in Table 5.2, indicated the reaction was reversible as the 
1H-31P HSQC-TOCSY showed 31P correlations to reaction product protons and 
31P correlations to NAD+ protons.  With the 1H-31P HSQC-TOCSY, NAD+ proton 
correlations could only be observed if the phosphine compound was associating 
and dissociating with the dihydronicotinamide ring during the TOCSY spinlock, 
indicating reaction reversibility.  Lastly, these initial experiments indicated the 
reaction yielded two products with different stereochemistry, likely with the 
phosphorus above or below the dihydronicotinamide ring, in a roughly 1 to 0.6 
ratio. 
 As evident from both one-dimensional (31P) and two-dimensional (1H-31P 
HSQC, 1H-31P HSQC-TOCSY) analyses, the latter of which is shown in Fig. 5.5 
and Table 5.2, there were two sets of phosphorus species observed in the NAD+ 
and THPP reaction mixture. The phosphorus species circa 34.4 ppm were 
interacting with the dihydronicotinamide ring. The phosphorus species circa -13.2 
ppm were interacting with one of the ribose rings. Additionally, two-dimensional 
(1H-13C HMBC) analysis of NAD+ alone and NADH alone with their spectral data 
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Figure 5.5. Two-dimensional 1H-31P NMR spectra of the NAD+ and THPP 
reaction mixture. Shown here is the (A) 1H-31P HSQC spectrum and (B) 1H-31P 
HSQC-TOCSY spectrum. Both spectra were acquired with a J-coupling constant 
of 11 Hz, and the latter spectrum with a TOCSY mixing time of 80 ms. The 
assignments are summarized in Table 2 to support the chemical structures of the 
reaction product and NAD+ alone as shown in Fig. 5.6, D. 
 
summarized in Tables 5.3 and 5.4, respectively, support structural assignments 
of these reference compound structures shown in Fig. 5.6, A and B. 
 
Table 5.2.  Chemical shifts from 1H-31P NMR correlation experiment† of  NAD+ and THPP 
reaction mixture 
Label δ (1H, ppm)‡ δ (
1H-31P HSQC, 
ppm) 
δ ( 1H-31P HSQC-
TOCSY, ppm) 
1 3.96 (1H), minor 4.35 34.3, minor 34.4 34.3, minor 34.4 
2 1.96 (m), minor 1.98 34.3 34.3 
3 1.54 (m) 34.3 34.3 
4 3.44 (m)  34.3 
5    
6    
7 7.10 (d, 1H, J = 1.8 Hz), minor 7.23 
(d, 1H, J = 1.8 Hz) 
34.3, minor 34.4 34.3, minor 34.4 
8 6.33 (at, 1H, J = 6.3 Hz), minor 6.28 
(at, 1H J = 6.3) 
34.3, minor 34.4 34.3, minor 34.4 
9 4.51   
10 4.67 (broad s), minor 4.69   
b 8.91 (d, J = 6.3 Hz)  34.3 
d 8.59 (d, J = 8.4 Hz)  34.3 
g 9.11 (s)  34.3 
δ ( 31P) 
δ (1H) δ (1H) 
δ ( 31P) 
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†Chemical shifts were determined from the HSQC and HSQC-TOCSY experiments shown in Fig. 
5.5 and correspond to site labels shown in Fig. 5.6, D. 
‡Listed next to each 1H-NMR chemical shift value is (multiplicity designation [s, singlet; d, doublet; 














†Chemical shifts were determined from the HMBC experiment and correspond to site labels 
shown in Fig. 5.6, A. 
‡Listed next to each 1H-NMR chemical shift value is (multiplicity designation [s, singlet; d, doublet; 
etc.], J-coupling constant).  
 
†Chemical shifts were determined from the HMBC experiment and correspond to site labels 
shown in Fig. 5.6, B. 
‡Listed next to each 1H-NMR chemical shift value is (multiplicity designation [s, singlet; d, doublet; 
dd, doublet of doublets], J-coupling constant).  
     A C 
  
Table 5.3.  Chemical shifts from 1H-13C NMR correlation experiment† of NAD+ 
Label δ (1H, ppm)‡ δ (13C, ppm) HMBC 
a 5.85 (d, 1H, J = 5.6 Hz) 98 b, g 
b 8.9 (d, 1H, J = 6.6 Hz) 140.3 a, c, d, g  
c 7.93 (at, 1H, J = 6.6 Hz) 126.6 b, e 
d 8.57 (d, 1H, J = 8.5 Hz) 143.6 b, f, g 
e  131.6  
f  163.2  
g 9.1 (s, 1H) 138.0 a, b, d, e, f 
Table 5.4.  Chemical shifts from 1H-13C NMR correlation experiment† of NADH 
Label δ (1H, ppm)‡ δ (13C, ppm) HMBC 
A 4.55 (d, 1H, J = 7.1 Hz) 93.1 B, G 
B 5.73 (d, 1H, J = 8.4 Hz) 121.4 A, C, D, G 
C 4.51 (1H) 103.4 B, E 
D 2.35 (dd, 1H, J = 3.4, 18.8 Hz),  
2.49 (d, 1H, J = 18.4 Hz) 
19.9 B, C, E, G 
E  97.5  
F  170.7  
G 6.68 (s, 1H) 136.7 A, B, D, E, F 
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Figure 5.6. Chemical structures of compounds based on the assignment of NMR 
spectral data. Assignments of (A) NAD+ structure, (B) NADH structure, (C) NAD+ 
and THPP reaction mixture structure, and (D) structures of NAD+ and THPP 
reaction mixture (left) and NAD+ alone (right) have alphanumeric site labels 
corresponding to chemical shift data presented in Tables 5.2-5.5.  
 
Further experiments were conducted, on an aged sample of NAD+ and THPP, 
to complete the structural assignment. These experiments included one 
dimensional (13C) and two dimensional (1H-1H COSY, 1H-1H TOCSY, 1H-13C 
HSQC, 1H-13C HMBC) analyses as shown in Fig. 5.7, the last of which has its 
spectral data summarized in Table 5.5. Also, the reaction product of NAD+ and 
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Figure 5.7. Two-dimensional NMR spectra of NAD+ and THPP reaction mixture. 
Shown here is the (A) 1H-1H COSY spectrum, (B) 1H-1H TOCSY spectrum, (C) 
1H-13C HSQC spectrum, and (D) 1H-13C HMBC spectrum. The assignments of 
panel D are summarized in Table 5.5 to support the chemical structure of the 
reaction product as shown in Fig. 5.6, C. 
†Chemical shifts were determined from the HMBC experiment shown in Fig. 5.7, D and 
correspond to site labels shown in Fig. 5.6, C. 
‡Listed next to each 1H-NMR chemical shift value is (multiplicity designation [s, singlet; d, doublet; 
m, multiplet; etc.], J-coupling constant). 
 
THPP was very similar to that of NAD+ and TCEP as determined by overlaying or 
stacking the one-dimensional proton spectra as shown in Fig. 5.8.  
 
Table 5.5.  Chemical shifts from 1H-13C NMR correlation experiment† of  NAD+ and THPP 
reaction mixture 
Label δ (1H, ppm)‡ δ (13C, ppm) HMBC 
1 3.96 (1H), minor 4.35 28.4 (J-CP = 47 Hz), 
minor 28.6 (J-CP = 48 Hz)  
5, 6, 7, 8, 9 
2 1.96 (m), minor 1.98 11.3 (J-CP = 44 Hz), 
minor 11.1 (J-CP = 45 Hz) 
3, 4 
3 1.54 (m) 21.6 (J-CP = 4 Hz),  
minor 21.8 (J-CP = 4 Hz) 
2, 4 
4 3.44 (m) 59.3 2, 3 
5  168.2  
6  94.6  
7 7.10 (d, 1H, J = 1.8 Hz),  
minor 7.23 (d, 1H, J = 1.8 Hz) 
139.3, minor 134.5 1, 5, 6, 8, 10 
8 6.33 (at, 1H, J = 6.3 Hz),  
minor 6.28 (at, 1H J = 6.3) 
126.6, minor 132.6 1, 7, 9, 10 
9 4.51 93.9 1, 8 









 To our knowledge, this is the first NMR characterization of a covalent adduct 
between NAD+ and TCEP or THPP. The reaction occurs at biologically relevant 
concentrations of NAD+ (0.5 mM) with TCEP and THPP concentrations (1 mM) 
typically used in experimental conditions. Stopped-flow kinetics indicate the 
reaction is reversible and occurs on a timescale comparable to that of TCEP 
reduction of disulfide bonds in DTT (43 M-1s-1), peptide substrates containing a 
CXXC motif (650 M-1s-1), and oxidized cysteines in proteins (1.5 - 813 M-1s-1).16,17 
We did not detect NADH formation, instead, NMR showed conclusive evidence 
for a covalent adduct of the phosphorus at the C4 position of the 
dihydronicotinamide ring. The reaction likely proceeds through a nucleophilic 
attack of the phosphine’s phosphorus atom at the C4 position of the 
dihydronicotinamide group of NAD+ similar to that of a tertiary phosphine 
attacking an alkyl halide to form a phosphonium ion. 
The dihydronicotinamide ring of NAD+ has electrophilic character and thereby 
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Figure 5.8. Covalent Adduct Reaction Product NMR spectra and resolved 
chemical structures. (A) 1H-NMR spectra stacked as (a) NAD+ with THPP and (b) 
NAD+ with TCEP. (B) Chemical structures of resolved covalent adduct product 
from the reaction of (i) NAD+ with THPP and (ii) NAD+ with TCEP.  
 
is susceptible to modifications by nucleophilic species. More fundamentally, 
NAD(P)+ and NAD(P)H differ from other coenzymes such as thiamine 
pyrophosphate, biotin, and pyridoxal phosphate, which return to their original 
forms upon completion of their catalytic cycles, whereas the pyridine 
dinucleotides appear modified with stereospecific hydrogen exchange at the C4 
position of the dihydronicotinamide ring, thus earning NAD(P)+ and NAD(P)H the 
title of cosubstrate.18 Of biological relevance is that various sulfhydryl compounds 
can form adducts at the C4 position of the dihydronicotinamide ring.19 Besides 
consistent UV absorption spectra, the infrared absorption spectra of covalent 
adduct compounds formed from the reaction of thiols (including benzyl 
mercaptan, 2-mercaptothiazole, β-phenylethyl mercaptan, ethyl mercaptan, 
thiocyanate ion, and thiophenol) with 1-substituted NAD+ demonstrate 
i ii 
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characteristic peak absorption at ~1560 cm-1, particularly due to a vinylogous 
amide group that often occurs in 1,4-dihydronicotinamide molecules.19 Sulfhydryl 
compounds such as cysteine and glutathione can add to the dihydronicotinamide 
ring of NAD+ to form NAD+-mercaptan addition complexes with UV absorbance 
maxima at 350 nm.20 It is of interest to note that the apparent association 
equilibrium constants for cysteine (2.4 x 10-9 M-1) and glutathione (1.6 x 10-9 M-
1)20 with NAD+ are dramatically 109- to 1010-fold smaller in magnitude than the 
Kaapp values for tris(alkyl)phosphine compounds with NAD+ observed here. 
Another example of observed NAD+ addition reaction with a nucleophilic species 
involves the bacterial NAD+-dependent enzyme urocanase, which forms a 
chromophore between competitive inhibitor imidazole-propionate and NAD+ with 
an observed UV absorbance peak at 335 nm.21 In this case, NMR evidence 
showed that the chromophore generated from this urocanase reaction was not 
NADH, but rather was a reversible complex of the inhibitor’s imidazole nitrogen 
forming a covalent adduct with the C4 position of the dihydronicotinamide ring of 
NAD+.21 Thus, the UV absorbance peak of 334 nm observed here for the covalent 
NAD+─tris(alkyl)phosphine adducts, is similar to that previously reported for 
various covalent NAD+ adduct species.  
 We could not find any previous reports of chemical reactivity between NAD+ 
and phosphine compounds. In 2017, however, Mayclin et al. from the Seattle 
Structural Genomics Center for Infectious Disease resolved a 1.45 Å X-ray 
crystal structure of the NADP+ cofactor-bound complex of bacterial short-chain 
dehydrogenase/reductase (SDR) from Burkholderia ambifaria (Figure 5.9).22 This 
structure was determined from a crystal grown in the presence of 5 mM NADP+ 
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and 1 mM TCEP (PDB Code: 5VPS). Whereas NADP+ was explicitly added to the 
crystallization experiment to obtain a structure of the functional enzyme, TCEP 
was included as an innocuous component of the enzyme stock solution buffer. 
The electron density maps clearly showed NADP+ bound to the Rao-Rossmann 
fold in the expected conformation (Figure 5.9, a). Unexpectedly, strong electron 
density indicated that the C4 atom of the dihydronicotinamide ring of NADPH had 
been covalently linked to the phosphorus atom of (Figure 5.9, b). The electron 
 
Figure 5.9. Structure of Burkholderia ambifaria SDR with a NADP+─TCEP adduct 
in the active site. (a) Ribbon cartoon model of the SDR protein with the adduct in 
pink sticks. The inset shows electron density for the adduct (polder omit, 3.0σ).  
(b) Closeup views of the adduct showing electron density for the P-C4 bond (left) 
and interactions with the carboxyethyl groups of TCEP (right). The X-ray crystal 
structure of SDR soaked with 5 mM NADP+ and 1 mM TCEP was graciously 
provided by Dr. Stephen J. Mayclin and Dr. Thomas E. Edwards. 
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density is consistent with the structure of the adduct determined from solution 
NMR. Thus, TCEP and NADP+ are also capable of forming a covalent adduct in 
an oxidoreductase active site. Whether the kinetics of the reaction is similar to 
that in solution remains unknown. Because TCEP and NAD(P)+ can form a 
complex in solution or in an enzyme active site, it raises the question as to how 
many structures of NAD(P)+-dependent oxidoreductases have been impacted by 
including TCEP or THPP in the crystallization milieu. Although the NADP+-TCEP 
adduct was captured in SDR, the same adduct could potentially cause disorder of 
the NAD(P)+ cofactor in other enzymes making it difficult to identify NAD(P)+-
binding interactions.  
 In addition to unintentional interference with crystallization and structural 
studies, TCEP and THPP are also likely to cause problems with enzyme assays 
and binding studies. As we observed, adding TCEP and THPP to NAD(P)+-
dependent assays would generate a rapid absorbance increase around 340 nm 
that, without proper controls, could be misinterpreted as enzyme activity. This 
would particularly be a problem with high-throughput assays that use only 
endpoint measurements. With respect to binding studies, the addition of 
tris(alkyl)phosphine compounds would potentially lead to lower concentrations of 
free NAD(P)+, resulting in anomalous errors in the determined binding constant. 
Also, the data could be convoluted by unknowingly having two species present, 
NAD(P)+ and the NAD(P)+─tris(alkyl)phosphine covalent adduct. Methods that 
measure changes in heat to quantify bimolecular binding events, such as 
isothermal titration calorimetry, would have additional complications due to heat 
contributions by NAD(P)+ reacting with TCEP or THPP during the titration.23  
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 We characterized the chemical reaction kinetics of 
(NAD+─tris(alkyl)phosphine) association reactions and identified the chemical 
structure of the reaction product molecule through NMR assignments. Evidence 
from stopped-flow spectrophotometry and multidimensional NMR indicate that 
the species formed with a UV absorbance maximum at 334 nm is a reversible 
covalent adduct between the tris(alkyl)phosphine compound’s phosphorus atom 
and the C4 position of the dihydronicotinamide group of NAD+. Side-by-side 
comparison of TCEP and THPP shows the reaction kinetics with NAD+ are faster 
with TCEP whereas THPP exhibits a 1.7-fold higher apparent equilibrium 
association constant for the NAD+─tris(alkyl)phosphine covalent adduct. In 
conclusion, the implications of our data concerning the 
(NAD+─tris(alkyl)phosphine) association reaction warrant caution be taken when 
using TCEP or THPP with NAD(P)+-dependent enzymes. 
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Major Conclusions and Future Directions 
MAJOR CONCLUSIONS 
 Pyrroline-5-carboxylate reductases have been identified as important 
housekeeping enzymes of L-proline biosynthesis, which generate the unique 
imino acid L-proline that serves as an instrumental structural component of 
proteins and participates in stress protection and redox homeostasis of cells 
across all three domains of life (eukaryota, bacteria, and archaea).1,2,3,4 In 
chapter two, we describe the circa 1.9 Å high resolution X-ray crystal structures of 
the binary complexes of HsPYCR1 with NADPH or L-Pro bound ligands that were 
obtained by our collaborators. These structures unequivocally identify the  
NADPH-binding site being located in the N-terminal Rao-Rossmann fold domain 
of HsPYCR1. A high-resolution X-ray crystal structure of a ternary complex of 
HsPYCR1 containing NADPH and an L-P5C/L-Pro analog, L-THFA, provides a 
mechanistic model of the Michaelis complex formed during hydride transfer. 
Functional analysis of  a highly conserved active site Thr238 by site-directed 
mutagenesis reveals substitution with Ala (T238A) results in a 10-fold diminution 
in catalytic efficiency with varied concentrations of L-P5C relative to the wild-type 
enzyme. These data suggest that the loss of Thr238 as a potential proton donor 
in the enzyme active site strongly hinders catalytic activity, perhaps by loss of a 
hydrogen bonding interaction with the imine nitrogen of the L-P5C substrate. 
 Based upon structural homology with human PYCR1, chapter three focuses 
on the functional and structural consequences in wild-type HsPYCR2 enzyme of 
two mutant variants, Arg119Cys and Arg251Cys, that were previously identified 
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in patients with microcephaly and hypomyelination.5 Arg119 and Arg251 are 
predicted to be important for the catalytic activity and structural stability of 
HsPYCR2. Henri-Michaelis-Menten kinetic analysis shows a 164-fold loss in 
catalytic efficiency for the Arg119Cys mutant, with varied concentrations of L-P5C 
substrate and fixed concentration of NADH cofactor, relative to the wild-type 
enzyme. The dramatic loss in activity could be due to mutation of Arg119 near 
the posterior wall of the enzyme’s active site leading to disrupted conformation 
flexibility of HsPYCR2 near the cofactor substrate binding site, thus leading to 
decreased kinetics of cofactor substrate entrance and egress.6 The Arg251Cys 
mutation has a profound effect on the thermostability and secondary structure of 
HsPYCR2 as determined by fluorescence-based thermal shift assays and circular 
dichroism, respectively. 
The binding order of L-P5C and NAD(P)H to HsPYCR1 and HsPYCR2 
enzymes was evaluated by product(s) inhibition studies using L-Pro, NADP+, or 
NAD+.7 Collective analysis of Henri-Michaelis-Menten kinetic data and Hanes-
Woolf plots of linear regressions indicate NADP+ and NAD+ are mixed 
noncompetitive inhibitors8 of HsPYCR1 and 2 against NADPH and NADH 
substrates, respectively. L-Proline is a competitive inhibitor8 of HsPCYR1 and 2 
with respect to L-P5C substrate. Taken together, these modes of product 
inhibition support a proposed sequential-ordered binding mechanism for 
HsPYCR1 and HsPYCR2 enzymes.7 Interestingly, serum levels of L-proline in 
healthy adult humans is reported to range from 125-633 µM with mean levels 
around 270 µM.9,10 The apparent competitive inhibition constants for both 
HsPYCR1 and HsPYCR2 determined with L-proline (KIC app = 2.61 ± 0.25 mM and 
136 
145 ± 8 µM, respectively) highlight HsPYCR2’s greater sensitivity to physiological 
L-proline concentrations,  suggesting that it is susceptible to product feedback 
inhibition by L-proline. In terms of NAD+, Yang et al.’s (2007) study estimated 
[NAD+] in mitochondria of HEK293 cells is 245.6 µM using MALDI-MS, which 
corresponds to 2053 pmol NAD+/mg mitochondrial protein.11 NADH may be lower 
than NAD+ levels (e.g., physiologic NAD+/NADH ratio ~0.1-10 in mammalian 
cells)12, and intracellular concentrations of NADP+ and NADPH are even lower 
than their non-phosphorylated forms wherein the NADP+ pool is predominantly in 
the reduced state.13 Thus, the apparent competitive inhibition constants 
determined here for both HsPYCR1 and HsPYCR2 with  NADP+ and NAD+, 
respectively (KIC app = 8.28 ± 1.36 mM and 792 ± 248 µM) as well as the 
corresponding apparent uncompetitive inhibition constants (KIU app = 3.92 ± 0.64 
mM and 326 ± 102 µM) highlight again that HsPYCR2 is more susceptible to 
product feedback inhibition by NAD+ than HsPCYR1. The physiologic levels of 
NADP+ are not high enough to effectively inhibit HsPYCR1. 
In chapter four, we performed in vitro experiments probing human PYCR-
mediated reverse direction reactions, which involve the reduction of NAD(P)+ into 
NAD(P)H using L-Pro, L-T4C, or DL-T2C as the reducing substrate with human 
PYCRs at biologically relevant pH 7.5. From these studies, we observed no 
substantial reverse activity of HsPYCR1 or HsPYCR2  with L-Pro or DL-T2C, 
however, substantial activity was observed with L-T4C. Upon further analysis of 
Henri-Michaelis-Menten saturation kinetics, we report that HsPYCR2 exhibits an 
apparent catalytic efficiency (136 M-1 s-1) with varied concentrations of L-T4C that 
is nearly 10-fold higher than that of HsPYCR1 (13.7 M-1 s-1) with varied 
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concentrations of L-T4C. Ligand inhibition kinetics evidence of L-Pro as a 
competitive inhibitor (KIC app = 15.7 mM) of HsPYCR1 with respect to L-T4C 
substrate. This data along with the 2.30 Å X-ray crystal structure of a 
HsPYCR1─L-T4C complex highly suggests  that L-T4C binds at the same active 
site region as L-Pro in the enzyme. Taken together, this experimental evidence 
assigns a novel enzyme function to human PYCRs. We propose PYCRs be given 
the new name L-thiazolidine-4-and-L-pyrroline-5-carboxylate oxidoreductase 
(TPCOR) to embody both enzyme activities. 
Upon encountering a PYCR1 inhibition assay protocol that included TCEP in 
the human PYCR-mediated reverse direction reaction,14 we set out to further 
examine the enzymatic and nonenzymatic reactions between  
tris(alkyl)phosphine compounds THPP or TCEP and NAD+ as detailed in chapter 
five. To that end, our body of evidence of the (NAD+─tris(alkyl)phosphine) 
association reaction indicates the following:  (i) the chemical reaction kinetics 
occurs rapidly within one second; (ii) optimal absorbance of the reaction product 
was observed at 334 nm; (iii) nearly identical observed rate constants, kobs, with 
four various reaction buffers show that the association reactions are not 
dependent on the composition of the reaction buffer; and (iv) THPP demonstrates 
an overall larger apparent association equilibrium constant with NAD+, Ka app, 
than compared to TCEP’s association with NAD+ (35.1 ± 2.3 M-1 versus 20.1 ± 
1.7 M-1). NMR one-dimensional and two-dimensional spectroscopy of the nuclei 
1H, 13C, and 31P collectively resolved the chemical structure of the (NAD+-
tris(alkyl)phosphine) association reaction product molecule as a covalent adduct 
between the phosphorus of THPP or TCEP interacting at the C4 position of the 
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dihydronicotinamide ring of NAD+. All in all, our in vitro findings concerning the 
(NAD+─tris(alkyl)phosphine) association reaction serves as a cautionary tale 
when using TCEP or THPP in NAD+-dependent enzyme activity assays due to 
artifactual background increases in absorbance around 340 nm by the reaction 
product molecule. 
FUTURE DIRECTIONS 
 From chapters two and three, elucidation of the sequential-ordered binding 
mechanism of HsPYCR1 and HsPYCR2 has the potential to guide the 
development of new inhibitors and/or substrate analogs as molecular probes for 
modulating human PYCR activity. For instance, D’Aniello et al. (2020) consider 
HsPYCR1 to be a potential therapeutic target against cases of hepatocellular 
carcinoma and breast cancer, but hitherto, no specific enzyme inhibitors have 
been developed.15 However, in the context of plants and development of 
herbicides specifically targeting and inhibiting plant P5CR activity, Forlani et al. 
(2008) have identified inhibitors with two phosphonic groups as the main 
structural feature for binding to the P5CR active site.16 In that study, the authors 
kept the bisphosphonate scaffold while diligently exploring analogs of the inhibitor 
(3,5-dichlorophenyl)aminomethylenebisphosphonic acid.16 
 Additionally, previous studies that have profiled metabolic alterations in the 
blood and plasma of HsPYCR2-deficient patients found no significant decreases 
in L-proline .5,17 However, it remains unknown what the concentrations of L-
proline and of its related metabolites are in the relevant affected neurological 
tissue and cerebrospinal fluid (CSF) of these patients. Thus, an appropriate next 
step would be to examine if HsPYCR2 deficiency causes abnormal L-proline  
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bioavailability in patients, especially in the CSF. 
 Upon observing that HsPYCR1 and HsPYCR2 utilize L-T4C as a substrate in 
chapter four, the next prudent course of action should involve knockout studies of 
HsPYCR1, HsPYCR2, and of both isozymes combined with L-Pro starvation 
studies of human tissue cells supplied with doses of L-T4C in growth media. 
From these studies, the measured endpoints of cellular L-Cys levels and the 
various redox states of L-Cys could describe how L-Pro homeostasis and L-Cys 
homeostasis interact at the level of PYCR bifunctional enzyme activity. From 
early in vivo studies done by Mackenzie et al. (1957), L-T4C was found to be a 
great sulfur replacement for L-cystine (oxidized form of L-Cys) to supplement 
animals with low L-methionine diets and promote growth.18  
Another set of studies could be done to explore if there is altered reactive  
nitrogen species (RNS) homeostasis with overexpressed HsPYCR1, HsPYCR2, 
and both isozymes. PYCR enzymes consume L-T4C, which is regarded as a 
major cellular nitrite scavenger. Taking L-T4C’s capacity as a nitrite scavenger 
and probe for the detection of RNS a step further, Kumagai et al. (2004)’s 
duodenal contents reflux rat model with the intervention of L-thioproline curtailed 
pathological tissue damage by the presence of RNS, i.e. nitric oxide and 
peroxynitrite, and N-nitroso compounds in gastroduodenal reflux contents.19 
Recent advances in imaging methods and visualization tools could allow for 
specific detection of RNS. For instance, one method relies on an iridium(III) 
complex used as a near-infrared phosphorescent probe for examining the 
interplay between nitric oxide and superoxide species and for detecting 
intracellular peroxynitrite levels of organisms both in vitro and in vivo.20 Another 
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novel approach involves the use of a chemiluminescent molecule (oxygen-
embedded quinoidal pentacene) tethered to a near-infrared nanoprobe for non-
invasive, in vivo, specific detection of peroxynitrite via a chemiluminescence 
resonance energy transfer mechanism.21 
 Aside from these novel research pursuits, L-proline metabolism is intimately 
linked with vital cellular processes including bioenergetics, anaplerotic reactions 
replenishing citric acid cycle intermediates, and cell signaling.22 The role of PYCR 
at the intersection of L-Pro and L-Cys homeostasis and the potential involvement 
of PYCR in RNS balance via L-T4C would further expand our understanding of 
the numerous physiological roles of PYCR enzymes. From the two major 
biosynthetic routes of L-proline formation mentioned in chapter one, this work 
primarily addresses the L-glutamate route with an emphasis on the final reductive 
step. In conclusion, the entirety of this thesis dissertation accomplishes both 
structural and kinetic characterization of human PYCR enzymes responsible for 
L-proline biosynthesis. 
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DL-P5C Substrate Stocks’ Chemical Synthesis Protocol 
 
DL-P5C Synthesis  
The synthesis of DL-P5C followed the method of Williams and Frank1 except 
the volume of each of the following components was reduced by two-fold:  DL-5-
hydroxylysine hydrochloride, sodium metaperiodate, glycerol, glycine, and HCl. 
After performing the reaction at 4 °C, the reaction mixture was loaded onto a 1.5 
cm (inner diameter) x 43.5 cm (length) borosilicate glass column (Kimble Chase) 
packed with Dowex 50WX4 cation exchange resin that had been equilibrated with 
2 M HCl. The column was then washed with 1 M HCl to elute the fractions. The 
concentration of DL-P5C in the collected fractions was determined by diluting a 4 
μl sample of each fraction into 16 μl of 1 M HCl which was then added to 180 μl of 
5 mM o-AB (prepared by diluting a 500 mM o-AB stock (in 100% ethanol) into 20 
mM Glycine-HCl, pH 2.0), resulting in a final 200 μl volume. DL-P5C reacts with 
o-AB to form a yellow conjugate that can be detected at 443 nm (ε443 = 2590 M-1 
cm-1).2 The DL-P5C/ o-AB mixtures (200 μl) were incubated at room temperature 
with mild shaker agitation for 24 h in a clear polystyrene 96-well flat bottom plate 
(Corning) covered in aluminum foil.  Absorbance at 443 nm was then recorded 
using a Synergy 2 Multi-Mode Plate-Reader (BioTek) with Gen5 Secure Reader 
Control and Data Analysis software (version 2.05.5, BioTek). The concentration 
of DL-P5C was determined using a modified equation of the Beer–Lambert–
Bouguer law3,4,5 which incorporates the mean absorbance of six replicates of a 
blank (5 mM o-AB in 20 mM Glycine-HCl, pH 2.0),  a microplate-based path 
length-well volume correction factor (2.19) determined from IR absorbance 
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measurements6 with 1 M HCl, and a dilution factor of 50-fold. Eluted fractions of 
DL-P5C in 1 M HCl were kept long-term as stock solutions at 4 °C. 
[DL-P5C] (mM) = �
((sample mean A443 −  blank mean A443) × 2.19)
(ε443 nm = 2.590 mM-1 cm-1) × (1 cm)
�  
×  50 (dilution factor) 
Characterization of DL-P5C by Electrospray Ionization Mass Spectrometry  
 Liquid chromatography-electrospray ionization-multiple reaction monitoring 
(LC-ESI-MRM) mass spectrometry analysis was performed to verify the presence 
of DL-P5C in the samples. The LC-ESI-MRM analysis was performed on a 4000 
QTrap from Sciex (Framingham, MA) operating in MRM analysis mode.  The 
electrospray source was optimized for positive mode with the following 
parameters:  declustering potential = 40 V, curtain gas = 30 L/min, ionization 
potential = 5500 V, temperature = 600 °C, ion source gas 1 = 60 and ion source 
gas 2 = 80.  The samples were loaded into sample vials and held at 5 °C until the 
injection time.  An Agilent LC 1200 HPLC system was used for the separation of 
the compounds, using a Waters X-Bridge Amide column (Waltham, MA) with 
dimensions of 4.6 mm x 100 mm.  The flow rate was maintained at 0.5 mL/min 
with the gradient as follows:  from 0 to 2 min 5% mobile phase A (20 mM 
ammonium acetate, 20 mM NH4OH, pH = 9.5) and 95% mobile phase B 
(acetonitrile); from 2 to 20 min from 5% to 70% A, at 20.2 min 95% A, at 24 min 











Appendix A Figure 1. Microplate-based DL-P5C concentration determinations 
and mass spectrometry analysis. The scatter plot summarizes microplate-based 
DL-P5C concentration determinations via o-AB colorimetric assay of absorbance 
measurements at 443 nm of one batch of chemically synthesized DL-P5C 
substrate in column eluted fractions. Then, liquid chromatography-mass 
spectrometry analysis was performed on three samples, prepared as (1/100) 
dilutions using acetonitrile solvent, from those eluted fractions as annotated in the 
scatter plot:  (A) Column Wash Flowthrough sample, (B) Elution Peak #1 sample, 
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Extended Methods and Procedure for HsPYCR2 Protein Purification 
Recombinant protein expression (pKA8H/PYCR2) vector DNA constructs 
were first transformed into DNA propagation host E. coli XL1-Blue 
Supercompetent Cells (Agilent Technologies), which were grown on separate LB 
Agar Miller plates containing 50 μg/ml ampicillin. Then, the recombinant protein 
expression pKA8H vector DNA constructs were transformed into protein 
expression host E. coli BL21 (DE3) pLysS competent cells (Novagen-EMD 
Millipore Sigma), which were likewise grown on separate LB Agar Miller plates 
containing 50 μg/ml ampicillin and 34 μg/ml chloramphenicol (Chem-Impex 
International). Using this pKA8H expression vector construct resulted in proteins 
with an N-terminal octahistidine tag followed by a tobacco etch virus protease 
cleavage site.  
Next, from those latter growth plates, a pipette-tip picked single colony of cells 
was inoculated into 15 ml starter liquid growth culture containing TB liquid media 
(prepared from the recipe in Sambrook et al. 1989 consisting of tryptone, yeast 
extract, glycerol, and water),1 50 μg/ml ampicillin, and 34 μg/ml chloramphenicol. 
Then starter culture was grown for 17 h overnight in an incubator-shaker at 37 °C, 
180 rpm. To scale up culture size, we transferred 2.5 ml starter culture into each 
of six 2 L flasks containing 1 L of TB liquid media and 50 μg/ml ampicillin to 
shake at 37 °C, 180 rpm, until reaching nearly synchronized cell densities 
associated with OD600 ≈ 0.8-1.0. At that point, the incubation temperature was 
lowered to 18 °C and the six flasks of culture were induced with 0.4 mM IPTG for 
cultures shaken at 180 rpm for 10 h. Then, we added 100 μg/ml chloramphenicol 
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to the six flasks of culture to be continued shaken at 180 rpm and 18 °C for 2 
additional hours to arrest ribosomal translation of bacterial proteins to further 
improve the solubility of the target overexpressed recombinant protein by means 
of affording the bacterial cells to divert their chaperone-assisted folding 
capabilities towards the target protein without continuous generation of 
aggregation-prone proteins.2  
Next, we harvested cells via repeated rounds of large rotor centrifugation 
(Avanti J-E High-Speed Centrifuge, Beckman Coulter) at relative centrifugal force 
(5400 x g) for 20 min at 4 °C to process all 6 L of culture into two 1000-ml 
centrifugation polypropylene bottles (Beckman Coulter), with supernatants 
decanted off and cell pellets stored at -80 °C overnight to promote cell lysis by 
freezing. Then with a metal spatula, we transferred cell pellets from both 
centrifugation bottles into a common glass beaker and let pellets thaw at room 
temperature on the lab countertop for 30 min. Next, the combined cell pellets 
were resuspended and lysed in NPI-5 cell lysis buffer (5 mM imidazole, 500 mM 
NaCl, 50 mM NaH2PO4, pH 7.5) with the addition of 500 µM Tris(3-
hydroxypropyl)phosphine (THPP) reducing agent (Strem Chemicals), 0.01% 
TritonX-100 detergent (Amresco), 0.01% Brij-35 polyoxyethylene detergent 
(Santa-Cruz Biotechnology), 10 mM βOG, and a mixture of five protease 
inhibitors: (i) 500 mM ε-amino-N-caproic acid dissolved in water, (ii) 50 mM 
PMSF dissolved in acetone, (iii) 2 mM leupeptin hemisulfate dissolved in water, 
(iv) 8 mM N-tosyl-L-phenylalanine chloromethyl ketone dissolved in ethanol, and 
(v) 13 mM N-α-p-tosyl-L-lysine chloromethyl ketone (Bachem) dissolved in water. 
The cell suspension was then subjected to sonication at knob setting 6 for total 
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processing time of 5 min with settings 5 s-pulse on and 15 s-pulse off, on a Sonic 
Dismembrator (Model F 550, Fisher Scientific). Next, cell lysates were poured 
into four 25 ml-centrifugation tubes fitted with stoppers and caps, to be subjected 
to small rotor 4 °C centrifugation at relative centrifugal force (30960 x g) for 1.5 hr 
before obtaining supernatants of target protein solution.  
After that, the target protein was purified by application into a borosilicate 
glass column (Kimble Chase) of 2.5 cm (diam.) x 24 cm (height) packed with 25-
ml resin bed of Ni2+-nitrilotriacetic acid Superflow resin (Qiagen) for motor-driven 
pulsatile tubing flow-immobilized metal affinity column chromatography in 4 °C 
cold room. The column purification proceeded with column volumes (CV) of an 
increasing imidazole concentration gradient (5 CV of 5 mM  10 CV of 60 mM  
6 CV of 500 mM imidazole) of 50 mM NaH2PO4-based buffers applied into 
column until final protein elution into automated glass test tube fraction collector 
set at 2 ml per fraction. Next, Bio-Safe Coomassie Blue G250 Stain (Bio-Rad) 
exposure-based SDS-PAGE of two precast 15-well gels 4-20 % Tris/Gly (Bio-
Rad, Mini-Protean TGX) was performed with 20 µl-aliquots of 20 eluted fraction 
tubes chosen randomly from 50 total tubes, where each aliquot was chemically 
reduced with SDS-Loading Buffer and (β)2-Mercaptoethanol (Acros Organics) 
and thermally reduced by 10 min boil at 100 °C, all ultimately to determine which 
eluted protein fractions to pool together. Next, in 4 °C cold room, the pooled 
protein fractions were collected into a regenerated cellulose dialysis tubing sac 
(Dialysis Snakeskin Tubing, ThermoFisher Scientific-Pierce Biotech) clipped 
closed at both ends and dialyzed at moderate stir atop stirring plate for three 
separate periods (24 hr5 hr5 hr) into fresh 1 L dialysis buffer (50 mM HEPES, 
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250 mM NaCl, 0.5 mM EDTA, 500 µM THPP reducing agent, 10% (v/v) glycerol, 
pH 7.5).  
Then, we performed two methods of protein concentration:  initially 
concentrating the large volume of dialyzed protein in 4 °C cold room using 5 kDa 
PLCC low bind 44.5 mm diameter ultrafiltration disc (EMD Millipore-Sigma) with 
an ultrafiltration stirrer cell (Model 8050, Amicon, EMD Millipore-Sigma) under 
airflow N2(g)-pressure until approximately 5 ml concentrated protein obtained, and 
if protein appeared visibly free of any aggregates/precipitates, then prepared 1 
ml-aliquots in 2 ml microtubes that are shock-frozen in liquid nitrogen followed by 
piercing tube lids with a fine needle and subjecting them to stand in a tube holder 
for freeze-dry vacuum lyophilization (FreeZone Bulk Tray Dryer, Labconco) 
carried out 3-5 h until approximately 250 µl concentrated protein remained in 
microtubes. For these lyophilized microtube samples, we subjected them to 
microdialysis in 4 °C cold room with inverted 15K MWCO Tube-O-Dialyzer tubes 
(G Biosciences-Geno Technology) at moderate stir atop stirring plate for three 
separate periods (24 hr5 hr5 hr) into fresh 500 ml dialysis buffer. Protein 
concentration was quantified by 660 nm Pierce Protein Dye Assay (ThermoFisher 
Scientific-Pierce Biotech) with bovine serum albumin standards’ curve prepared 
by spectrophotometric measurements using 1 cm-path length 1.5 ml polystyrene 
cuvettes (USA Scientific) with a Varian Cary Bio 50 UV-Vis Spectrophotometer 
(Agilent Technologies). At this point, all protein samples were distributed into 500 
µl aliquots that were shock-frozen in liquid nitrogen and stored at -80 °C. 
Samples of purified wild-type, R251C mutant, and R119C mutant enzymes were 
subjected to SDS-PAGE under reducing conditions and visualized all together on 
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a Bio-Safe Coomassie Blue G250-stained 4-20% gradient precast 
polyacrylamide-Tris-Gly HCl, 10-well MP TGX gel (Fig. 3.2). 
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